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Abstract 
 
Protein kinase C δ (PKC-δ) is a novel member of the PKC family of serine-threonine 
kinases. PKC-δ structure is widely conserved within the PKC family and has a catalytic 
region and regulatory region. The regulatory region has two main sub domains C1 
and C2. Although several studies have investigated the role of the C1 domain, little is 
known about the function of the C2 domain, however there is some evidence that it 
acts as a protein interaction domain.  
 PKCs are involved in a wide variety of cellular functions within cancer. PKC-δ has 
been demonstrated to have a particular involvement with the apoptotic processes of 
a cancer cell. A pro-apoptotic role for PKC-δ has been identified, whereby tyrosine 
phosphorylation of particular residues induces translocation to the nucleus, 
alongside a similar translocation event for caspase-3. In the nucleus, caspase-3 
cleaves the regulatory and catalytic regions to form a free catalytic domain that is 
uninhibited by the regulatory portion. This free catalytic region causes the induction 
of the apoptotic pathway. Conversely an anti-apoptotic role has also been identified 
for PKC-δ. This was found in MDA-MB-231 cells, which have a ras mutation. Due to 
this mutation in these cells, ERK1/2 phosphorylation is high. Without PKC-δ activity 
the high phosphorylation levels induce apoptosis. PKC-δ acts on a pathway to reduce 
ERK1/2 phosphorylation, thus facilitating cell survival.  
This study aimed to investigate the role of the PKC-δ C2 domain within breast cancer 
cells. Through use of these techniques, the role of the C2 domain was examined in 
order to consider its utility as a drug target to treat breast cancer. 
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• Constructs were developed of pIRESneo2 vector with myc-tagged C2 domain 
and myc-tagged PKC-δ sequences 
• Breast cancer cell lines, MDA-MB-468, MDA-MB-231 and MCF-7, were stably 
transfected with a vector control and myc-δC2 construct. MDA-MB-231 and 
MCF-7 were also transfected with myc-PKC-δ. 
• Cell lines developed were examined for alterations due to the presence of 
the C2 domain or PKC-δ over-expression 
As the C2 domain is proposed to be a protein interaction domain, we hypothesized 
that over-expression of this domain would interfere with endogenous PKC-δ 
interactions, through competitive inhibition, and thus we could identify C2 domain 
roles. The effect on the cells of the endogenous PKC-δ would be opposed by the C2 
domain. Thus the role of endogenous PKC-δ could also be clarified for a particular 
situation - it would be the opposite of the effects induced by the myc-δC2 on the 
cells. 
In the MDA-MB-468 stable cell lines, immuno-fluorescence examination of the myc-
δC2 cells showed the myc-δC2 was localised at the ends of actin protrusions from the 
bulk of the cell. The myc-δC2 expressing cells had a more extensive cytoskeleton than 
the Vector control cells, possibly suggesting improved attachment to a surface. An 
experiment examining this illustrated that the myc-δC2 cells appeared to attach in a 
shorter time period. This implies that the role of the endogenous PKC-δ is to 
discourage cell attachment and promote an invasive phenotype, this is in agreement 
with the literature. 
During sub-culture of the MDA-MB-468 cell lines it became apparent that the myc-
δC2 cells were growing at an increased rate over the Vector cell lines. This was 
quantified and indeed the myc-δC2 cells did increase in cell number more than the 
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Vector cells. This was also the case with the MDA-MB-231 cells but not with the MCF-
7 cells. Growth is a balance of proliferation and apoptosis. This effect indicates that 
PKC-δ is pro-apoptotic, or anti-proliferative. MCF-7 cells lack caspase-3 and thus pro-
apoptotic effects of PKC-δ would be affected in this cell line. As the myc-δC2 did not 
have an effect in these cells we examined apoptosis to see if these effects could be 
attributed to differences in apoptosis.  
The MDA-MB-468 cells expressing myc-δC2 had higher viability than the Vector cells.  
This fits with the cell number data, indicating that a lower level of apoptosis has led 
to a greater cell number, and advocates a pro-apoptotic role for PKC-δ. This was not 
the case in MDA-MB-231 cell lines where Vector cells had higher viability. This agrees 
with the literature describing PKC-δ displaying an anti-apoptotic role in this cell line, 
but does not fit with the cell number data. Thus, differences in cell number are likely 
due to effects on proliferation, although this was not investigated. MCF-7 cells 
showed no differences indicating the apoptotic program of these cells is indeed 
affected by the lack of caspase-3.  
Serum starvation is a commonly used method to induce apoptosis. MDA-MB-468 cell 
lines were serum starved in order to examine the effects. The apoptosis profile was 
altered and myc-δC2 cells showed lower viability than the Vector cells, indicative of 
an anti-apoptotic effect of PKC-δ. An anti-apoptotic effect is observed in MDA-MB-
231 cells, where the effect was proteasome dependent. This was also the case in this 
situation. The anti-apoptotic effect is related to levels of phosphorylated ERK1/2, 
where high levels are pro-apoptotic. The phosphorylation status was examined and 
illustrated a much higher level of phosphorylation in myc-δC2 cells over Vector cells 
when starved. This indicates myc-δC2 is inhibiting the de-phosphorylating role of 
PKC-δ in these apoptotic cells. Thus it appears that the C2 domain acts as a ‘sensor’ 
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to serum status, appropriating PKC-δ effects in apoptotic pathways according to the 
serum status, the method of which is unknown.  
This study has highlighted the importance of the PKC-δ C2 domain in breast cancer 
apoptosis. The effects appear to require a fully active PKC-δ pro-apoptotic pathway, 
and are dependent on the serum status of the cells. Further investigation would be 
required to identify a level of serum for use in vitro that is relevant to an in vivo 
tumour situation. If low levels are more relevant to a clinical state then it may be 
possible to target the C2 domain with drugs to allow induction of apoptosis. The 
differences between the cell lines clearly show that the phenotypic analysis of 
tumours would be vital to identifying whether such treatment would be applicable, 
as effects of any drug would vary greatly across tumour types. MDA-MB-468 and 
MDA-MB-231 are both triple negative cell lines (i.e. they do not express 
progesterone, oestrogen or HER2 receptors); however the strong differences seen in 
this case indicate further phenotypic analysis would be essential. 
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 Chapter 1: Introduction 
 
1.1 Cancer 
 
Cancer is the third largest cause of death in the world (following cardiovascular 
disease and infectious and parasitic disease). As such, treatment of this 
complicated disease is a major concern across the world (Mathers et al., 2008). 
Historically, toxic agents have been used as cancer treatments. However this type 
of treatment frequently demonstrates extensive effects upon non cancerous cells 
leading to toxicity problems and poor tolerance levels (Hanahan and Weinberg, 
2011). 
Cancers can develop from a single mutated cell. Expansion of the mutant cell 
forms a tumour. The mutations acquired by this cell are enabling and hereditary  
(Hanahan and Weinberg, 2011); they allow the cell to undergo dynamic changes 
that greatly affect the genotype and phenotype. Tumourigenesis is a multistep 
process involving the acquisition of numerous genetic alterations that may 
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produce either dominant gain of function or recessive loss of function effects. 
Particular mutations will enable the cells to have an advantage over surrounding 
cells, thus allowing the population to expand. 
Hanahan and Weinberg have catalogued several traits of cancer cells; these 
describe the key issues which cells must overcome in order to develop into a 
cancer. These hallmarks are: self-sufficiency in growth signals, insensitivity to 
anti-growth signals, tissue invasion & metastasis, limitless replicative potential, 
sustained angiogenesis and evading apoptosis, deregulating cellular energetics, 
avoiding immune destruction, genome instability & mutation and tumour-
promoting inflammation (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 
2011). 
By understanding the hallmarks of cancer and learning more about how cancer 
works and progresses, we have enabled research to be targeted into producing 
successful treatments for this intricate disease. Reflection upon these hallmarks 
can assist us in constructing a successful treatment protocol. The pathways 
involved must be considered, and possible alterations allowing cell survival 
predicted. Several components may be targeted at once in order to provide the 
best outcome by limiting the ability for the cells to further mutate and survive. 
The targeted approach shows great promise for future therapies. 
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1.2 Breast cancer  
 
1.2.1 Epidemiology 
Breast cancer produces the highest number of cancer cases in women across the 
world (Bonadonna et al., 2001; Mathers et al., 2008), and also in the UK (Ferlay et 
al., 2010). In England in 2008, 39,681 women were diagnosed (Office for National 
Statistics, 2010). Breast cancer is the most common cause of death from cancer 
in females in the Americas, Eastern Mediterranean, and Europe. It is second most 
common in Africa and South-East Asia, and fifth in the Western Pacific (Mathers 
et al., 2008). The development of effective treatments is therefore a major 
concern for the hundreds of thousands of patients across the world. 
The occurrence of breast cancer is affected by the surrounding culture and 
environment. This is exemplified in a study comparing rates of breast cancer in 
Osaka, Japan compared with Japanese migrants to Hawaii, USA between 1988 
and 1992. The rates of breast cancer in this migrant population were seen to 
increase to approach the rates in the local population (Weinberg, 2007). 
Several risk factors for breast cancer have been identified; these are related to an 
overall increase in exposure to the hormone oestrogen. Factors that increase 
breast cancer risk include: early menarche, late menopause, postmenopausal 
obesity and hormone replacement therapy (Bonadonna et al., 2001). Studies 
have demonstrated that oestrogen can induce and promote rodent mammary 
tumours (Forrest, 1974). This data correlates cell-based studies with 
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epidemiological data indicating that oestrogen plays a very important role in 
breast cancer. The administration of anti-oestrogens has anti-tumour effects. 
Anti-oestrogenic therapy is used in the clinic against oestrogen receptor positive 
cancers to great effect (Early Breast Cancer Trialists' Collaborative Group, 1998). 
 
1.2.2 Anatomy of normal breast tissue 
The normal breast tissue is fatty and contains many lobes where milk is produced 
following child-birth. The lobes are made up of many lobules, where the milk is 
secreted. The lobules drain into ducts that channel the milk to the nipple. 
Hormonal changes during the menstrual cycle cause the tissue to proliferate and 
shrink back again. In pregnancy, the proliferation is more sustained and extensive 
remodelling occurs, whereby more ducts and lobules form. The ability for breast 
tissue to grow and shrink suggests the presence of mammary stem cells (Polyak, 
2007). These would divide upon hormonal stimulation. The exact mechanisms of 
breast tissue development and homeostasis remain to be elucidated.  
Within the breast tissue, the ductal and lobular structure is retained within a 
basement membrane (Fig. 1.1). Studies indicate that breast stem cells divide and 
differentiate into two subtypes, myo-epithelial and luminal. The myoepithelial 
cells attach to the basement membrane, whilst the luminal cells further 
differentiate into luminal/alveolar or ductal epithelial cells. Ductal cells may, or 
may not, have oestrogen receptors.  
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Figure 1.1: A schematic of the development of cells from the mammary stem 
cells in the duct and lobular unit in normal breast tissue (Polyak, 2007). The 
grey line surrounding the duct and lobule indicates the basement membrane.  
 
 
1.2.3 Breast cancer development, progression and manifestation  
Breast cancer, like other cancers, begins with an initiation event, where 
carcinogenic action causes mutation (King and Robins, 2006).  This is followed by 
promotion, where the mutated cell proliferates; in breast cancer this can be 
caused by oestrogen. The mutated breast cell is promoted to survive and 
proliferate; more mutations may occur during this process, which results in the 
 
6 
formation of a tumour.  Following this, the tumour undergoes progression into a 
more aggressive phenotype (King and Robins, 2006).  
The early events of breast cancer have not been fully identified, however certain 
histological events have been associated with an increased risk of breast cancer; 
these are lobular or ductal atypical hyperplasias (AH) (Roses, 1999).  The 
presence of AH does not mark the site/s at which breast cancer will develop, but 
act as markers for breast cancer development in the ensuing 10-15 years, which 
may be in either breast.  AH include lobular carcinoma in situ (LCIS). LCIS is 
different to ductal carcinoma in situ (DCIS), which can progress into an invasive 
cancer (Roses, 1999).  Between 12-20% of cases will recur within 10 years despite 
surgery to conserve the breast and radiotherapy (Thompson et al., 2008).   
In breast cancer, lesions are primarily in the form of DCIS. DCIS is the term used 
to describe a situation where cells originating from the epithelium of the ductal 
structures proliferate abnormally following an initiation event. The abnormal 
proliferation is a result of a malignant transformation of cells. In DCIS the cells are 
retained at their origin by the basement membrane. Approximately 50% of DCIS 
will progress into invasive disease if untreated (Thompson et al., 2008).  
Development from DCIS involves breaking through the basement membrane; this 
occurs as the cells progress into a more aggressive phenotype. The loss of the 
basement membrane allows the tumour to be invasive and metastatic (Polyak, 
2007). Breast cancer most commonly develops from the epithelium of ductal 
structures. The mechanisms behind progression from DCIS require investigation. 
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Where breast cancer develops an invasive and metastatic phenotype it will 
spread beyond the original tumour site. There have been suggestions that 
tumours can act on distant tissues to ‘condition’ them in order to provide 
suitable sites for colonisation (Sleeman and Cremers, 2007).  The hypothesis of 
pre-metastatic niche formation is supported by the observation that particular 
tumour types have a penchant for metastasising to particular organs (Sleeman 
and Cremers, 2007). In breast cancer secondary tumours often form in the skin, 
the subcutis of the chest wall and the lymph nodes (Bonadonna et al., 2001).  The 
mechanism surrounding this predisposition is not elucidated.  However, recent 
studies have indicated that production of growth factors and cytokines from 
tumour cells can recruit VEGFR1+ bone marrow progenitor cells and myeloid cells 
to a specific region (Sleeman and Cremers, 2007).  The bone marrow progenitors 
add to the vasculature and extracellular matrix of the pre-metastatic niche, while 
the myeloid cells produce S100A8 and S100A9 proteins which attract 
disseminating tumour cells (Hiratsuka et al., 2006; Sleeman and Cremers, 2007).  
Growth factors and cytokines inducing a pre-metastatic niche is demonstrated 
where conditioned media from tumour cells that are capable of specific 
metastases is injected into animals.  A pre-metastatic niche then forms in 
relevant organs (Sleeman and Cremers, 2007).   
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1.2.4 Breast cancer molecular classification 
Breast cancer is slightly unusual amongst cancers due to the hormonal 
involvement in the homeostasis of the tissue; many cancers are not affected by 
hormones. This hormonal involvement means that the cancer cells may express 
oestrogen and/or progesterone receptors; if this is the case they are considered 
to be ER+ and/or PR+ (Metz and Hampshire, 2007). These tumours respond to 
the oestrogen and/or progesterone in the blood, which stimulates the growth of 
the cells. Where the receptor is absent, the hormone has no effect on growth. 
This dependence provides an opportunity for treatment of the cancer. The anti-
oestrogen drug tamoxifen acts by preventing oestrogen binding the receptors on 
the cell surface. Aromatase inhibitors which decrease the levels of oestrogen in 
the blood can be used in post-menopausal patients (Metz and Hampshire, 2007).  
Study of breast cancer is complicated by it being a conglomeration of diseases, 
where different cells in a tumour have multiple characteristics (Polyak, 2007).  
These differences create clinical issues whereby the cancer varies greatly 
between patients.  Tumour profiling has revealed five major subtypes of breast 
cancer cells: luminal A, luminal B, HER2+/ER-, normal breast-like and basal-like 
(Polyak, 2007) (Table 1.1).  HER2+ is also referred to as Erb-B2. These subtypes 
are evident at DCIS.  The sub-types of breast cancer relate to differences in the 
patient’s relapse-free period and their overall survival (Hu et al., 2006). In 
general, tumours consisting of basal-like cells lead to a worse prognosis, with 
those consisting of luminal A subtype giving the best prognosis (Polyak, 2007).  
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The normal breast-like tumour sub-set, have a similar gene expression pattern to 
normal, non-cancerous, tissue. They are negative for all five key markers: ER, PR, 
HER2, cytokeratins 5/6 and EGFR (Munirah et al., 2011; Nielsen et al., 2004). The 
luminal sub-types express the ER gene and also express keratins 8/18, as found in 
luminal epithelia.  Expression of ER is also correlated with the transcription 
factors GATA-binding protein 3, X-box binding protein 1 and hepatocyte nuclear 
factor 3α (Perou et al., 2000). The luminal sub-types can be further divided into A 
and B. Luminal A cancers have a better prognosis and a greater average age of 
diagnosis (Hu et al., 2006). High expression of ERα, GATA-binding protein 3, X-box 
binding protein 1, hepatocyte nuclear factor 3α, trefoil factor 3 and oestrogen-
regulated LIV-1 indicates a luminal A sub-type. Low to medium expression levels 
indicates a luminal B sub-type (Sørlie et al., 2006). The HER2+, or Erb-B2 tumour 
sub-set express the Erb-B2 oncogene and the genes co-expressed with this but do 
not express ER. These tumours are sensitive to the drug herceptin (Menard et al., 
2003). Basal-like tumours express the keratins found in breast basal cells, 
keratins 5/6 and/or 17. They do not express ER or any of the co-expressed genes 
described above, for example GATA-binding protein 3, or HER2+. 
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Table 1.1: The five sub-types of breast cancer 
Sub-type Expression 
Luminal A Express keratins 8/18 and high levels of ERα, GATA-
binding protein 3, X-box binding protein 1, hepatocyte 
nuclear factor 3α, trefoil factor 3 and LIV-1  
Luminal B Express keratins 8/18 and low to medium levels of ERα, 
GATA-binding protein 3, X-box binding protein 1, 
hepatocyte nuclear factor 3α, trefoil factor 3 and LIV-1 
HER2+/ER- Express the Erb-B2 oncogene. Negative for ER 
Normal breast-like Negative for ER, PR, HER2, cytokeratins 5/6 and EGFR 
Basal-like Express keratins 5/6 and/or 17. Negative for ER 
ER: Oestrogen Receptor, PR: Progesterone Receptor, EGFR: Epidermal Growth 
Factor Receptor 
 
1.2.5 Breast cancer monitoring and treatment 
A treatment program tailored to a tumour profile remains elusive. However, 
recent development and approval of drugs such as Herceptin (for HER2+ tumours) 
is demonstrative of expansion of research in this area.  
 
1.2.5.1 Markers 
In breast cancer, markers can be used for staging, determining prognosis, and 
monitoring throughout treatment.  Markers are proteins associated with tumour 
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cells that are detectable in tissue or body fluids.  Markers may be on the cell 
surface, secreted, or molecules that mark cell turnover in a non-specific manner 
(Pannall and Kotasek, 1997). 
Carcinoembryonic antigen (CEA) is a cell surface glycoprotein with a role in cell-
cell adhesion (Pannall and Kotasek, 1997).  In individuals with early disease, CEA 
is elevated in 25% of cases, while with advanced disease elevation occurs in 75% 
of patients.  CEA is particularly notable with bone and liver metastases and can 
be studied to monitor a response to therapy.  
The CA 15-3 assay is most useful for monitoring breast carcinoma, it uses two 
antibodies and detects Mucin-1 (MUC-1).  MUC-1 is a membrane bound highly 
glycosylated protein. It is frequently less glycosylated in cancer (Agrawal et al., 
1998) where expression is elevated (Mukherjee et al., 2005).  In normal glandular 
epithelium, MUC-1 is expressed at the apical membrane (Quin and McGuckin, 
2000).  In breast carcinoma, MUC-1 protein is found throughout the cytoplasm; 
where high cytoplasmic expression is identified, the patient prognosis is poorer.  
The concentration detected in the assay can reflect the tumour burden, while a 
particularly high level is indicative of metastatic cancer (Pannall and Kotasek, 
1997).  In early breast cancer assay sensitivity varies from 0-36%; however it is 
100% sensitive in advanced disease.  Elevation can occur in other benign and 
malignant diseases.  During monitoring of breast cancer, a decrease 
demonstrates a treatment response. However, lack of a decrease does not 
exclude the existence of a response (Pannall and Kotasek, 1997).  Normal levels 
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after treatment indicates better prognosis compared with those where it does 
not. 
Monitoring of breast cancer can also use tissue polypeptide antigen (TPA) which 
is reflective of cell proliferation rather than tumour mass, thus arguably a more 
sensitive progression indicator (Pannall and Kotasek, 1997).  TPA originates from 
cytokeratins; soluble fragments are released during cell growth and division.  TPA 
levels are related to the breakdown of cytokeratins 8, 18 and 19, which are more 
abundant in malignant tissues.  Increase can also occur with infection. 
In addition the HER2 and ER status of tumours can be examined. This aids 
identification of the tumour subtype (see 1.2.4). This enables a more directed 
approach to be utilised in cancer treatment. For example, HER2+ tumours can be 
treated using Herceptin, whilst tumour cells negative for HER2 expression will not 
respond to this treatment.  
 
1.2.5.2 Treatment 
Traditionally breast cancer has been treated using chemotherapies commonly 
utilised throughout a variety of cancers. These are not designed against a specific 
target, instead they are designed to affect cells that grow at an increased rate to 
the majority of cells in the body. Such cells include cancer cells, but also bone 
marrow, where new blood cells are constantly being produced. Thus 
chemotherapy can also have side-effects on these cells and cause the patient to 
develop anaemia or even leukemias. These drugs may target DNA to cause 
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damage, thus initiating the cells’ intrinsic detection mechanisms and inducing 
apoptosis. In breast cancer, typical regimens include doxorubicin and 
cyclophosphamide for 3 months, or cyclophosphamide, methotrexate and 
fluorouracil for 6 months (Metz and Hampshire, 2007). Chemotherapy may be 
given prior to surgery in order to try and shrink the tumour and make excision 
less difficult. 
Hormone therapy is a more recent treatment option. These are designed to 
inhibit binding of a stimulatory factor with the cell surface receptors in question. 
This treatment is traditionally against oestrogen receptors and prevents the 
growth-stimulatory effects of oestrogen binding. ER+ tumours can be treated 
with tamoxifen (Metz and Hampshire, 2007). Tamoxifen is usually taken for 5 
years following surgery. This treatment dramatically reduces recurrence risks 
whilst also prolonging survival and preventing the development of a secondary 
breast cancer in the other breast. Aromatase inhibitors are a newer therapy that 
decreases the oestrogen levels in the body (Metz and Hampshire, 2007).  Drugs 
for this treatment include letrozole. These are only given in post-menopausal 
women. 
HER2/neu+ tumours can also be targeted using a similar mechanism, but 
involving the HER2/neu receptor. Herceptin, a monoclonal antibody, is used for 
this type of treatment. HER2/neu is a growth factor receptor, where growth 
factors binding the cells are stimulated to divide. Herceptin-receptor binding 
prevents this stimulatory signalling and prevents cell division. This causes the cell 
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to enter apoptosis. Herceptin is often given with traditional chemotherapeutic 
regimens (Metz and Hampshire, 2007). 
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1.3 Protein kinase C δ 
 
1.3.1 The Protein kinase C family 
PKC-δ is a 78kDa member of a large family of kinases, which fall within a sub-
group of the AGC kinases  (Hanks and Hunter, 1995).  PKCs are generally 
activated by the presence of calcium ions (Ca2+) and diacylglycerol (DAG); 
however, the diversity amongst the family members is considerable.  
Consequently, the influence of calcium and DAG is only applicable for the 
classical PKCs, PKC-α, β1, β2 and γ (Mellor and Parker, 1998).  Novel PKC 
isozymes, PKC-δ, ε, η and θ, do not respond to Ca2+ but remain responsive to 
DAG (Mellor and Parker, 1998).  Finally, the atypical PKCs, PKC-ζ and ι are 
unresponsive to both. These differences in activation are mirrored by structural 
differences (Fig. 1.2). The classical isoforms contain 4 conserved domains (C1-C4). 
The C1 responds to DAG and the C2 to calcium. However in novel isoforms, the 
classical C2 domain is absent, instead there is a C2-like domain which has an 
altered structure preventing its ability to respond to calcium (Pappa et al., 1998).  
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Regulatory domain
DAG Ca2+
 
Figure 1.2: Classical PKC structure compared with novel PKC structure 
 
1.3.2 PKC-δ primary structure  
1.3.2.1 The catalytic domain 
PKC-δ comprises of catalytic and regulatory portions.  The catalytic domain has 
two conserved domains C3 and C4 that are conserved amongst all PKCs. The 
pseudosubstrate site of the regulatory domain, positioned between the C1 and 
C2 domains, binds at the C4 domain where it (auto)-inhibits kinase activity (Xu et 
al., 2004). The crystal structure of the PKC-δ catalytic domain has not been solved 
but it is available for the most closely related PKC-θ catalytic domain. The PKC-θ 
structure was solved in complex with staurosporine, a protein kinase inhibitor 
that acts by preventing ATP binding (Xu et al., 2004). Alignment analysis using 
CLUSTALW2 shows 64% identical protein sequence between the two isoforms 
(Fig. 1.3).  
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CLUSTAL 2.1 multiple sequence alignment 
 
 
sp|Q05655|KPCD_HUMAN      MAPFLRIAFNSYELGSLQ-AEDEANQPFCAVKMKEALSTERGKTLVQKKPTMYPEWKSTF 59 
sp|Q04759|KPCT_HUMAN      MSPFLRIGLSNFDCGSCQSCQGEAVNPYCAVLVKEYVESENGQMYIQKKPTMYPPWDSTF 60 
                          *:*****.:..:: ** * .:.** :*:*** :** :.:*.*:  :******** *.*** 
 
sp|Q05655|KPCD_HUMAN      DAHIYEGRVIQIVLMRAAEEPVSEVTVGVSVLAERCKKNNGKAEFWLDLQPQAKVLMSVQ 119 
sp|Q04759|KPCT_HUMAN      DAHINKGRVMQIIVKGKNVDLISETTVELYSLAERCRKNNGKTEIWLELKPQGRMLMNAR 120 
                          **** :***:**::     : :**.** :  *****:*****:*:**:*:**.::**..: 
 
sp|Q05655|KPCD_HUMAN      YFLEDVDCKQSMRSEDEAKFPTMNRRGAIKQAKIHYIKNHEFIATFFGQPTFCSVCKDFV 179 
sp|Q04759|KPCT_HUMAN      YFLEMSDTKDMNEFETEGFFALHQRRGAIKQAKVHHVKCHEFTATFFPQPTFCSVCHEFV 180 
                          ****  * *:  . * *. *.  :*********:*::* *** **** ********::** 
 
sp|Q05655|KPCD_HUMAN      WGLNKQGYKCRQCNAAIHKKCIDKIIGRCTGTAANSRDTIFQKERFNIDMPHRFKVHNYM 239 
sp|Q04759|KPCT_HUMAN      WGLNKQGYQCRQCNAAIHKKCIDKVIAKCTGSAINSRETMFHKERFKIDMPHRFKVYNYK 240 
                          ********:***************:*.:***:* ***:*:*:****:*********:**  
 
sp|Q05655|KPCD_HUMAN      SPTFCDHCGSLLWGLVKQGLKCEDCGMNVHHKCREKVANLCGINQKLLAEALNQVT---- 295 
sp|Q04759|KPCT_HUMAN      SPTFCEHCGTLLWGLARQGLKCDACGMNVHHRCQTKVANLCGINQKLMAEALAMIESTQQ 300 
                          *****:***:*****.:*****: *******:*: ************:****  :      
 
sp|Q05655|KPCD_HUMAN      QRASRRSDSASSE-PVGI----------------YQGFEKKTGVAGEDMQDNSGTYGKIW 338 
sp|Q04759|KPCT_HUMAN      ARCLRDTEQIFREGPVEIGLPCSIKNEARPPCLPTPGKREPQGISWESPLDEVDKMCHLP 360 
                           *. * ::.   * ** *                  * .:  *:: *.  *: ..  ::  
 
sp|Q05655|KPCD_HUMAN      EG---------SSKCNINNFIFHKVLGKGSFGKVLLGELKGRGEYFAIKALKKDVVLIDD 389 
sp|Q04759|KPCT_HUMAN      EPELNKERPSLQIKLKIEDFILHKMLGKGSFGKVFLAEFKKTNQFFAIKALKKDVVLMDD 420 
                          *          . * :*::**:**:*********:*.*:*  .::************:** 
 
sp|Q05655|KPCD_HUMAN      DVECTMVEKRVLTLAAENPFLTHLICTFQTKDHLFFVMEFLNGGDLMYHIQDKGRFELYR 449 
sp|Q04759|KPCT_HUMAN      DVECTMVEKRVLSLAWEHPFLTHMFCTFQTKENLFFVMEYLNGGDLMYHIQSCHKFDLSR 480 
                          ************:** *:*****::******::******:***********.  :*:* * 
 
sp|Q05655|KPCD_HUMAN      ATFYAAEIMCGLQFLHSKGIIYRDLKLDNVLLDRDGHIKIADFGMCKENIFGESRASTFC 509 
sp|Q04759|KPCT_HUMAN      ATFYAAEIILGLQFLHSKGIVYRDLKLDNILLDKDGHIKIADFGMCKENMLGDAKTNTFC 540 
                          ********: **********:********:***:***************::*::::.*** 
 
sp|Q05655|KPCD_HUMAN      GTPDYIAPEILQGLKYTFSVDWWSFGVLLYEMLIGQSPFHGDDEDELFESIRVDTPHYPR 569 
sp|Q04759|KPCT_HUMAN      GTPDYIAPEILLGQKYNHSVDWWSFGVLLYEMLIGQSPFHGQDEEELFHSIRMDNPFYPR 600 
                          *********** * **..***********************:**:***.***:*.*.*** 
 
sp|Q05655|KPCD_HUMAN      WITKESKDILEKLFEREPTKRLGVTGNIKIHPFFKTINWTLLEKRRLEPPFRPKVKSPRD 629 
sp|Q04759|KPCT_HUMAN      WLEKEAKDLLVKLFVREPEKRLGVRGDIRQHPLFREINWEELERKEIDPPFRPKVKSPFD 660 
                          *: **:**:* *** *** ***** *:*: **:*: ***  **::.::********** * 
 
sp|Q05655|KPCD_HUMAN      YSNFDQEFLNEKARLSYSDKNLIDSMDQSAFAGFSFVNPKFEHLLED 676 
sp|Q04759|KPCT_HUMAN      CSNFDKEFLNEKPRLSFADRALINSMDQNMFRNFSFMNPGMERLIS- 706 
                           ****:******.***::*: **:****. * .***:** :*:*:.  
 
Results for Total Sequence 
SeqA Name Length SeqB Name Length Score 
1 sp|Q05655|KPCD_HUMAN 676 2 sp|Q04759|KPCT_HUMAN 706 64.0 
 
Results for Kinase Domain Sequence (highlighted) 
SeqA Name Length SeqB Name Length Score 
1 sp|Q05655|KPCD_HUMAN 334 2 sp|Q04759|KPCT_HUMAN 333 72.0 
 
Figure 1.3: Alignment analysis of PKC-δ protein sequence showing comparison 
with PKC-θ performed using CLUSTALW2. PKC-δ sequence (KPCD_HUMAN) 
(GENE ID: 5580 PRKCD (Homo sapiens)), PKC-θ sequence (KPCT_HUMAN) 
(GENE ID: 5588 PRKCQ (Homo sapiens)). Highlighted region shows PKC-θ 
 
18 
kinase domain protein sequence expressed by Xu et al, in comparison with 
PKC-δ. 
 
The Xu et al paper (2004) determines the kinase domain (of PKC-θ) expressed for 
structural studies to be residues 362 to 706. Alignment analysis of this region of 
the PKC-θ sequence identifies a region of the PKC-δ sequence which has 72% 
identical sequence (Fig. 1.3 highlighted). The domain studied by Xu et al is highly 
conserved with that of the PKC-δ sequence, thus it is likely to bear strong 
similarities in structure. 
 
The PKC-θ crystal structure shows the conserved core of the catalytic domain 
consists of a small N-terminal lobe and a larger C-terminal lobe. The two are 
linked by a hinge of four amino acid residues. The N-terminal lobe consists of a β-
sheet structure, which contains five β-strands (β1-5 in Fig. 1.4), and two α-helices 
(αB-C in Fig. 1.4). The C-terminal lobe is primarily helical consisting of eight α-
helices. Positioned at the interface between the N-terminal and C-terminal lobes 
is the active site. This is formed by an adjacent ATP binding site and a peptide-
substrate binding site. A glycine-rich loop, between the N-terminal lobe β1 and 2 
strands, indicated in Figure 1.4, binds phosphate. The loop appears very mobile 
as a multitude of conformations are seen amongst crystals.  
There are three catalytically vital residues, one lysine and two aspartic acid, 
which are conserved among all protein kinases. Surrounding the active site is 
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helix αC, this aligns and binds the substrate for catalysis. An activation loop, 
containing one of the essential aspartic acid residues, also contains a essential 
phospho-threonine residue (position 538) shown in Figure 1.4. Phosphorylation 
of this threonine residue is required for activity (Liu et al., 2002); it enables the 
active site to form the correct conformation. 
 
 
Figure 1.4: Crystal structure of the catalytic domain of PKC-θ. The N-terminal 
lobe is in light blue and the C-terminal lobe in dark blue. The ring structure in 
the centre is staurosporine. (Xu et al., 2004) 
 
In the ATP-binding site, staurosporine bonds, via hydrogen-bonds, with three 
residues. Similar hydrogen bonding between the staurosporine lactam ring and 
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the glutamic acid and leucine residues has been seen on each occasion the ATP 
binding site region of a protein kinase structure has been solved.  
Structural studies indicate that there are three main conformations of the 
catalytic domain: ‘open’, ‘closed’ and ‘intermediate’ (Johnson et al., 2001; Xu et 
al., 2004). In the Xu et al study, the N and C-terminal lobes generally form the 
‘intermediate’ state. The positioning of the glycine-rich loop (which binds 
phosphate) is more variable. In this PKC-θ structure, the glycine-rich loop is seen 
to position inside the phosphate-binding site. In an ATP-binding situation this 
positioning would interfere with the nucleotide phosphate by allowing a closed 
conformation to be both induced and stabilised. The residues critical for catalysis 
are significantly inaccessible in this case. These conformational changes 
exemplify the flexibility of the PKC-θ structure in response to ligand binding. 
The activation loop, part of the C-terminal lobe, forms part of the substrate 
binding surface. In combination with αC helix it can also create a docking surface 
for co-factors. Amongst the wider group of kinases, these two regions, the 
activation loop and the αC helix, are highly variable. Phosphorylation of the 
activation loop can induce structural changes whereby folding allows formation 
of an active site. For PKC-θ, the phosphorylated residue is threonine 538, 
positioned between two invariable motifs of Asp-Phe-Gly and Thr-Pro-Asp. All 
three oxygens of the phosphate group on Thr-538 are involved in hydrogen-
bonding (Fig. 1.5). The phosphorylation of this residue is critical for catalysis, and 
alanine substitution reduces enzyme activity 100-fold (Liu et al., 2002) whereas a 
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mutant of T538E shows a three-fold decrease in enzymatic activity (Xu et al., 
2004). 
 
 
Figure 1.5: The structure of the activation loop and αC helix necessary for 
catalysis. Light blue indicates the N-terminal lobe and dark blue the C-terminal 
lobe. 
 
1.3.2.2 The regulatory domain 
The regulatory domain of PKCs was first identified in 1986, as a region separate 
to the catalytic part, able to bind diacylglycerol, calcium ions and 
phosphatidylserine (Lee and Bell, 1986). The regulatory portion of the protein is 
further segmented into a C1 domain, an autoinhibitory or pseudosubstrate 
sequence, and a C2 domain. In novel forms the C2 domain is replaced by a C2-like 
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domain, which is positioned at the N-terminus (Steinberg, 2008). In the inactive 
state the PKC regulatory region folds over and interacts with the catalytic region, 
thus regulating inappropriate catalytic activity. Activation of PKC-δ induces the 
release of C1 and C2, thus freeing the catalytic domain and allowing it to act.   
The pseudosubstrate sequence is N-terminal to the C1 domain and resembles the 
consensus sequence at which PKC isozymes bind and phosphorylate (Mellor and 
Parker, 1998). However, the phosphate-receiving serine or threonine is replaced 
by an alanine residue. In PKC-δ, binding of DAG or phorbol esters induces an 
activating conformational change. This releases the pseudosubstrate site, and 
leads to protein activation (Steinberg, 2008).  
 
1.3.2.3 PKC-δ C1 domain 
The C1 domain is a region of the regulatory domain of all PKCs. In classical and 
novel PKCs it is activated by DAG or phorbol ester binding (Ono et al., 1989). It is 
a 5kDa globular domain comprising of two β-sheets (Zhang et al., 1995) and is 
rich in cysteine residues (Ono et al., 1989).  The C1 domain is a conserved domain 
that is not only present in the PKC isoforms, but also in several other proteins 
including DAG kinase and PKD. In classical and novel isozymes there are two 
cysteine-rich regions; in atypical isozymes there is only one of these regions 
(Solodukhin et al., 2002). The cysteine-rich regions form  zinc finger structures; 
these are coordinated by two Zn2+ ions (Kazanietz et al., 1995). When the two β-
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sheets of the C1 domain are moved apart, a DAG and phorbol ester binding 
pocket is revealed (Giorgione et al., 2006). 
The C1 domain has been shown to sub-divide into two regions, a C1A and a C1B 
region (Hurley et al., 1997). Each of these regions contains a cysteine-rich zinc 
finger. These regions respond to DAG and phorbol esters (which mimic the action 
of DAG) (Cho, 2001).  In PKC-α, -βII, -δ and -ε C1A is seen to bind with a high 
affinity to DAG and C1B to phorbol esters (Stahelin et al., 2004; Steinberg, 2008). 
The differences in the C1 domain of the atypical isoforms means that it does not 
retain its normal function due to an impaired ligand-binding pocket (Giorgione et 
al., 2006).  
Binding of DAG to the PKC-δ C1 domain is phosphatidylserine (PS) dependent 
(Mellor and Parker, 1998; Stahelin et al., 2004). Interactions with PS allow the 
positioning of the C1 domain to be such that it can penetrate the membrane 
bilayer and bind DAG (Steinberg, 2008). Binding to DAG allows membrane 
targeting; the C1 is critical for this localisation and activation (Stahelin et al., 
2004). The PKC-δ C1 domain has a further capability that has not been identified 
in other isoforms. Tyrosine residues 155 and 187 can be phosphorylated. This can 
induce signalling differences that may, for example, cause enhanced growth (see 
1.3.3).  
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1.3.2.4 PKC-δ C2 domain 
The C2 domain is another domain of the PKC regulatory region. In classical 
isoforms the domain interacts with calcium ions, but this ability is lost in the C2 
domain of the novel isoforms (Ponting and Parker, 1996). The C2 domain is larger 
than the C1 domain with an approximate size of 16kDa (Giorgione et al., 2006).  It 
is also globular and composed primarily of β-strands, 8 in all, positioned anti-
parallel. Strands β1, β4, β7 and β8 form one β-sheet, whilst strands β2, β5 and β6 
form another (Figure 1.6). The C2 domain is conserved in synaptotagmins and 
phospholipases as well as PKCs (Ponting and Parker, 1996). The conservation of 
the C2 domain is demonstrated in crystal structures of numerous proteins; these 
indicate that there are two types of C2, the S-type and P-type (Essen et al., 1997). 
The two types show different arrangement of folding. The S-type variant is seen 
in synaptotagmin 1, whilst the P-type variant is seen in phospholipase C-δ and 
phospholipase A2 (Essen et al., 1997). Sequence analysis of PKC C2 domains 
indicates that classical PKCs adopt the S-type topology, whilst novel PKCs adopt 
the P-type.  
The PKC-δ C2 crystal structure confirms the P-type topology (Pappa et al., 1998). 
Superimposition of this structure with the relevant domains of synaptotagmin I 
and phospholipase C-δ reveal a similar core of four hydrophobic residues of 
leucine (position 5), proline (position 28), Phenylalanine (position 59) and a 
further leucine (position 108).  
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The PKC-δ C2-like domain does not respond to calcium ion levels as, although it 
has the general C2 domain features, it does not feature the loops that coordinate 
with calcium ions (Pappa et al., 1998). In fact the part of the C2 structure 
demonstrating the greatest contrast to other C2 structures is the area important 
in calcium ion-binding. This area is adjacent to three loops towards one end of 
the structure. In the PKC-δ C2 these loops show a considerably different 
conformation. Four out of the five residues which normally co-ordinate with the 
calcium ions are absent. The residue remaining is Asp79, which plays a structural 
role in the domain. Although there are many structural differences, the C2 
domain does still bind PS (Pappa et al., 1998). Binding of PS in novel PKCs appears 
to be constitutive.  
 
 
 
 
 
 
 
 
   
Figure 1.6: PKC-δ C2 domain structure showing the 8 β-strands (1-8). C 
indicates the C-terminal end, and N, the N-terminal end of the domain. 
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It is thought that the C2-like domain functions as a protein interaction domain in 
PKC-δ (Dekker and Parker, 1997; Mellor and Parker, 1998). For example, Lopez-
Lluch et al (2001) showed the C2 domain binding f-actin in neutrophils. This was 
an important interaction for enabling the redistribution of f-actin.  
 
1.3.3 PKC-δ regulation 
The PKC family of proteins are traditionally known to be activated via calcium ion 
and lipid binding (in the form of diacylglycerol (DAG)). Novel forms of PKCs, such 
as PKC-δ, are not affected by calcium ions, but can still be activated by DAG. This 
binding occurs at the C1 domain and allows the PKC-δ to be recruited to a 
membrane. In classical forms of PKC, the C2 domain shows some affinity for 
membranes where, following calcium activation, the C2 domain targets the 
membrane where C1 can bind. In PKC-δ, the C2 domain has no affinity for 
membranes; instead the C1 domain has an increased affinity (two orders of 
magnitude higher) (Giorgione et al., 2006). The C1A portion of the C1 domain is 
the region that interacts with the DAG (Stahelin et al., 2004). PKC-δ preferentially 
relocates to phosphotidylserine (PS) rich membranes. Interaction with PS allows 
the C1 to ‘unlock’ and bind DAG. The residue Glu177 is key in controlling DAG 
accessibility to the C1 domain (Stahelin et al., 2004).  
There are several tyrosine residues in PKC-δ and it has been considered that this 
may be a method of targeting the protein to the correct cellular region in order 
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to exert its effects appropriately. For example, the literature describes a situation 
where tyrosine phosphorylation occurred at two residues Tyr64 and Tyr155 in 
order to cause translocation of PKC-δ to the nucleus where it is cleaved and has 
pro-apoptotic effects (Humphries et al., 2008).  
Phosphorylation of different tyrosine residues has been identified after 
treatment of cells with etoposide. In this case, the affected residues are Tyr64 
and Tyr187 (Blass et al., 2002). Phosphorylation of these residues appears to be 
linked to etoposide-induced apoptosis. Following etoposide treatment, the PKC-δ 
became phosphorylated. This induced nuclear translocation where it was 
subsequently cleaved by caspases. Both the regulatory and catalytic domains 
were found necessary for this apoptotic pathway to occur. Mutants of PKC-δ, 
where 5 tyrosine residues were mutated to phenylalanine, showed decreased 
apoptosis. Caspase-3 activation and cleavage of the mutant PKC-δ were also 
lowered (Blass et al., 2002). Subsequent generation of mutants identified Tyr64 
and 187 as the key participants. 
H2O2 stimulation has been found to affect tyrosine phosphorylation. Tyrosine 
phosphorylation of residues 311, 332 (in the hinge region) and 512 (in the 
catalytic domain) has been identified (Konishi et al., 2001). Tyr311 appears to be 
the predominant site of phosphorylation. This tyrosine phosphorylation coincides 
with an increase in the activity of PKC-δ; however membrane targeting does not 
occur. An in vitro study identified that Lck could phosphorylate the Tyr311 
residue, and that this produced an increase in PKC-δ activity. Mutation analysis 
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was performed on the three residues, and although all three are phosphorylated 
following H2O2 stimulation, only Tyr311 mutation to phenylalanine produced an 
effect on activity.  
With respect to protein binding in H2O2 stimulated conditions, Morita et al (2008) 
found that EGFR phosphorylates Tyr332, but does not also do this under EGF 
treatment. They also identified PKC-δ p-tyr binding with an adaptor protein 
p66Shc (which contains two p-tyr binding domains), which they hypothesize may 
play a role in stress-signalling. 
Tyrosine 311 has been identified to be phosphorylated under further conditions. 
It is seen in αMβ2 (integrin) signalling, where clustering caused translocation of 
PKC-δ to the plasma membrane and Tyr311 phosphorylation by Hck and Lyn (Xue 
et al., 2010). Activation of PKC-δ has been found to be required for angiotensin II 
induced migration of vascular smooth muscle cells. Phosphorylation of Tyr311 
was identified as vital for this process (Nakashima et al., 2008).  
Additional phosphorylated tyrosine residues have also been identified. A Tyr52 
residue was identified to become phosphorylated in response to IgE receptor 
binding. Mutation studies showed the mutant was not phosphorylated following 
stimulation (Szallasi et al., 1995).  
Thrombin activity was found to cause tyrosine phosphorylation of Tyr311 and 
Tyr565 in platelets (Hall et al., 2007). Thrombin binding receptors PAR1 and PAR4 
induced activity of Src kinase and phospholipase C (PLC). Treatment of PMA also 
induced this phosphorylation and was dependent on Src activity. Membrane 
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recruitment of the PKC-δ was essential for phosphorylation, but phosphorylation 
was not required for membrane localisation. Both thrombin and PMA induce this 
translocation, however PMA does this independently of PLC. The thrombin 
activation causes an increase in PKC-δ activity (Hall et al., 2007). 
 
1.3.4 PKC-δ functional studies 
1.3.4.1 Gene knockout and knockdown studies 
In order to study the function of PKC-δ, several groups have prevented PKC-δ 
activity through the use of knockouts, or knockdowns using siRNA (Leitges et al., 
2001; Miyamoto et al., 2002; Steinberg, 2004).  PKC-δ knockouts are able to 
develop and reproduce normally but have defects in immunity and 
vascularisation (Steinberg, 2004). With respect to the immune system, the 
knockouts have hyperproliferative B-cells. This leads to the development of 
immune-complex glomerulonephritis, which is inflammation of the glomeruli in 
the kidney; this can result in renal failure. Hyperproliferation can also cause 
lymphocyte infiltration into organs (Miyamoto et al., 2002). There are also 
defects in neutrophil function. This was discovered in a stroke model where the 
absence of PKC-δ led to a reduction in reperfusion injury following thrombolysis. 
This was found to be associated with reduced migration of neutrophils into the 
tissue (Chou et al., 2004). 
The PKC-δ knockout mice have also been examined with respect to their 
likelihood to develop arteriosclerotic lesions where veins had been grafted into 
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carotid arteries. Vessels from the mice were further examined in vitro where the 
vessel from knockout mice showed further differences. Following UV irradiation 
fewer reactive oxygen species were produced. In addition when H2O2 treated, 
they were resistant to apoptosis (Leitges et al., 2001). 
In addition, studies have examined PKC-δ knockout mice for differences in 
apoptosis. PKC-δ-/- mice were examined to see if the absence of PKC-δ would 
protect salivary gland from apoptosis following treatment with γ-irradiation. This 
was the case, as the induction of apoptosis was suppressed by more than 60%. 
The knockout mice parotid cells showed defects in cytochrome C release 
following etoposide treatment. Caspase-3 activation was also reduced. The 
activation of p53 was examined following etoposide and γ-irradiation; this 
showed no differences between knockout or wild-type cells. This indicated 
activity of PKC-δ was after this point in the apoptotic induction mechanism. JNK is 
differentially activated between the cell types, suppression of activation is noted 
in knockout mice. PKC-δ must, therefore, act upstream of this point in DNA-
damage induced apoptosis (Humphries et al., 2006; Reyland et al., 1999). 
PKC-δ siRNA has been used to knockdown endogenous PKC-δ in order to examine 
cell binding via E-cadherin. In EGFR over-expressing cells, EGF can induce cell 
scattering. This process was found to be mediated by PKC-δ. EGF signalling 
caused internalisation of E-cadherin, thus releasing cell binding and allowing 
motility. By knocking-down PKC-δ, the internalisation of E-cadherin was 
prevented and therefore cell scattering was also inhibited (Singh et al., 2009). 
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1.3.4.2 The role in apoptosis 
Apoptosis, programmed cell death, is a method of eliminating cells for tissue 
homeostasis. The activation of this mechanism is complex with numerous 
activating and inhibiting proteins involved (Koriyama et al., 1999). PKC-δ has 
been identified to have a role in the apoptotic mechanism, and although this role 
has not been fully elucidated, numerous stages of this pathway have been 
revealed (see below).  
During induction of apoptosis the full PKC-δ protein is cleaved, thus activating it 
and allowing it to initiate the apoptotic program in the nucleus, however its 
precise activity remains unknown (Koriyama et al., 1999). When treated with 
apoptotic agents, camptothecin or etoposide, cleaved protein fragments at 
40kDa can be identified on a western blot. Caspase-3 (or caspase-3-like) was 
found to be the enzyme responsible for cleavage of PKC-δ. This was discovered 
when Ac-DEVD-cho (acetyl-Asp-Glu-Val-Asp aldehyde), which specifically 
prevents caspase-3 family activity, had an inhibitory effect on fragment 
formation (Koriyama et al., 1999). The caspase-3 cleavage sites are unknown, 
however the size of fragments indicates that cleavage occurs in the hinge region.  
As mentioned above, in order to perform its apoptotic function, PKC-δ was found 
to translocate to the nucleus; such translocation would require a nuclear 
localisation signal (NLS). The NLS of PKC-δ was found to be in the C-terminal end 
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of the protein (Humphries et al., 2008). The reason why this sequence does not 
localise PKC-δ to the nucleus in non-apoptotic cells, and instead allows it to 
remain in the cytoplasm is as yet unclear. There is suggestion that tyrosine 
phosphorylation is involved in this process. Without this phosphorylation the 
PKC-δ is in a conformation wherein the nuclear localisation signal is shielded, 
thus preventing translocation. Phosphorylation at tyrosine residues 64 and 155, 
in the N-terminal regulatory domain, has been found to induce a change that 
reveals the NLS, thus directing nuclear translocation. Mutation of these residues 
to phenylalanine prevented apoptotic induction. However the phosphorylation 
itself is not seen to be vital for nuclear localisation, as a mutant from tyrosine to 
aspartic acid, which is phosphomimetic, allows nuclear accumulation.  
The tyrosine phosphorylation of PKC-δ can be induced through treatment of 
apoptotic agents such as etoposide (Humphries et al., 2008). Etoposide 
treatment of parC5 cells shows an increase in PKC-δ phosphorylation at 30 
minutes of treatment, peaking at 60 minutes and decreased to normal levels 
after 90 minutes of treatment (Humphries et al., 2008). The proteins responsible 
for this phosphorylation are Src-like tyrosine kinase family members and c-Abl; 
inhibition of these proteins using the Src inhibitor PP2, blocks both basal tyrosine 
phosphorylation and that induced by etoposide treatment (Kajimoto et al., 2010).  
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1.3.4.3 Other important cancer-related functions of PKC-δ 
In multicellular organisms the processes of proliferation and apoptosis are 
regulated in order to maintain tissue homeostasis. The two processes are 
normally regulated in non-cancerous tissues, however where proliferation is 
increased over the normal levels, neoplasias result, which can be malignant. 
Uncontrolled cell proliferation is a hallmark of cancer. Proliferation is a highly 
complex process mediated by cell cycling during which an increase in cell size and 
volume of intracellular organelles and other material precedes cell division.   
PKC-δ has been shown to demonstrate anti-proliferative activity (Vucenik et al., 
2005). IP6 has been seen to have an anti-cancer function in vitro and in vivo, 
where it has inhibited growth through inducing cell cycle arrest at G1. IP6 
treatment of MCF-7 cells induced an increase in activity of PKC-δ.  
However the role of PKC-δ in proliferation is not clear (Griner and Kazanietz, 
2007; Jackson and Foster, 2004). A role of PKC-δ as a positive regulator of growth 
has also been indicated; this is via activity in the Ras/ERK1/2 pathway (Grossoni 
et al., 2007; Keshamouni et al., 2002; Lønne et al., 2009). Thus it seems PKC-δ 
may perform a multitude of downstream functions dependent on the activating 
signal, differential tyrosine phosphorylation status (Brodie and Blumberg, 2003; 
Griner and Kazanietz, 2007), and associated proteins.  
The structure of the cytoskeleton is important with respect to a cell’s ability to 
become motile and metastasize. Lopez-Lluch et al (2001) described PKC-δ binding 
the actin cytoskeleton in neutrophils. This interaction was via the C2 domain. 
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PKC-δ localised with f-actin filaments in the lamellipodia at the leading edge. The 
binding, and action, of PKC-δ enables the remodelling of the cytoskeleton and 
motility of the neutrophil (Lopez-Lluch et al., 2001). If this motility was facilitated 
in cancer, a cell may be able to relocate and form a secondary tumour. 
Additional studies have examined the interactions associated with PKC-δ and the 
cytoskeleton. Chen et al (2007) further demonstrated PKC-δ binding the 
cytoskeleton and also noted the PKC-δ phosphorylation of adducin.  Adducins 
promote spectrin and actin interactions allowing the formation of a meshwork.  
Phosphorylation of adducin downgrades these interactions, suggesting that 
phosphorylation may allow breakdown of the meshwork. Where PKC-δ was over-
expressed, membrane protrusions were identified. At the edges of the 
protrusions, PKC-δ, adducin and phosphoadducin were detected. This indicates 
that by acting on adducing PKC-δ may enhance cell motility.  
A further role for PKC-δ in cytoskeleton structure has been identified; this is 
related to the MUC-1 protein. The MUC-1 cytoplasmic domain has been found to 
interact with several proteins including: β-catenin, erbB receptors, src, GSK-3β 
and PKC-δ (Schroeder et al., 2003).  PKC-δ phosphorylates a threonine residue in 
a T41DR sequence, this allows β-catenin to be recruited to the MUC-1 (Ren et al., 
2002).  β-catenin thus dissociates from E-cadherin, which is important in cell-cell 
contacts at adherens junctions. When bound to β-catenin, E-cadherin is linked to 
the cytoskeleton via α-catenin (Ren et al., 2002) (Fig. 1.7).  The movement of β-
catenin permits loss of contacts, allowing cell motility (Schroeder et al., 2003).   
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Figure 1.7: The involvement of MUC-1, β-catenin and PKC-δ in cell adhesion 
and motility. β-catenin binds E-cadherin to the cytoskeleton via α-catenin in 
order to maintain cell contacts and rigidity. On phosphorylation of MUC-1, by 
PKC-δ, β-catenin dissociates from E-cadherin, and α-catenin and the 
cytoskeleton, and bind MUC-1. The loss of β-catenin from the complex enables 
cell motility (Ren et al., 2002). 
 
1.3.5 PKC-δ C2 interactions 
Several studies suggest that the C2 domain of PKC-δ may be a protein interaction 
domain. Dekker and Parker (1997) were the first to identify a C2-like domain in 
PKC-δ. They found that this region bound to the PKC-δ substrate GAP-43.  
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A later study further examined the role of PKC-δ C2 binding in neutrophils (Lopez-
Lluch et al., 2001). They discovered that the C2 domain bound f-actin. When the 
C2 region was injected into areas where there was no localisation of actin, there 
was major disruption to the actin cytoskeleton. 
Benes et al (2005) examined the C2 domain to discover if there was a particular 
region that could be attributed to the protein binding activity demonstrated in 
the literature. They found that, in addition to the two families of 
phosphotyrosine binding (PTB) domains known, there was a third type of which 
the C2 domain can also be considered a member.  PTBs were initially identified in 
classical PKC’s where they allowed calcium and lipid binding.  The C2 domain 
present in PKC-δ is also seen in other PKCs where the calcium binding property is 
not retained; in PKC-δ the PTB lipid binding property is also lost.   
An interaction was identified between PKC-δ and a transmembrane protein 
CDCP1, which is over-expressed in colon cancer (Benes et al., 2005).  A 
correlation between the CDCP1 tyrosine phosphorylation state and the 
interaction with the PKC-δ regulatory domain was noted.  This suggested that the 
regulatory domain of PKC-δ contained a PTB region.  Screens of a 
phosphotyrosine peptide library and a subset of peptides containing tyrosine or 
phenylalanine at a position 3 residues C-terminal to phosphotyrosine showed the 
regulatory domain did indeed have a PTB with a consensus sequence of Y/F-S/A-
V/I-pY-Q/R-X-Y/F-X (Benes et al., 2005). These screens also suggested that MUC-1 
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may have such a sequence, inferring a possible interaction at the C2 domain in 
the role described in 1.3.4.3. 
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1.4 PKC-δ and breast cancer 
 
1.4.1 Clinical correlations 
A study in 1989 examined clinical samples from normal breast tissue and breast 
tumours. They identified that the levels of PKC found in the samples from the 
tumours were higher than in normal breast tissue (O'Brian et al., 1989). A further 
study (Gordge et al., 1996), showed the increase in PKC activity to be calcium-
dependant .  
A later study, in 2008, specifically examined PKC-δ expression in clinical samples. 
PKC-δ expression was greater in ER+ tumours compared with ER- tumours. In 
addition, a higher level of PKC-δ expression correlated with reduced survival of 
the patient. The grade 3 tumours had higher PKC-δ expression than the grade 1 
and 2 tumours, correlating with the findings related to survival (McKiernan et al., 
2008). 
PKC-α was also found to share a correlation with the ER status of tumours; PKC-α 
and PKC-δ levels were examined in combination to further investigate this 
feature. Where PKC-δ and PKC-α levels were examined, high PKC-δ was found in 
ER+ tumours, whilst high PKC-α was found in ER- tumours. Where PKC-δ was 
expressed and PKC-α was not, these patients had an endocrine response to 
tamoxifen 6-times longer than those with PKC-δ and PKC-α expression (Assender 
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et al., 2007). This suggests that examining both PKC-δ and PKC-α levels could 
enable a treatment regime tailored to the patients requirements. 
 
1.4.2 Cellular studies 
In addition to the clinical research, studies in cell lines have also examined PKC 
levels. These studies showed that PKC levels were higher in tumours that were 
ER- compared with those that were ER+ (O'Brian et al., 1989).  
Specific isoform studies examined the correlations between PKC-δ levels and ER 
status further. Shanmugam et al (1999) found oestrogen treatment of ER+ MCF-7 
breast cancer cells resulted in decreased PKC-δ protein levels. This indicates a 
role for PKC-δ in ER signalling.  In addition, the expression of the PKC-δ and PKC-α 
isoforms in ER+, either tamoxifen sensitive or resistant, and ER- cell lines were 
examined. The ER+ cells lines expressed PKC-δ but very little PKC-α levels. This 
was the opposite in ER- cell lines. The tamoxifen resistant ER+ cell lines strongly 
expressed both isoforms (Assender et al., 2007). Treatment resistance is a 
growing problem in oncology. This data indicates PKC-δ may have a role in 
tamoxifen resistance. Possible roles of PKC-δ need to be investigated further in 
order to develop methods for overcoming resistance.  
Further investigation into tamoxifen-resistance showed PKC-δ aided cell growth 
where cells were oestrogen sensitive (Nabha et al., 2005). Over-expression of 
PKC-δ in tamoxifen sensitive cells led to cells developing resistance. Higher PKC-δ 
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levels are found in tamoxifen resistant tumours than sensitive tumours. This 
indicates PKC-δ could be a target for treatment in tamoxifen resistance. 
A further study examined radiation sensitivity in relation to PKC-δ activity.  PKC-δ 
was found to protect against ionising radiation. Where cells were treated with an 
anti-sense oligonucleotide against PKC-δ, cell survival, following 5.6Gy γ-
radiation, was inhibited (McCracken et al., 2003).  
 
1.4.3 Apoptosis 
In order to better understand how PKC-δ aids or hinders cell survival, the 
involvement of PKC-δ in apoptosis has been studied in numerous cell types 
(Brodie and Blumberg, 2003). These studies indicate a pro-apoptotic role for PKC-
δ (see 1.3.4.2). Similar studies have been performed in MDA-MB-231 breast 
cancer cells. These showed that PKC-δ had an anti-apoptotic activity in these cells 
(Lønne et al., 2009). Investigation of this effect showed that the anti-apoptotic 
mechanism was active due to a ras mutation in the cell line. This mutation causes 
over-phosphorylation of ERK1/2. The PKC-δ inhibited NEDD4, which would 
normally ubiquitinylate MKP3 causing its degradation. MKP3 reduced the 
phosphorylation level of ERK1/2 to a level at which it was not fatal, thus allowing 
the cells to survive. This activity was proteasome-dependent. Where proteasome 
activity was inhibited the MKP3 could not be degraded, therefore the de-
phosphorylation of ERK1/2 was still possible and the cells survived (Lønne et al., 
2009). 
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1.4.4 Cytoskeleton and metastasis 
PKC-δ has been shown to interact with the cytoskeleton in numerous cell types 
(see 1.3.4.3). The cytoskeleton enables a cell to form a stable structure; the 
cytoskeleton links to focal adhesions where the cell attaches to a surface. 
Alterations in the cytoskeletal links to the adhesive structures allow the cell to 
become flexible and motile. Evidence indicates that PKC-δ interaction with the 
cytoskeleton may affect the ability of cells to become motile, as described below. 
Kiley et al (1999b) demonstrated that PKC-δ displayed a positive effect towards 
metastasis in breast cancer cell lines.  Relative levels of PKC-δ were greater in 
those cell lines which displayed a highly metastatic growth pattern.  PKC-δ over-
expression in cell lines displaying low or moderate metastatic activity showed 
significant increase in anchorage-independent cell growth.  This anchorage-
independent growth was inhibited when the regulatory fragment of PKC-δ was 
over-expressed.  Examination of this effect revealed the sub-cellular localisation 
of PKC-δ and phosphorylation of adducin was altered.  This suggests a link by 
which PKC-δ may alter a cell’s migration and adhesion phenotype. 
Further studies by Kiley et al (1999a) have additionally indicated an important 
role for PKC-δ in metastasis of breast cancer.  Cell lines were developed from 
mammary tumours in the rat fat pad, one of these demonstrated a more rapid 
growth pattern and greater metastatic potential.  Upon examination, a 3-fold 
greater expression of PKC-δ was discovered.  Upon induction of PKC-δ regulatory 
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fragment expression in mice, the growth of primary tumours was not affected, 
however the development of metastases were reduced. 
PKC-δ interactions demonstrate a clear relationship with metastasis through the 
literature. However, when contemplating the Kiley papers (1999a; 1999b) it is 
worth noting that the over-expression of the regulatory domain could create the 
illustrated effect through ‘mopping up’ of DAG and thus thwarting PKC-δ 
activation, rather than binding to the catalytic domain and preventing its action. 
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1.5 Studying PKC-δ C2 domain in breast cancer cell lines 
 
MDA-MB-468 (Cailleau et al., 1978), MDA-MB-231 (Cailleau et al., 1974) and 
MCF-7 (Soule et al., 1973) are well characterised cell lines originating from breast 
adenocarcinomas. All are epithelial type obtained from female patients of 51-69 
years of age. Numerous differences have been observed in the literature 
between these cell lines, some of which are summarised in Table 1.2 (Lønne et 
al., 2009; Rincon et al., 2004; Shanmugam et al., 2001). Differences in signalling 
have been noted, whereby inhibition of the ERK1/2 pathway supports survival in 
MDA-MB-231 cells but does not in MDA-MB-468 and MCF-7 (Lønne et al., 2009). 
Thus as breast cancer tumours display wide heterogeneity, it is hoped that a 
more complete picture of PKC-δ involvement, in differing breast cancers, can be 
obtained by studying these three cell lines which, although all originating from 
breast epithelial adenocarcinomas, demonstrate significant differences. 
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Table 1.2: Differences between MDA-MB-468, MDA-MB-231 and MCF-7 cell 
lines 
 MDA-MB-468 MDA-MB-231 MCF-7 
Karyotype1 hypodiploid hypotriploid hypotriploid to 
hypotetraploid 
Oestrogen receptor1 - - + 
Progesterone receptor1 - - - 
Her2 receptor2 - - - 
Ras mutation3 - + - 
PKC-δ levels4 As MCF-7 Lower than MCF-7 Higher than MDA-
MB-231 
Retinoic acid activates 
PKC-δ to lower IRS-15 
- - + 
Genistein response6 Apoptosis Growth arrest Stimulates growth 
1(Cell lines service) 2(Tseng et al., 2006; Yamaguchi et al., 2005) 3(Lønne et al., 2009) 
4(Shanmugam et al., 2001) and thesis data 5(Rincon et al., 2004) 6(Dampier et al., 2001) 
 
Literature demonstrates the extensive involvement of PKC-δ in signalling events 
within the cells (Chen et al., 2009; Kharait et al., 2006; Khwaja and Tatton, 1999; 
Vucenik et al., 2005). PKC-δ been identified as a key component of the apoptotic 
pathway, whereby its nuclear translocation and cleavage between the regulatory 
and catalytic domains allow its action in the nucleus (DeVries-Seimon et al., 2007; 
Humphries et al., 2008). Due to the wide action of PKC-δ, creating cell lines which 
over-express the protein, and which over-express the C2 domain of the protein, 
allows analysis of the effects on cell signalling pathways.  
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1.6 Aims 
 
The C2 domain is a regulatory domain that has been identified as a protein 
binding region in particular circumstances. Expression of the C2 domain was 
hypothesised to interfere with endogenous PKC-δ activity through competitive 
inhibition of interactions with binding partners; Figure 1.8 is an illustration of this 
hypothesis. The reactions of the cells to myc-δC2 expression will indicate the role 
of the endogenous PKC-δ in the cells. There may be differing roles with the 
differing cell lines and roles of PKC-δ.  
 
 
 
 
 
 
Figure 1.8: Model for the hypothesis of how the myc-δC2 over-expression will 
affect endogenous PKC-δ. The endogenous PKC-δ C2 domain is out-competed 
for the binding partner, thus the normally occurring pathway is affected. 
 
This thesis investigates this premise, and the effects of myc-δC2, or myc-PKC-δ, 
expression upon the cell lines. The interruption of endogenous PKC-δ signalling 
by myc-δC2 aims to reveal alterations in the cell profile, thus allowing analysis of 
Binding 
Partner 
myc-δC2 
PKC-δ 
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endogenous PKC-δ activity. Identification of myc-δC2 localisation aims to reveal 
information regarding the role for the C2 domain in PKC-δ function. Subsequent 
analysis of the cell lines and their differences will allow further, in-depth, 
clarification of the importance of the C2 domain to PKC-δ activity. Literature 
evidence indicates PKC-δ plays a role in key factors such as cell death and motility 
(Humphries et al., 2008; Kiley et al., 1999b). Thus, this investigation aims to 
reveal a clearer picture as to whether the C2 domain may be a suitable target for 
interfering with these key processes to provide a cancer treatment.   
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 Chapter 2: Materials and Methods 
 
2.1 Materials 
 
Table 2.1: Buffers 
Buffer Recipe Storage 
10x TAE  0.8M Trizma base(Sigma, Gillingham, UK), 
1.1% glacial acetic acid, 0.1M EDTA 
Room 
Temperature 
(RT) 
1x PBS 1 tablet (Oxoid, Basingstoke, UK) dissolved 
in 100ml water, tablets contain: sodium 
chloride 8g/l, potassium chloride 0.2g/l, di-
sodium hydrogen phosphate 1.15g/l, 
potassium dihydrogen phosphate 0.2g/l 
RT 
Cell lysis 
MUC-1 lysis buffer  50mM tris-HCl pH7.6, 150mM NaCl, 0.1% 
Nonidet P-40 substitute, 1mM 
dithiothreitol (DTT), 1 (cOmplete mini 
EDTA-free) Protease inhibitor cocktail 
tablet (Roche, Basel, Switzerland) 
-20°C 
IP lysis buffer stock  150mM NaCl, 1% Nonidet P-40 substitute, 
50mM Tris-HCl pH8 
RT 
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10x Phosphatase 
inhibitor mix  
250mM β-glycerophosphate, 100mM 
sodium tartrate, 50mM sodium molybdate, 
100mM sodium vanadate 
-20°C 
IP lysis buffer  90% IP lysis buffer stock, 10% 10x 
Phosphatase inhibitor mix, 1 Protease 
inhibitor cocktail tablet 
-20°C 
SDS-PAGE and Western blotting 
20x Running buffer  0.8M Tricine, 1.2M Trizma base, 70mM 
sodium dodecyl sulphate (SDS), 50mM 
sodium bisulphite 
RT 
Towbin transfer buffer  25mM Trizma base, 200mM glycine, 1mM 
SDS, methanol was added just prior to use 
in the ratio 8ml buffer to 2ml  methanol 
RT 
PBST PBS with 0.1% Tween 20 RT 
PBSTM PBST with 0.5% Marvel milk powder RT 
Flow cytometry 
10x FITC-AnnexinV 
binding buffer 
0.1M HEPES pH7.4, 1.4M NaCl, 25mM 
CaCl2, made in water  
4°C 
Hypotonic 
fluorochrome solution  
40μM sodium citrate, 1% Triton X-100, 
50μg/ml propidium iodide, 0.1mg/ml 
RNase A (Sigma, Gillingham, UK)  
4°C 
Immunofluorescence 
Fixation buffer  4% formaldehyde, 0.1% glutaraldehyde, in 
PBS 
-20°C 
Permeabilization 
buffer  
0.5% triton X-100, in PBS -20°C 
Quenching buffer  1mg/ml sodium borohydride, in PBS Fresh 
Blocking buffer  5% goat serum, in PBS -20°C 
FITC-Phalloidin 0.1% FITC-Phalloidin, in PBS Fresh 
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solution 
 
Table 2.2: Antibodies 
Antibody Usage Storage 
PKC-δ antibody  
(western) 
1:500 PKC-δ antibody (C-20 and C-17) diluted in 
PBST (sc-937 and sc-213, Santa Cruz 
Biotechnology, Santa Cruz, CA,USA) 
Fresh 
c-myc antibody 
(western) 
1:500 c-myc antibody (9E10)diluted in PBST 
(GTX75953, GeneTex, Irvine, CA,USA) 
Fresh 
ERK1/2 antibody 
(western) 
1:1000 ERK1/2 antibody diluted in PBST (4696S, 
Cell Signalling Technology, Danvers, MA, USA) 
Fresh 
Phosphorylated-
ERK1/2 antibody 
(western) 
1:1000 phosphorylated ERK1/2 antibody diluted 
in PBST (9101S, Cell Signalling Technology, 
Danvers, MA, USA) 
Fresh 
Phosphorylated-
tyrosine antibody 
(western) 
1:500 p-tyrosine antibody diluted in PBST 
(ab9319, Abcam, Cambridge, UK) 
Fresh 
Histone antibody 
(western) 
1:2000 histone H3 antibody diluted in PBS and 
5% milk (ab1791, Abcam, Cambridge, UK) 
-20°C 
Anti-rabbit antibody 
(western) 
1:2000 anti-rabbit antibody diluted in PBST 
(NA934V, GE Healthcare, Little Chalfont, UK) 
Fresh 
Anti-mouse antibody 
(western) 
1:2000 anti-mouse antibody diluted in PBST 
(NA931V, GE Healthcare, Little Chalfont, UK) 
Fresh 
c-myc antibody 
(immunofluorescence) 
1:50 dilution of c-myc antibody (9E10) in 
blocking buffer (GTX75953, GeneTex, Irvine, 
CA,USA) 
Fresh 
Goat anti-mouse 
antibody 
(immunofluorescence) 
1:500 Goat anti-mouse DyLight 549 conjugated 
antibody in blocking buffer (35508, Thermo 
Scientific Pierce Protein Research Products, 
Rockford, IL,USA) 
Fresh 
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Table 2.3: Cell lines 
Cell line Growth requirements 
MDA-MB-468 
(Cailleau et al., 1978) 
Sourced from ATCC* 
RPMI 1640 (Sigma, Gillingham, UK) and 10% (heat inactivated) 
Fetal Bovine Serum (Sigma, Gillingham, UK), 37°C and 5% CO2 
Transfectants: 350µg/ml G418 (Source Biosciences Lifescience, 
Nottingham, UK) 
MDA-MB-231 
(Cailleau et al., 1974) 
Sourced from ATCC 
RPMI 1640 and 10% (heat inactivated) Fetal Bovine Serum, 37°C 
and 5% CO2 
Transfectants: 350µg/ml G418 
MCF-7 (Soule et al., 
1973) 
Sourced from ATCC 
RPMI 1640 and 10% (heat inactivated) Fetal Bovine Serum, 37°C 
and 5% CO2 
Transfectants: 500µg/ml G418 
*ATCC is the American Type Culture Collection (Teddington, UK) 
 
Restriction enzymes 
NotI, BamHI, XbaI, NheI, T4 DNA polymerase and Shrimp Alkaline Phosphatase 
(Promega, Madison, WI, USA) 
Quick ligase and SmaI (New England Biolabs, Hitchin, UK) 
 
Other Cloning reagents 
Oligonucleotides (Sigma-Genosys, Haverhill, UK) 
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Strataprep DNA extraction kit (Stratagene, La Jolla, CA, USA) 
Loading dye 6x (New England Biolabs, Hitchin, UK) 
1Kb DNA Marker (New England Biolabs, Hitchin, UK) 
16.7% marker to 66.6% water and 16.7% loading dye 
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2.2 Methods 
 
2.2.1 Cloning pIRES-myc-δC2 
Primers were designed which would bind either side of the myc-δC2 sequence in 
the pEFLINKtag-myc-δC2 construct (Fig. 2.1 and 2.2, also see Fig. 3.3), and which 
would enable incorporation of NotI and NheI restriction sites on either end of the 
amplified sequence. The sequence was PCR amplified, using Pfu polymerase. 
Following PCR, 3’ A-overhangs were added using Taq polymerase in order for the 
insert to be compatible with the pCR2.1 TOPO shuttle vector (Invitrogen, Paisley, 
UK). Once reacted together, as in the TOPO TA Cloning kit (Invitrogen, Paisley, 
UK) instructions, the construct was transformed into OneShot Top10 chemically 
competent Escherichia coli (Invitrogen, Paisley, UK) and grown up before 
collection of the construct using Wizard Plus Minipreps (Promega, Madison, WI, 
USA) kit. NotI and NheI enzymes were used for splicing myc-δC2 sequence from 
the pCR2.1TOPO vector into pre-digested pIRESneo2 empty vector (Clontech, 
Saint-Germain-en-Laye, France).   
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ACTGTGTTCACTAGCAACCTCAAACAGACACCATGCCGGAGCAGAAGCTGATATCCGAGGAGGACC
TGGCCATGGCCGGATCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTGCACCGTTCCTGCGCATCT
CCTTCAATTCCTATGAGCTGGGCTCCCTGCAGGCGGAGGACGACGCAAGCCAGCCTTTCTGTGCCG
TGAAGATGAAGGAGGCACTCACCACAGACCGAGGGAAGACTCTGGTACAGAAGAAGCCCACCATGT
ACCCTGAGTGGAAGTCAACATTCGACGCCCACATCTATGAAGGCCGTGTCATCCAGATCGTGCTGA
TGCGGGCAGCTGAAGACCCCATGTCGGAGGTGACCGTGGGCGTGTCAGTGCTGGCTGAGCGCTGCA
AGAAGAACAACGGCAAGGCTGAGTTCTGGCTGGACCTGCAGCCTCAGGCCAAGGTGCTGATGTGTG
TGCAGTATTTCCTAATTCCTCGAGATCGATTAGACTAGTCTAGAAATTCACCCCACCA 
 
Figure 2.1: The pEFLINKtag-myc-δC2 insert sequence. Underlined sections 
indicate primer binding sequences, yellow highlighted areas the myc tag 
sequence, and the red highlighted letters indicate the beginning and ends of 
the C2 sequence. 
 
Forward primer: 5’-GCCGGCTAGCACTGTGTTCACTAGCAAC-3’ 
Reverse primer: 5’-GCATGCGGCCGCTGGTGGGGTGAATTTCTAGACT-3’ 
 
Figure 2.2: Primer sequences for either side of the myc-δC2 sequence. The 
incorporated restriction sites are highlighted. A NheI restriction site was 
incorporated in the forward primer, and a NotI restriction site in the reverse 
primer. Four extra bases were added on the 5’ ends of each primer to enable 
the restriction enzymes to bind. 
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2.2.2 Cloning pIRES-mycPKC-δ 
In order to create the pIRES-myc-PKC-δ construct, first the PKC-δ sequence was 
spliced out of the pEFLINKtag-myc-PKC-δ using XbaI and NotI, but the myc-tag 
was left in the vector.  The δC2 sequence was then spliced out of the pIRES-myc-
δC2 vector construct using BamHI and NotI, but the myc-tag was left intact within 
the vector. After running the samples on an agarose gel, the fragments for the 
PKC-δ sequence and the pIRES-myc were isolated. The two fragments were then 
ligated together to form the pIRES-myc-PKC-δ construct.  
 
2.2.3 Plasmid purification 
When generating more plasmid for cloning reactions, or when growing up 
transformed colonies to check for the presence of the correct construct, plasmid 
was purified from the culture using a Wizard Plus Minipreps kit. In this kit, the 
culture was spun down in order to concentrate the cells into a pellet. Then the 
pellet was re-suspended and lysed following the kit protocol. The plasmid DNA 
was eluted from the purification column in 100μl nuclease-free water.  
When constructs were required for transfection, larger preparations of the 
constructs were made. First by transforming OneShot E.coli with the construct, 
and then growing up single colonies in 200ml LB broth with 100μg/ml ampicillin 
before extracting the plasmid using Wizard Plus Maxipreps kit (Promega, 
Madison, WI, USA). 
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2.2.4 Cell culture 
MDA-MB-468 cells were grown in RPMI-1640 medium with 10% FBS in Corning 
75cm2 vented flasks.  To sub-culture, media was aspirated and cells washed in 
10ml of sterile PBS solution.  1ml of trypsin (Sigma, Gillingham, UK) was added 
and the cells incubated at 37°C to allow trypsinisation.  Flasks were tapped to 
dislodge cells and observed under the microscope until detached.  6ml of media 
was added to neutralise the trypsin.  Two new flasks containing 10ml media were 
prepared and 2ml of the detached cells added to each.  Remaining cells were 
disposed of.  Cultures were incubated at 37°C in 5% CO2 in a humidified 
incubator.  
 
2.2.5 Stable transfection 
2.2.5.1 MDA-MB-468 cells 
The MDA-MB-468 cell line was transfected using FuGENE6 (Roche, Basel, 
Schweiz) transfection reagent. Reactions were set up for transfecting with pIRES-
myc-δC2, pIRES-myc-PKC-δ and pIRES vector alone, along with a cell control.  
Cells were seeded at 8.7 x 105 density in a circular plate with a 10cm diameter 
with 11.6ml media. These were incubated for approximately 2-3 days to ensure 
attachment had occurred and growth had begun.  
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The volumes in the reaction mixes are shown in Table 2.4. Volumes of DNA were 
calculated in order to add 5.6μg DNA. Firstly FuGENE6 was added to a microfuge 
tube containing the serum-free (SF)-RPMI. The microfuge tubes were vortexed 
and then incubated at room temperature for 5 minutes. Secondly the DNA was 
added to these mixtures and the tubes vortexed before incubating at room 
temperature for 15-30 minutes. The solutions were added dropwise to the plated 
cells whilst swirling the plate to mix. 
 
Table 2.4: Volumes of serum-free (SF) RPMI, DNA and FuGENE6 in transfection 
samples. 
 SF-RPMI FuGENE6 DNA 
pIRES-myc-δC2 562.6μl 17.4μl 11.8μl 
pIRES-myc-PKC-δ 562.6μl 17.4μl 6.7μl 
pIRES Vector 
control 
562.6μl 17.4μl 10.4μl 
Cell Control 580μl - - 
 
Cells were incubated for approximately 2-3 days to allow transfection and 
production of the protein coded for by the transfected plasmid. Then G418 
antibiotic was added to the plates so that a concentration of 350μg/ml (identified 
in a kill-time experiment, see Table 3.1) was reached. 
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2.2.5.2 MDA-MB-231 and MCF-7 cells 
The MDA-MB-231 and MCF-7 cell lines were transfected using FuGENEHD 
(Promega, Madison, WI, USA) transfection reagent. As with MDA-MB-468 cells, 
reactions were set up for transfecting with pIRES-myc-δC2, pIRES-myc-PKC-δ and 
pIRES vector alone, along with a cell control. 
MDA-MB-231 cells were seeded at 2.5 x 106 density in a 10cm plate with 12ml 
media. MCF-7 cells were seeded at 1.87 x 106 density in a 10cm plate with 12ml 
media. Plates were incubated for approximately 1-2 days to ensure attachment 
had occurred and growth begun.  
The volumes in the reaction mixes are shown in Table 2.5. Volumes of DNA were 
calculated in order to add 20μg DNA. The SF-RPMI and DNA were mixed in a 
microfuge tube and vortexed. To these reactions, 60μl FuGENEHD was added. 
The microfuge tubes were vortexed and then incubated at room temperature for 
10 minutes. The solutions were added to the plated cells whilst tilting the plate to 
mix. 
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Table 2.5: Volumes of serum-free (SF) RPMI and DNA in transfection samples. 
 SF-RPMI DNA 
pIRES-mycC2 959μl 41μl 
pIRES-mycPKC-δ 977μl 23μl 
pIRES Vector control 964μl 36μl 
Cell Control 1000μl - 
 
Cells were incubated for approximately 60 hours before G418 was added to the 
plates. MDA-MB-231 cells were treated for a concentration of 350μg/ml. For 
MCF-7 cells G418 was added to the plates for a concentration of 500μg/ml. 
 
2.2.6 Cell lysis 
Lysis buffer was added to the cells and incubated on ice for 30 minutes. For a 
T75, 750μl was used, for a 10cm plate, 500μl was used. The cells were scraped 
from the flask/plate and the lysate put into a microfuge tube. The lysate was 
homogenised using 10 compressions of a syringe with a 25G needle. Cell lysate 
was cooled briefly on ice and centrifuged at 17000xg for 20 minutes at 4°C.   
On occasions where a particular number of cells needed to be lysed, cells were 
trypsinised and counted, the relevant number of cells was pipetted into a 
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microfuge tube which was then centrifuged for 3 minutes at 500xg. The 
supernatant was removed and lysis buffer added (approximately 500μl) to the 
cell pellet. Cells were resuspended before incubating on ice for 30 minutes to 
allow lysis. As above the lysate was then homogenized with a needle and 
centrifuged. 
 
2.2.7 Bradford assay 
When the amount of protein loaded onto a gel was required to be equivalent 
across all samples, a Bradford assay was performed. Bio-Rad protein assay 
reagent (Bio-Rad Laboratories, Hemel Hempstead, UK) was diluted 1 in 4 with 
reverse osmosis (RO) filtered water. 1ml of diluted reagent was added to each 
cuvette required. 2µl sample was added to the cuvette (performed in triplicate) 
and left to react for a few minutes. Cuvettes were mixed and colour measured, 
compared to a blank control, on a UV-VIS spectrometer at 595nm. Averages of 
the triplicates were calculated, and this value used to find the amount of protein 
in the sample, using a standard curve. The volume of sample required for a 
particular amount of protein was then calculated, and this was added to a gel. 
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2.2.8 SDS-PAGE 
The 4-20% gradient gel (Expedeon, Harston, UK) was removed from the storage 
packet and the wells rinsed twice with deionised water.  20x RunBlue running 
buffer (Expedeon, Harston, UK) was diluted to 1x with deionised water prior to 
use.  This was poured between the cassettes and half way up the reservoir.  4x 
loading buffer (Expedeon, Harston, UK) was mixed with the samples in the ratio 1 
part buffer to 3 parts sample (as manufacturer recommends).  The gel was 
loaded with 7μl RunBlue Prestain Markers (Expedeon, Harston, UK) and 
approximately 20μl samples and run at 180V for approximately 35-45 minutes. 
 
2.2.9 Western blotting 
The SDS-PAGE gel was removed from the cassette and trimmed.  Using the 
Hoefer TE70X semi-dry transfer kit (Hoefer Inc., Holliston, MA, USA), layers were 
compiled of a Mylar mask (optional), 3x 3MM paper, nitrocellulose membrane, 
gel and 3x 3MM paper.  Bubbles were omitted and the lid closed.  The transfer 
was run for 1½  hours at 38mA per gel. 
The blot was blocked in PBST with 0.5% milk powder for 1 hour before incubation 
overnight at 4°C with primary antibody.  One 15 minute wash followed by three 5 
minute washes were done in PBST, followed by 1 hour incubation with secondary 
antibody.  A further 15 minute wash followed by three 5 minute washes were 
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done in PBST, ECL reagent (GE Healthcare, Little Chalfont, UK) was added to the 
blot and incubated for 1 minute.  Films were exposed for variable lengths of time 
(approximately 15-30 seconds) and developed with Kodak GBX processing 
chemicals for autoradiography films (Sigma-Aldrich, Dorset, UK). 
 
2.2.10 Immuno-precipitation 
The supernatant was removed from the centrifuged lysate and put into a fresh 
pre-cooled microfuge tube.  10μl of the primary antibody (e.g. PKC-δ antibody) 
and 50μl of protein A/G agarose beads (Alpha Diagnostics International, San 
Antonio, TX, USA) were added to the lysate.  The samples were incubated in the 
cold room overnight whilst rotating. Tubes were centrifuged and the pellet 
washed 3 times in PBS before resuspending in approximately 50μl PBS. Control 
immunoprecipitation reactions could be run using no primary antibody or no 
beads. Loading buffer was added to the resuspended reactions, which were 
heated for 10 minutes at 70°C. The reactions were centrifuged for 10 minutes at 
17,000xg and the supernatant removed. The supernatant was added to a SDS-
PAGE gel for analysis. 
Prior to lysis of samples for immunoprecipitation, some samples were treated 
with phorbol 12-myristate 13-acetate (PMA) (Sigma, Gillingham UK) for 30 
minutes at 100nM. 
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2.2.11 Sub-cellular fractionation 
Cells were harvested and then centrifuged at 500xg for 5 minutes. Cells were 
washed by resuspending in 1ml PBS at 4°C. Cells were counted on a 
haemocytometer and between 1 and 6 x106 cells transferred to a 1.5ml 
microfuge tube. Microfuge tubes were centrifuged for 3 minutes at 500xg before 
the supernatant was removed. Five buffers (from the Subcellular Protein 
Fractionation kit, Pierce Biotechnology, Rockford, IL, USA) were used for the 
various fractions, depending on the number of cells to be lysed, varying volumes 
of buffer were prepared (Table 2.6). Appropriate volumes of buffers were 
measured out for the number of samples and Halt inhibitor cocktail was added at 
1:100. NEB+ (Bound-nuclear extraction buffer) buffer was supplemented with 5µl 
of 100mM CaCl2 per 100µl and 3µl of micrococcal nuclease per 100µl, in addition 
to the inhibitor cocktail. CEB (cytosolic extraction buffer), MEB (Membrane 
extraction buffer) and NEB (Nuclear (soluble) extraction buffer) were stored on 
ice, whilst NEB+ and PEB (Cytoskeletal (pellet) extraction buffer) were left at 
room temperature. 
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Table 2.6: Volumes of fractionation buffers used.  
Number of cells 
 (x106) 
CEB (µl) MEB (µl) NEB (µl) NEB+ (µl) PEB (µl) 
1 100 100 50 50 50 
2 200 200 100 100 100 
3 300 300 150 150 150 
4 400 400 200 200 200 
5 500 500 250 250 250 
6 600 600 300 300 300 
 
Following addition of CEB to the pellet, the samples were incubated at 4°C mixing 
for 10 minutes. They were centrifuged at 500xg for 5 minutes and supernatant 
removed and stored as the cytoplasmic extract. MEB was added to the pellet and 
samples vortexed for 5 seconds before incubating at 4°C with mixing for 10 
minutes. Samples were centrifuged at 3000xg for 5 minutes and the supernatant 
removed and stored as the membrane extract. NEB was added to the pellet and 
samples vortexed for 15 seconds before incubating at 4°C with mixing for 30 
minutes. Samples were centrifuged at 5000xg for 5 minutes and the supernatant 
removed and stored as the soluble nuclear extract. NEB+ was added to the pellet 
and samples vortexed for 15 seconds before incubating at 37°C for 5 minutes. 
Samples were vortexed for 15 seconds before being centrifuged at 17000xg for 5 
minutes and the supernatant removed and stored as the chromatin-bound 
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nuclear extract. PEB was added to the pellet and samples vortexed for 15 
seconds before incubating at room temperature for 10 minutes. Samples were 
centrifuged 17000xg for 5 minutes and the supernatant removed and stored as 
the cytoskeletal extract. Sample fractions were stored at -80°C until use for 
downstream analysis. 
 
2.2.12 Immuno-fluorescence  
Coverslips were sterilised by soaking in ethanol and then air-dried in a Category II 
cabinet. A Type I collagen (Sigma, Gillingham, UK) coating was added by pipetting 
a 1mg/ml solution onto the surface and allowing to air-dry. Prepared coverslips 
were then placed in a well of a 6-well plate with 2ml media and cells seeded at 
approximately 25,000/ml. The plates were incubated for a couple of days.  
Coverslips were retrieved from the wells and washed by immersing in PBS. 
Fixation buffer was added for 20 minutes, followed by 3 PBS washes. 
Permeabilisation solution was added to the coverslips and incubated for 15 
minutes, followed by 4 PBS washes. Quenching buffer was added for 15 minutes, 
followed by 3 PBS washes. Blocking buffer was added and left for 2 hours before 
the addition of 1:50 9E10 primary antibody to relevant coverslips. The coverslips 
were incubated at 4°C overnight. The following day coverslips were washed 4 
times in PBS before secondary antibody (at 1:500 dilution) was added and 
incubated for 30 minutes, whilst covered in foil, followed by a further 3 PBS 
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washes. FITC-phalloidin solution was added to the cells for 40 minutes, with foil 
covering, and succeeded by 4 PBS washes. Finally, cells were mounted onto 
slides, using a drop of Vectashield (with DAPI) (Vector Laboratories Inc., 
Burlingame, CA, USA), left to dry for approximately 1 hour, and sealed with clear 
nail varnish. Slides were stored in the dark at 4°C until use. 
 
2.2.13 Annexin V/Propidium iodide flow cytometry assay 
Cells were seeded in wells of a 6-well plate at 2 x 105. They were incubated 
overnight to attach and grow. Relevant wells were then treated with 
camptothecin (Sigma, Gillingham, UK) at final concentration of 500nM for MDA-
MB-468 cells and 2μM for MDA-MB-231 cells. Where SU 6656 (Sigma, Gillingham, 
UK) was used to treat cells, cells were left to attach for approximately 2hours, 
and SU 6656 added at 100nM concentration. Cells were then incubated for a 
further 24 hours.  
When starvation was used to challenge the cells, the cells were left to settle, then 
media with FBS was removed, the wells washed and media without FBS added 
back in. With MG-132 (Calbiochem, Nottingham, UK) treatment, cells were 
treated for 24 hours or 5 hours following 65 hours starvation. With the 24hour 
treatment, 100nM MG-132 was added when the cells were starved. For the 5 
hour treatment, 100nM MG-132 was added following the appropriate starvation 
period, and the plate swirled to mix. 
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After this incubation the medium (and any floating cells) were removed from the 
wells and put into labelled FACS tubes. The cells remaining in the wells were then 
trypsinised in 200μl trypsin. 800μl of media was added to inactivate the trypsin 
and the cell suspension added to the medium in the relevant FACS tube. The 
tubes were centrifuged for 5 minutes at 1200rpm. The supernatant was poured 
off, the pellets flicked to break them up, 2ml media added to the tubes and then 
they were vortexed gently. The samples were kept on ice whilst the cells were 
counted on a haemocytometer.  
Following counting, 1 x 105 cells were aliquoted into a fresh FACS tube, 1ml PBS 
added and vortexed gently. Tubes were centrifuged at 12000rpm for 5 minutes. 
Supernatant was poured off and the tubes flicked to break up the pellet. 100μl 1x 
binding buffer was added to the pellet and tubes vortexed. 5μl FITC-AnnexinV 
(BD Pharmingen, Oxford, UK) was added and the tubes vortexed before 
incubating for 15 minutes at room temperature in the dark. Following this 
incubation, 400μl 1x binding buffer and 10μl propidium iodide (50μg/ml in PBS) 
were added and the tubes vortexed. The tubes were incubated for 10 minutes on 
ice in the dark before analysis. 
 
2.2.14 Cell attachment 
Cells were counted and 100,000 added to 1 ml of media in a 6-well plate. For 
each cell line, three wells were prepared. The plates were incubated for 15 
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minutes. The plate was swirled to resuspend unattached cells that had settled, 
and the media removed and placed in a 7ml plastic vial. The cell suspension in 
each was counted and these counts recorded. The average of the three counts 
was converted to a percentage; this was the percentage of cells remaining 
unattached after 15 minutes incubation. 
 
2.2.15 Statistical analysis 
Firstly consider the following definitions: 
 
Population: ‘All members of a group about which you want to draw a conclusion’ 
(Levine and Stephan, 2011). For example, all voters in the UK or the daily output 
of cream cakes from a factory production line. 
 
Sample: ‘A part of the population selected for analysis’ (Levine and Stephan, 
2011). For example, UK voters selected to take part in a survey or 100 cream 
cakes selected from a production line. 
 
Variable: ‘A characteristic of an item or an individual that will be analysed using 
statistics’ (Levine and Stephan, 2011). For example, the income of a household or 
the weight of a cake. 
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Following collection of a sample from a population, descriptive statistics are used 
to describe a variable of the sample. Data shows a tendency to group around a 
particular value, rather than evenly spreading out across a range (Rowntree, 
2000). Measures of central tendency are used to identify the properties of a data 
set. One descriptive statistic that is a measure of central tendency is the ‘mean’. 
The mean aims to find the middle point of the data set, however the calculation 
of the mean includes all data selected and as such, data points that are extreme 
can distort the impression of where the central tendency lies. 
The mean is calculated as follows: 
?̅? = ∑𝑥𝑖
𝑛
 
 
Where ?̅? is the mean, 𝑥𝑖 are the data points and 𝑛 is the number of data points in 
the data set (Rumsey, 2010).  
For example, in the following sample of student pulse rates: 
 
 67, 69, 69, 70, 74, 75, 75, 76, 78, 79 beats per minute 
 
The mean would be: 
 
?̅? = 67 + 69 + 69 + 70 + 74 + 75 + 75 + 76 + 78 + 7910  
?̅? = 73.2 beats per minute 
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Data points collected in a sample will vary from each other. Thus it is useful to 
describe the dispersion of the data points in a sample in order to properly 
compare two samples. A method of achieving this is to calculate the standard 
deviation. The standard deviation takes all data points into account (Rowntree, 
2000). The standard deviation is a description of the typical distance from any 
data point to the centre, or the mean (Rumsey, 2010). As with the mean it can 
also be affected by outliers. If all data points in a sample were exactly the same 
then the mean would also be the same, as there would be no deviation from this 
mean amongst the data point, then the standard deviation would be 0 
(Rowntree, 2000). The greater the dispersion of the data points in the sample, 
the larger the standard deviation would be. The equation to calculate the 
standard deviation is given by: 
 
𝑠 = �∑(𝑥𝑖 − ?̅?)2
𝑛 − 1  
 
Where s is the standard deviation, 𝑥𝑖 is a sample value, ?̅? is the sample mean and 
𝑛 is the number of values in the sample (Rumsey, 2010).  
 
Consider the following examples: 
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 Example A: 69, 71, 73, 74, 81, 82 
 Example B: 119, 128, 133, 134, 135, 143 
 
With Example A, the mean is 75, and in Example B, the mean is 132. Let us first 
consider how far each data point is from the mean: 
 
 Example A:   69    71    73    74   81    82 
           -6     -4     -2    -1    +6   +7 
 Example B:   119     128     133     134     135     143 
           -13       -4        -1       +2       +3       +11 
 
If we added up all these deviations, they would equal each other out, with the 
negative values equalling the positive ones, so to remove the negative signs, we 
square the values: 
 
 Example A:   -6      -4     -2     -1     +6     +7 
           36     16      4       1     36     49 
 Example B:  -13       -4      -1      +2       +3      +11 
          169       16       1       4         9        121 
 
Next we find the mean of these deviations by adding them together and dividing 
by the number of values minus 1, or n-1, in this case we divide by 5: 
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Example A:   36 + 16 + 4 + 1 + 36 + 495  
 
 Example B:  169 + 16 + 1 + 4 + 9 + 1215  
 
This gives the variance, which is the squared standard deviation. In Example A 
this is 28.4, and in Example B this is 64. By taking the square root of the variance, 
we can find the standard deviation: 
 
 Example A:  √28.4  =  5.33 
 Example B:  √64     =  8  
 
The standard deviation shows that in Example A there is less deviation from the 
mean than in Example B. This is indicated by a lower standard deviation value. 
 
Whereas descriptive statistics are used to summarize the observations made, 
inferential statistics can be used to generalize from that sample to the wider 
population (Rowntree, 2000). Samples are taken from a population and there will 
typically be variation amongst the samples. The standard error of the mean is a 
 72 
measure of how the sample mean varies from a population of sample means. It 
allows us to understand how accurately we can generalise from the sample 
statistic to the population parameter. Thus to find the standard error of the 
population we imagine a population of sample means and examine the sampling 
distribution of the sample means by finding the standard deviation. However we 
only have one sample, with a mean and a standard deviation, and must estimate 
the standard error of the mean from this. Standard error of the mean is 
dependent on the standard deviation of the sample and the size of the sample. It 
is calculated as follows (Rumsey, 2010): 
𝜎?̅? =  𝜎𝑥
√𝑛
 
 
Where 𝜎?̅? is the standard error of the mean, 𝜎𝑥 is the population standard 
deviation and √𝑛 is the square root of the sample size (Rumsey, 2010). A small 
standard error of the mean, indicates that the mean of this sample would be 
close to the mean of the population. For example, if a sample of 100 exam results 
had a standard deviation of 30 marks: 
 
𝜎?̅? =  30
√100 = 3 
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The standard error of the mean is 3 marks. If the standard deviation of the 
sample is smaller, say 15 marks, there is an impact on the standard error of the 
mean, as shown below: 
𝜎?̅? = 15
√100 = 1.5 
 
In addition, if the size of the sample is increased, say to 400 exam results, there is 
also an impact on the size of the standard error of the mean:  
𝜎?̅? = 30
√400 = 1.5 
 
The size of the standard deviation has a greater impact on the size of the 
standard error of the mean than the sample size. This is observed in the above 
examples, where a decrease by half in the standard deviation, allows for a 
decrease of half in the standard error of the mean. However an increase of four 
times the sample size, only has an impact of halving the standard error of the 
mean. A change in the numerator has a greater impact on the result than the 
change in the denominator. This issue is examined below: 
 
Calculation of the standard error of the mean is summarised by the equation: 
𝑠
√𝑛
  
If both s and n are increased by a factor of 2 we have the following: 
2𝑠
√2𝑛
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This can also be written as:  
𝑠
√𝑛
× 2
√2
 
The value 2 is greater than the square root of 2, thus there would be an increase 
due to the greater impact of a change in the numerator on the result. 
 
A further consideration of inferential statistics is to examine two or more 
different samples and question whether or not they indicate an actual difference 
in populations (Rowntree, 2000). This can be done using statistical significance 
tests; a common test is the Student’s t-test. 
If pulse rates are measured in two random samples of 50 males and 50 females, 
testing can examine whether they are so similar that they should be considered 
as one population or if they are so different that two populations are indicated. 
Tests can examine whether this difference is significant, in terms of either 
standard deviation (Example A) or mean (Example B) (Rowntree, 2000).  
 
 
 
 
 
Prior to testing we must consider the cautious convention of the null hypothesis. 
This is to begin by assuming, or hypothesizing, that there is no real, statistically-
significant, difference between the samples (Rowntree, 2000). This hypothesis 
says that the population parameters of the groups are equal (Levine and 
Heart Rates 
Example A Example B 
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Stephan, 2011). Testing examines this hypothesis to assess the difference and 
identify whether the null hypothesis is correct or whether a mutually exclusive 
alternative hypothesis should replace it. A simple alternative hypothesis is that 
there is a difference between the samples. The null hypothesis remains accepted 
unless we find the difference between the samples is too great to believe that 
they could originate from one population, and thus the alternative hypothesis is 
correct. However, failure to reject the null hypothesis is not proof that is it 
correct (Levine and Stephan, 2011). 
Consider this sampling distribution for the test statistic, say the difference 
between the mean of the two samples: 
 
 
 
 
 
We are testing if the mean of sample A is equal to the mean of sample B. There 
are regions of the sampling distribution where a value would be considered non-
rejected and regions where it would be considered to be rejected. Critical values 
mark the points at which a null hypothesis would be rejected instead of not being 
rejected. The regions of rejection indicate the areas where the value of the test 
statistic, in this case the difference between the sample means, would be unlikely 
to fall if the null hypothesis was correct. If the test statistic value falls within 
Region of 
rejection 
Region of 
rejection Region of 
non-rejection 
Critical values 
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these regions, the null hypothesis is rejected (Levine and Stephan, 2011). The 
critical values are set by a decision upon the risk considered acceptable of making 
either a type I or type II error. A type I error is where the null hypothesis is 
rejected when it is true. For example, if it is stated that there is a difference 
between two sample means, when in fact there is not. Prior to testing a risk level 
α is set, traditionally this is 0.05, or smaller (Rowntree, 2000). This would mean 
that there is a probability that in 5 out of 100 times, a type I error could occur by 
chance. A type II error occurs if the null hypothesis is not rejected when it is false 
(Levine and Stephan, 2011). This would mean that the samples are from two 
distinct populations, but the difference was not determined by the test. A 
method of limiting type II errors is to use a larger sample size so that differences 
are more easily detected.  
The p-value can be found with statistical testing, this gives an indication of 
whether the null hypothesis should be rejected (Rumsey, 2010). This is 
considered in parallel with the risk level α set previously. If the p-value obtained 
is smaller or equal to α, the null hypothesis should be rejected. 
The alternative hypothesis may not be as simple as to say that there is a 
difference in the samples, it may say, for example, that there is in increase from 
sample A to B. This is where we consider tailed testing. A two-tailed test is used 
where the alternative hypothesis states that there is a significant difference 
between the two sample means (Rowntree, 2000). A one-tailed test would be 
used where the alternative hypothesis says that there is a significant difference in 
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a particular direction. As an example, consider a drug treatment that aims to 
lower blood pressure. The alternative hypothesis may say that there is a 
difference between a drug-treatment group and a placebo-treatment group, 
where we should use a two-tailed test. Or the alternative hypothesis may say 
that the drug-treatment group will have a lower blood pressure than the 
placebo-treatment group; in this case a one-tailed test should be implemented. 
If we were testing using a two-tailed test and using a α of 0.05 (5%), the test 
would look to see if the value was in the regions of rejection either side of the 
region of non-rejection. The critical values are set so that there is no more than a 
2.5% chance that the drug-treatment mean differs from the placebo-treatment 
mean, in either direction, for the null hypothesis to be rejected. (Rowntree, 
2000). 
 
 
 
 
 
 
However if we were using a one-tailed test, the test would focus on one arm of 
the diagram. Thus the critical value would be lowered. Thus a one-tailed test can 
make it more likely for a type I error to occur (Rowntree, 2000).  
 
Critical values 
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Student’s t-tests can be performed as unpaired or paired tests. An unpaired test 
can be performed on two groups of data to examine if there is a difference in the 
sample means of the two groups. In this test the sample variance is pooled to 
form one estimate of the variance covering the two samples (Levine and 
Stephan, 2011). A paired test is also performed on two samples to test if there is 
a difference in sample means. However, here the individuals in a sample are 
paired together, for example with a sample of 6 sets of identical twins. Each set 
of twins is paired. This has the effect of minimizing the chance of the two sample 
groups being too different, thus introducing bias (Rumsey, 2010). As an example, 
we can return to the situation where a drug treatment was used that aimed to 
reduce blood pressure. At the beginning of the study the blood pressure reading 
of the patients would be taken, and patients could be paired according to these 
values, one of the pair would be drug-treated and the other placebo-treated. This 
pairing would allow a more thorough reflection of the drug effects, rather than 
being complicated by differences in the beginning blood pressure values present 
in the two treatment groups (Levine and Stephan, 2011). 
Critical value 
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Finally let us consider how a Student’s t-test works. We will first study a two-
tailed, unpaired test. The equation to calculate the t-value is (Levine and 
Stephan, 2011): 
 
𝑡 = (?̅?1 − ?̅?2) − (𝜇1 − 𝜇2)
�𝑠𝑝2 �
1
𝑛1
+ 1𝑛2�  
 
Where ?̅? are the sample means, μ are the population means, 𝑠𝑝2 is the pooled 
estimate of the variance, and 𝑛 are the sample sizes. Before using this 
calculation, the pooled estimate of the variance must be calculated by the 
following equation: 
 
𝑠𝑝
2 = (𝑛1 − 1)𝑠12 + (𝑛2 − 1)𝑠22(𝑛1 − 1) + (𝑛2 − 1)  
 
We are going to determine whether the cost of a restaurant meal in a major city 
differs from the cost of a similar meal in the suburbs (Levine and Stephan, 2011). 
This will be done using an α=0.05 level of significance. Data is collected from 50 
city and 50 suburban restaurants. The mean cost in the city restaurants was 
$41.46, with a variance of 192.91 squared dollars, whilst the mean cost in the 
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suburban restaurants was $39.96, with a variance of 123.99 squared dollars. Thus 
we first calculate the estimate of the pooled variance: 
 
𝑠𝑝
2 = (49 × 192.91) + (49 × 123.99)49 + 49 = 158.45 
 
Next we can calculate the t-value (where the population means are unknown and 
thus are substituted by 0): 
 
𝑡 = (41.46 − 39.96) − 0
�158.45 � 150 + 150� = 41.46 − 39.96√158.45 × 0.04 = 1.5√6.338 = 0.596 
 
The next step is to look up the critical value of t in the t-tables using 50+50-2=98 
degrees of freedom, under 0.025 (0.05/2). The critical value is 1.9845. The t-value 
we calculated was 0.596, as this is less than the critical value 1.9845, the null 
hypothesis is not rejected. 
 
Next a two-tailed, paired test; the equation to calculate t is (Levine and Stephan, 
2011): 
 
𝑡 = 𝐷� − 𝜇𝐷𝑠𝐷
√𝑛
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Where 𝐷� is the mean difference, 𝜇𝐷 is the difference between the population 
means, 𝑠𝐷 is the sample standard deviation, and 𝑛 is the sample size. Before 
using this equation, values for 𝐷� and 𝑠𝐷 must be calculated. This is done using 
the following equations: 
𝐷� = ∑ 𝐷𝑖𝑛𝑖=1
𝑛
 
 
𝑠𝐷 = �∑ (𝐷𝑖 − 𝐷�)2𝑛𝑖=1𝑛 − 1  
 
As an example, we want to find whether, to α=0.05, a difference exists between 
the Doppler echocardiography results that two observers made on 23 patients 
(Levine and Stephan, 2011). Consider the following data: 
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Patient Observer A Observer B Difference 
(A-B) 
1 4.8 5.8 -1.0 
2 5.6 6.1 -0.5 
3 6.0 7.7 -1.7 
4 6.4 7.8 -1.4 
5 6.5 7.6 -1.1 
6 6.6 8.1 -1.5 
7 6.8 8.0 -1.2 
8 7.0 8.1 -1.1 
9 7.0 6.6 0.4 
10 7.2 8.1 -0.9 
11 7.4 9.5 -2.1 
12 7.6 9.6 -2.0 
13 7.7 8.5 -0.8 
14 7.7 9.5 -1.8 
15 8.2 9.1 -0.9 
16 8.2 10.0 -1.8 
17 8.3 9.1 -0.8 
28 8.5 10.8 -2.3 
29 9.3 11.5 -2.2 
20 10.2 11.5 -1.3 
21 10.4 11.2 -0.8 
22 10.6 11.5 -0.9 
23 11.4 12.0 -0.6 
 
The sum of all these differences, ∑ 𝐷𝑖
𝑛
𝑖=1 , is -28.3. Thus the 𝐷� is calculated as: 
 
𝐷� = −28.323 = −1.23 
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From this, the 𝑠𝐷 can be calculated: 
 
𝑠𝐷 = �8.968722 = 0.638 
 
These figures can be input into the t-test equation (where the 𝜇𝐷 is unknown and 
thus substituted with 0): 
 
𝑡 = 𝐷� − 𝜇𝐷𝑠𝐷
√𝑛
= −1.23 − 00.638
√23 = −9.24 
 
This t-value can be looked up in the t-tables to find the critical value of t using 23-
1=22 degrees of freedom, under 0.025 (0.05/2). The critical value is -2.0739. As 
the t-value was -9.24, and this is less than the critical value -2.0739, the null 
hypothesis can be rejected. 
 
Statistical analysis packages, such as excel, do these calculations and deliver a p-
value; when the data shown in the paired t-test example is analysed in excel we 
obtain a p-value of 4.96 × 10−9. This means that the probability of obtaining a t-
value greater than 2.0739 or less than -2.0739 by chance is less than 
0.0000005%, or 5 in 1 thousand million. This is considerably well within our 
stated α of 5%, and can definitely be considered a significant difference. 
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 Chapter 3: Development of stable cell lines expressing myc-δC2 or myc-PKC-δ 
 
It is known that PKC-δ is involved in many cellular processes, including apoptosis 
(Steinberg, 2004); however, little is known about how its C2 domain is involved. 
In order to study PKC-δ, and its C2 domain in apoptosis of breast cancer cells, cell 
lines were developed that over-expressed the δC2 domain or full length PKC-δ. 
Breast cancer cells (MDA-MB-468, MDA-MB-231 and MCF-7) were transfected 
with constructs of pIRES-myc-δC2 pIRES-myc-PKC-δ or pIRES Vector, and stable 
transfectants selected. For MDA-MB-468 cells, colonies were picked from the 
plate and grown up as clonal populations. All remaining colonies were pooled 
together as a collection of clones. For MDA-MB-231 and MCF-7 cell lines, only a 
pool collection was developed. Expression studies showed that the δC2 and myc-
PKC-δ were expressed in the appropriate cell lines. The transfected populations 
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will enable examination of how important the C2 domain is in interactions that 
facilitate the apoptotic role of PKC-δ.   
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3.1  Introduction 
 
The PKC-δ C2 domain is specific to the protein, it is part of the regulatory domain 
and has been shown to have protein binding capabilities (Benes et al., 2005; 
Dekker and Parker, 1997; Mellor and Parker, 1998). We hypothesize that over-
expression of the C2 domain will block these protein binding events, through 
competitive inhibition, thus blocking endogenous PKC-δ activity.  
In the literature, groups have utilised several methods to examine the action of 
PKC-δ (Blass et al., 2002; Chen et al., 2010; Hall et al., 2007; Humphries et al., 
2006; Kajimoto et al., 2010). This has included use of PKC inhibitors; however, 
these are not specific to the PKC-δ isoform (Soltoff, 2007). Studies have also used 
siRNA; however, use of this is dependent on protein turnover and can have off-
target effects (Jackson et al., 2003). Knockout animals could also be used for such 
studies, however due to the nature of the PKC family having overlapping roles, 
the development of such animals may lead to compensatory mechanisms 
developing whereby other family members take over the roles of PKC-δ. In 
addition, these methods would not enable the specific study of the C2 domain 
and its roles in PKC-δ activity. 
3.1.1  pIRESneo2 
The pIRESneo2 vector was used because it contains several useful elements for 
our purpose (Fig. 3.1). The vector contains a human cytomegalovirus (CMV) 
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major immediate early promoter/enhancer which allows transcription machinery 
to bind, and for enhancer-binding proteins to also bind allowing an increased rate 
of transcription (Foecking and Hofstetter, 1986; Pasleau et al., 1985; Thomsen et 
al., 1984). Following this region is a multiple cloning site (MCS), followed by three 
stop codons covering all reading frames (Fig. 3.1). The stop codons following the 
MCS would prevent translation of the protein sequence past this point. A 
synthetic intron is next in the sequence, this is present as it was found to 
enhance mRNA stability (Huang and Gorman, 1990). This is followed by an 
internal ribosome entry site (IRES) (Fig. 3.1) (from encephalomyocarditis virus), 
which allows translation of a further open reading frame from the same mRNA 
(Dorner et al., 1984; Jang et al., 1988). The first ribosome site is at the 5’ end of 
the mRNA. This is positioned prior to a neomycin phosphotransferase coding 
sequence, from which, the protein confers resistance to G418 antibiotic. Lastly is 
a polyadenylation signal, originating from bovine growth hormone sequence 
(Goodwin and Rottman, 1992).  
The pIRESneo2 vector was designed in such a manner that through positioning 
the neomycin phosphotransferase gene to a translation position following the 
gene of interest and the IRES, the inserted gene of interest should always be 
expressed (Martinez-Salas, 1999; Wagstaff et al., 1998). The selective pressure 
for antibiotic resistance means that the neomycin phosphotransferase is required 
for survival, thus the positioning of this gene following the gene of interest 
means both genes are transcribed, rather than just the neomycin 
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phosphotransferase. In addition, experimental evidence indicates that expression 
from an IRES is slightly lower than from a more traditional cap-dependant type 
(Wagstaff et al., 1998), thus in order to achieve resistance to the G418 antibiotic 
treatment by neomycin phosphotransferase expression, it is likely that the 
expression levels of the protein of interest would be slightly higher. 
Also contained within the vector is a collection of features designed for 
replication of the vector within a bacterial system. An ampicillin resistance gene 
region containing a bacterial promoter, transcription start point, ribosome 
binding site and β-lactamase coding sequence are positioned for reading and 
transcription in the opposite direction to the eukaryotic-suitable features. This 
region allows selection of bacteria that contain the plasmid from a wider 
population, from which the plasmid can be prepared and used in mammalian cell 
transfection experiments. 
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Figure 3.1: pIRES vector map showing details of the multiple cloning site 
(MCS). 
 
3.1.2  Using pIRESneo2 
PKC-δ was available in pEFLINKtag constructs that had previously been made and 
used within the group. The pEFLINKtag constructs are suitable for expression of 
protein, however they would have to be co-transfected into cells with an 
additional construct containing a selectable marker to allow cell line selection. A 
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potential problem with this method is that the neomycin resistance vector can be 
incorporated, as it is beneficial to the cells survival, however the construct 
containing the sequence for the protein required to be expressed may not. The 
cells were required to express the protein in a stable fashion in order to allow the 
effects to be seen within the intracellular environment. The pIRESneo2 constructs 
would contain both a neomycin resistance gene for selection, and the gene of 
interest.  
Once transfected, cells can express the protein whose sequence is contained 
within the construct, however cells may not necessarily maintain this expression. 
Constant, stable expression was required for lengthy experiments. The 
expression of the neomycin resistance gene enables cells to grow in the presence 
of G418, which is an antibiotic that can stop polypeptide synthesis in both 
prokarya and eukarya. Thus through G418 treatment of transfected cells, cells 
can be selected that stably express the construct.  
The stable cell line method was chosen so that studies could be done on a 
relatively homogeneous population. In a transient system, where cells have not 
been selected for expression, there may be a proportion of the population that 
are not expressing the construct. Thus small effects of the transfected DNA may 
be picked up in a selected transfection system, which would not be in a transient 
system.  
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3.1.3  Approaches to transfection 
There are many methods to achieve transfection of cells. Chemical transfection is 
a commonly used system (Reese, 2004). The efficiency of transfection is greatly 
improved when the DNA is precipitated in the presence of cells. This can be 
simply done by mixing with calcium chloride solution and adding to cells (Graham 
et al., 1973). The precipitate settles on the cells and is internalised through a 
process of endocytosis (Reese, 2004). Once inside, a proportion of the DNA will 
be released into the nucleus where it can be expressed or integrated into the 
genome.  
Electroporation is frequently used in bacterial transformation, but can also be 
used for mammalian transfection (Reese, 2004). An electric field pulse is used to 
induce pores to open within the membrane; DNA can enter through these pores 
(Neumann et al., 1982). Whereas pores can form in 1μs, healing can take minutes 
(Reese, 2004). The pulse amplitude and duration are critical to forming pores to 
successfully transfect, while also not damaging the cell to the point it cannot 
repair (Reese, 2004). 
For liposome-mediated transfection (Fraley et al., 1980; Schaefer-Ridder et al., 
1982), DNA is contained within a liposome cluster which fuses with the 
membrane, thus facilitating transport of the DNA into the cell (Reese, 2004). 
Liposomes used for this process are spheres of cationic lipids which form a 
unilamellar vesicle; these vesicles bind along the negatively charged DNA. Due to 
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their cationic nature they are also more readily able to interact with a negatively 
charged cell membrane than uncharged liposomes, thus promoting fusion and 
transportation of the DNA across the membrane (Reese, 2004). Liposomal 
transfection enables the DNA to enter without endocytosis, thus escaping 
endosome mediated degradation (Reese, 2004). 
Several peptide sequences, for example, the tetra-peptide serine-proline-lysine-
lysine, have been demonstrated to enable transfection (Legendre and Szoka, 
1993; Reese, 2004; Wu et al., 1989; Wu and Wu, 1988). The positive lysine 
residues interact with the negative DNA backbone and enable close packing. The 
peptides bind to the DNA, condense it, and increase its amenability for cell entry. 
DNA can also be injected directly into cell nuclei (Diacumakos, 1973; Reese, 
2004). This is technically difficult and must be done individually to each cell. The 
integration efficiency of DNA introduced in this manner varies widely, dependant 
on the organism from which the cells originate. The method has been used on a 
wider scale for gene therapy for cancer, whereby DNA is injected into tumour or 
muscle cells in order to encourage expression of an antigen which produces an 
immune response (Reese, 2004). 
Viral vector systems may also be used to introduce DNA into cells, it is referred to 
as transduction. Desired DNA can be inserted into the viral genome, when the 
virus is added to cells the DNA is inserted into the cells with the viral genome, as 
would normally happen with a viral infection (Hamer and Leder, 1979; Mulligan 
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et al., 1979). Some viruses normally integrate their genome into the host genome 
(e.g. Adeno-associated Virus), this can be utilised to enable the foreign DNA to 
enter the genome as well (Reese, 2004). Adeno-associated Viruses display a 
reliable feature whereby the integration of the DNA is in a predictable location, 
however other viruses, such as Retroviruses, insert at a random location, thus 
possibly having detrimental effects on the cell (Reese, 2004).  
 
The cell lines were made following transfection of the cells using a proprietary 
form of lipid-based delivery of a pIRESneo2 construct. The G418 encouraged 
integration of the DNA into the genome, as without doing this, the cells would be 
killed. 
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3.2  Results 
 
3.2.1  Untransfected cell line endogenous expression 
The literature has compared the endogenous PKC-δ levels of MCF-7 and MDA-
MB-231 cells (Shanmugam et al., 2001), but not MDA-MB-468 cells. Here, 
endogenous expression of PKC-δ in all these cell lines was measured. For each 
cell line the same number of cells were lysed and either the same number of cell 
equivalents, or the same amount of total protein was analysed (Fig. 3.2).  
Examining expression in the lysate of 1.25 million cells, the MDA-MB-231 cells 
were found to have the lowest level of endogenous PKC-δ (Fig. 3.2A) The MDA-
MB-468 and MCF-7 cells have considerably higher expression. Through band 
intensity analysis it was found that MDA-MB-468 expression is 29 times higher 
than that of MDA-MB-231 cells. MCF-7 expression has a relative intensity of 25. 
There is also a lower intensity band in the MDA-MB-468 and MCF-7 cell lines, 
present around 55kDa, attributed to a breakdown product. When considering 
both of these bands, it indicates that the levels of PKC-δ in the MDA-MB-468 and 
MCF-7 cell lines are much higher than the MDA-MB-231 cell line. The difference 
between the MCF-7 and MDA-MB-231 cell lines has also been identified in the 
literature (Shanmugam et al., 2001).  
When 10μg of total protein for each cell line was loaded onto the gel (Fig. 3.2B), 
an overall similar pattern of expression was observed. The MCF-7 cell line shows 
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a relative intensity of 3, compared to MDA-MB-231 at 1, and the MDA-MB-468 
cell line is higher still at a relative intensity of 6.  
    
Figure 3.2: Endogenous expression levels of PKC-δ in MDA-MB468, MDA-
MB-231 and MCF-7 cell lines. A: equal volume of lysate from 1.25 million 
cells, B: 10μg protein loaded. Equivalent experiments demonstrated 
comparable patterns across four experiments. 
 
The difference in expression levels of PKC-δ between the cell lines is broad. It 
may thus be predicted that introducing the PKC-δ C2 domain in different cell 
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background would lead to different responses due to the different levels of 
endogenous PKC-δ. Perhaps higher levels of PKC-δ will mean that a greater 
number of PKC-δ pathways are active, thus affecting the cellular phenotype. 
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3.2.2 Generation of the pIRES-myc-δC2  and pIRES-myc-PKC-δ 
constructs 
The pIRES-myc-δC2 construct was made by amplifying the myc-δC2 sequence 
from the pEFLINKtag-myc-δC2 construct using PCR, and ligating the product into 
the shuttle vector pCR2.1-TOPO. The sequence was then excised from the shuttle 
vector and ligated into the digested pIRESneo2 vector (Fig. 3.3). 
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Figure 3.3: Ligation scheme for developing the pIRES-myc-δC2 
construct. The myc-tagged C2 domain was amplified using PCR, and 
restriction sites added at either end. These were then utilised to 
encorporate the insert into the cut pIRES vector. 
 
For the pIRES-myc-PKC-δ construct, the pIRES-myc-δC2 construct was digested in 
order to remove the C2 sequence, but retain the myc-tag within the vector. Then 
the ‘PKC-δ’ sequence was excised from the pEFLINKtag-myc-PKC-δ construct and 
pEFLINKtag-myc-δC2
Used PCR to amplify myc-δC2 
region and incorporate NotI
and NheI sites onto either side
pCR2.1-TOPO-myc-δC2
Ligated PCR 
fragment into 
pCR2.1TOPO 
vector (shuttle 
vector)
Excised myc-δC2 fragment and 
ligated into pIRES vector using 
NotI and NheI sitespIRES-myc-δC2
 
99 
ligated into the pre-digested pIRES construct containing the myc-tag, but not the 
C2 sequence (Fig. 3.4). 
 
 
Figure 3.4: Ligation scheme for developing the pIRES-myc-PKCδ 
construct. The protein inserts were excised, exclusive of the myc-tag, 
then the PKC-δ insert spliced into the pIRES vector containing the myc-
tag. 
 
The maps of the final constructs are shown in Figure 3.5. Both contain the 
ampicillin resistance and neomycin resistance markers necessary for replication 
in bacteria, and development of stable cell lines, respectively. The pIRES-myc-δC2 
pEFLINKtag-myc-PKC-δ pIRES-myc-δC2
Myc-tag
Myc-tag
pIRES-myc-PKC-δ
Spliced-in
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construct has retained its NotI restriction site, however it has been destroyed in 
the pIRES-myc-PKCδ construct. 
 
 
Figure 3.5: Maps of the constructs pIRES-myc-δC2 and pIRES-myc-PKC-δ. 
The Blue rectangle signifies the insert, with the red region symbolising 
the myc-tag sequence. Positions of restriction sites are identified with 
arrows. Ampr and Neor are the ampicillin and neomycin resistance 
genes respectively.   
  
pIRES-myc-PKC-δ
XbaI/NotI
Ampr
Neor
Myc-tag
pIRES-myc-δC2
NheI
NotI
Ampr
Neor
Myc-tag
BamHI
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3.2.3  Stable transfection and confirming protein expression 
 
3.2.3.1  Pre-transfection 
Prior to transfection, a ‘kill-time’ experiment was performed studying the length 
of time needed for different G418 concentrations to kill the parent cells. The aim 
was to find a concentration that killed cells in approximately 5-7 days, as this 
would enable the cells to be expressing enough protein to be resistant to the 
G418, if the plasmid was present. If the cells were killed too quickly, there may 
not be enough time to transcribe and translate the protein, thus even those cells 
transfected successfully would die. This experiment was run on MDA-MB-468 
cells; Table 3.1 shows that 350μg/ml G418 was a suitable concentration for 
selection of transfectants for this cell line. This concentration was also used for 
selection in MDA-MB-231 cells. 
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Table 3.1: Kill-time experiment data, for testing the G418 concentration 
necessary to kill MDA-MB-468 cells in 5-7 days. +: no killing, ~: some 
killing (30-70% cells remaining), -: all cells killed. 
  Neomycin Concentration (µg/ml) 
D
ay
s 
af
te
r 
tr
ea
tm
en
t 
 0 50 100 200 350 500 
1 + + + + + + 
2 + + + + + + 
3 + + + + + + 
4 + + + + + ~ 
5 + + + + ~ - 
6 + + + ~ - - 
7 + + + - - - 
 
Following transfection and selection of MCF-7 cells using 350μg/ml G418, is 
became clear that the concentration was not high enough to kill the MCF-7 cells. 
Thus a further ‘kill-time’ experiment was run prior to the next transfection to test 
concentrations from 500μg/ml and higher (Table 3.2). 500μg/ml was found to be 
sufficient. 
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Table 3.2: Kill-time experiment data, for testing the G418 concentration 
necessary to kill MCF-7 cells in 5-8 days. +: no killing, ~: some killing 
(30-70% cells remaining), -: all cells killed. 
  Neomycin Concentration (µg/ml) 
D
ay
s 
af
te
r 
tr
ea
tm
en
t 
 
500 1000 2000 3000 4000 5000 
3 + + - - - - 
6 ~ - - - - - 
7 ~/- - - - - - 
8 - - - - - - 
 
 
3.2.3.2 Transfection of MDA-MB-468 
The MDA-MB-468 cell line was transfected using FuGENE6 transfection reagent, 
with pIRES-myc-δC2, pIRES-myc-PKC-δ or with the pIRES vector alone. A non-
transfected control was used to study the progression of cell death following 
G418 treatment and to observe that no colonies arose following the selection 
step, as this would indicate plasmid contamination. The MDA-MB-468 cells were 
seeded at 8.7 x 105 density in a 10cm dish, based upon the manufacturer’s 
recommended seeding of 1.5 x 105 cells in a well of a 6-well plate.  
Following transfection and selection procedures, colonies appeared first in the 
plate for pIRES-myc-δC2 transfected cells. Several colonies were picked using 
trypsin-soaked discs and expanded into clonal populations. The remaining 
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transfectants were pooled together and grown as a pIRES-myc-δC2 transfected 
pool. The next colonies to arise were on the plate for pIRES vector control- 
transfected cells. Several individual colonies were expanded and a pool 
population prepared. No colonies developed in the plate for pIRES-myc-PKC-δ 
transfected cells. Transfection was repeated multiple times but no colonies 
developed. This may be due to a biological effect of PKC-δ over-expression on 
these cells. Microscope study of the plates occasionally identified a few cells 
which appeared apoptotic and did not form colonies. 
In order to confirm the expression of the myc-δC2 fragment in the MDA-MB-468-
myc-δC2 cells (and the absence of this in the Vector control cells) cell lysates 
were prepared, run on SDS-PAGE, western blotted and probed with the c-myc 
antibody 9E10. This detects the myc-tag on the myc-C2 expressed protein. In 
Figures 3.6 and 3.7, the myc-δC2 band is clearly seen at approximately 15kDa in 
the MDA-MB-468-myc-δC2 clone and pool cell lysates; it is absent from the 
vector control clone and pool cell lines. 
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Figure 3.6: Expression of myc-δC2 in the MDA-MB-468-myc-δC2 clonal 
cell lines and its absence in the vector control clonal cell lines (open 
arrow). The bands seen at approximately 35kDa are endogenous c-myc 
bands (closed arrow). A and B are two clonal populations of 
transfectants. 
 
 
 
myc-δC2 band 
Cross-reacting c-myc band 
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Figure 3.7: Expression of myc-δC2 in the MDA-MB-468-myc-δC2 pool cell 
line and the absence of the band in the Vector control pool cell line 
(open arrow). The bands seen at approximately 35kDa are endogenous 
c-myc bands (closed arrow). 
 
During sub-culture of these cells differences in cell growth became apparent, 
with the myc-δC2 cells apparently growing faster than the Vector cells. This effect 
is further investigated in Chapter 5. 
 
Cross-reacting c-myc band 
myc-δC2 band 
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3.2.3.3  Transfection of MDA-MB-231 
The MDA-MB-231 cell line was transfected using FuGENEHD transfection reagent. 
As with MDA-MB-468 cells, cells were transfected with pIRES-myc-δC2, pIRES-
myc-PKC-δ or with the pIRES vector alone. An untransfected cell control was also 
prepared. The manufacturer suggested seeding 1-2 x 104 cells per well of a 96-
well plate. Thus by using a 10cm dish, with a relative surface area 170 times 
greater, 1.7-3.4 x 106 cells would be required and as such, cells were seeded at 
2.5 x 106 density. G418 was added at 350μg/ml to enable selection of stable 
transfectants. 
After the selection process, colonies first began to develop in the plate of cells 
that had been transfected with the pIRES-myc-δC2 construct, similar to MDA-MB-
468. As with the MDA-MB-468 transfection, the next colonies formed were from 
the plate transfected with the pIRES vector alone, and used as a control cell line. 
Contrary to the MDA-MB-468 transfections, colonies ultimately did arise on the 
plate transfected with pIRES-myc-PKC-δ construct.  
The differences between the development of transfected cells is exemplified in 
Figure 3.8. This figure demonstrates the differences between the development of 
colonies following transfection, where the only difference was the construct 
transfected into the cells. Panels 1A and 1B were taken 22 days following 
transfection of the MDA-MB-231 cells. Panel 1A shows pIRES-myc-δC2 
transfected cells and 1B shows pIRES-Vector control transfected cells; there is 
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approximately 75% confluence in 1A while the first cells have only just arisen in 
1B where confluence is approximately 5%. On day 35 after transfection (13 days 
later) the pIRES-Vector control cells (2A) have significantly increased in number 
so that they are approximately 60% confluent. At this time point, the pIRES-myc-
PKC-δ transfected cells have only just started to grow and are at approximately 
5% confluence (2B).   
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Figure 3.8: The development of transfected cells. Pictures 1A and 1B 
were taken 22 days following transfection. 1A: pIRES-myc-δC2 
transfected cells, 1B: pIRES-Vector control transfected cells; there is 
approximately 75% confluence in 1A while in 1B confluence is 
approximately 5%. At day 35 following transfection, pictures 2A and 2B 
were taken. 2A: pIRES-Vector control transfected cells, 2B: pIRES-myc-
1A 1B
2A 2B
myc-δC2 pIRES 
pIRES myc-PKC-δ 
D
ay 22 
D
ay 35 
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PKC-δ transfected cells; cells in 2A are approximately 60% confluent, 
while cells in 2B are approximately 5% confluent. 
 
As with the MDA-MB-468 cell lines, the presence and absence of relevant myc-
tagged protein needed to be confirmed. As shown in Figure 3.9, the Vector 
control cell lysate showed a band at approximately 35kDa. The myc-PKC-δ lysate 
lane has an additional strong band at approximately 85kDa, which is the correct 
size for myc-tagged PKC-δ, thus confirming its expression. The myc-δC2 cell lysate 
does not show this band but does have a band at approximately 15kDa, the 
predicted size for the myc-δC2 fragment. Thus expression of myc-PKC-δ and myc-
δC2 in the selected pools of MDA-MB-231 transfected cells is confirmed.  
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Figure 3.9: Expression of myc-PKC-δ in the 231-myc-PKC-δ cell line, this 
band is absent in the 231-myc-δC2 and vector control cell lines (open 
arrow). Expression of myc-δC2 is seen in the 231-myc-δC2 cell line, but 
is absent in both the 231-myc-PKC-δ and vector control cell lines 
(curved arrow). The bands seen at approximately 35kDa are 
endogenous c-myc bands (closed arrow). 
 
Cross-reacting c-myc band 
mycPKC-δ band 
myc-δC2 
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As with the MDA-MB-468 cells, the sub-culturing process revealed that there may 
be differences in the growth of the cell lines. The myc-δC2 cells also appear to 
grow faster than the Vector cells. In addition, the myc-PKC-δ cells appeared to be 
growing at an increased rate. These observations are investigated further in 
Chapter 5. 
 
3.2.3.4  Transfection of MCF-7 
Transfection of the MCF-7 cells followed the same method as with the MDA-MB-
231 cell line except that cells were seeded at the slightly lower density of 1.87 x 
106 cells per 10 cm dish. Utilising a G418 concentration of 500μg/ml (Table 3.2), 
colonies arose first in the pIRES-myc-δC2 transfected plate, then the Vector 
control plate, and finally in the pIRES-myc-PKC-δ transfected plate (as with MDA-
MB-231 cells). Pool populations of the three cell lines were established. 
The expression of myc-PKC-δ and myc-δC2 was confirmed by western blotting 
(Fig. 3.10). A band at approximately 35kDa was observed in the Vector control 
lane. The myc-δC2 cell lysate showed an additional band at approximately 15kDa, 
the expected size for the myc-δC2 fragment. No 15kDa size band was observed in 
the myc-PKC-δ cell lysate, but a strong band is observed at the predicted size of 
myc-PKC-δ (approximately 85kDa).  
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Figure 3.10: Expression of myc-δC2 is seen in the MCF7-myc-δC2 cell 
line, but is absent in both the MCF7-myc-PKC-δ and vector control cell 
lines (open arrow). Expression of myc-PKC-δ is seen in the MCF7-myc-
PKC-δ cell line, this band is absent in the MCF7-myc-δC2 and vector 
control cell lines (curved arrow). The bands seen at approximately 
35kDa are endogenous c-myc bands (closed arrow). 
 
 
  
Cross-reacting c-myc band 
myc-δC2 band 
myc-PKC-δ band 
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3.3 Discussion 
 
pIRES constructs were transfected into MDA-468, MDA-231 and MCF-7 cells. 
Stable cell lines were developed expressing myc-δC2 or containing pIRESneo2 as 
a Vector control. Only MDA-MB-231 and MCF-7 cells developed myc-PKC-δ 
expressing cell lines. This was confirmed by western blotting. This is the first time 
cell lines have been developed over-expressing the C2 domain of PKC-δ. This will 
allow the effect of endogenous PKC-δ C2 domain to be examined through 
competitive inhibition of its activity.  
MDA-MB-468 did not develop a myc-PKC-δ cell line, but the other parent cell 
lines did. However, the myc-PKC-δ expressing cell lines in MDA-MB-231 and MCF-
7 took longer to develop than the Vector controls. This suggests that the over-
expression of PKC-δ may be detrimental, or even fatal, to the cells and indicates 
that the MDA-MB-468 cells are more sensitive to PKC-δ over-expression. This 
effect could be related to the presence of already high PKC-δ levels within these 
cells, as shown in Figure 3.2. There is evidence that PKC-δ acts in a pro-apoptotic 
manner (Reyland, 2007), perhaps increasing PKC-δ levels any further floods this 
pathway and the cells enter apoptosis. The lower endogenous PKC-δ levels in the 
MCF-7 and MDA-MB-231 cells may prevent this critical level being attained, thus 
allowing cell survival. The pro-apoptotic pathway of PKC-δ involves caspase-3 
(Reyland, 2007). MCF-7 cells also showed high PKC-δ levels, although not as high 
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as in MDA-MB-468 cells. MCF-7 cells do not express caspase-3, thus perhaps this 
is a reason why they do not act similarly to MDA-MB-468 cells. 
All parental cell lines developed myc-δC2 expressing cells more quickly than the 
Vector control (and myc-PKC-δ cells). This is an indication of a positive effect of 
myc-δC2 activity on the cells in allowing them to demonstrate improved ability to 
survive. It seems likely that this may be mirrored in future experiments.  
The cell lines developed will allow further investigation into the effects of PKC-δ 
over-expression and also into the role of the C2 domain in PKC-δ. The literature 
has illustrated a protein binding role for the C2 domain; we hypothesized that it 
would be likely that this protein binding role was more extensive than the 
literature has shown thus far. The specificity of the C2 domain for PKC-δ is a new 
method which can help identify PKC-δ specific activities that cannot be shown so 
comprehensively with the inhibitors available at present. The cell lines we have 
developed here will be examined in further detail, aiming to discover new roles 
and actions for PKC-δ and the C2 domain.  
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 Chapter 4: Localisation of myc-δC2 and associated differences 
 
The MDA-MB-468 cell lines are the primary focus of this chapter. We used 
immuno-fluorescence to look at the positioning of myc-δC2 and studied the 
localisation of PKC-δ using sub-cellular fractionation. Myc-δC2 was localised to 
the extreme periphery of the cells. Differences in actin cytoskeleton were 
observed between myc-δC2 and vector cells, such that the myc-δC2 cells had a 
more extended cytoskeleton with protrusions extending from the main bulk. 
Despite myc-δC2 having a clear impact on the cells, the localisation of 
endogenous PKC-δ did not show any difference between the myc-δC2 and vector 
cells, as determined by cell fractionation. As the impact of myc-δC2 on the 
cytoskeleton increased the cell surface area, it was possible that the attachment 
of cells may have been affected. This was examined in a brief study looking at the 
percentage of cells remaining unattached from a surface following 15 minutes 
incubation. The differences seen with the cells’ cytoskeletal structures appear to 
correlate with attachment. 
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4.1  Introduction 
 
After the introduction of the myc-δC2 domain it was important to see where the 
protein domain was localised. The localisation may indicate possible roles for the 
domain itself and for PKC-δ and the actions it may be competitively inhibiting.  
PKC-δ has been found to bind to the cytoskeletal factors f-actin and adducin 
(Chen et al., 2007; Lopez-Lluch et al., 2001). Literature evidence suggested PKC-δ 
may bind to the cytoskeleton via the C2 domain (Lopez-Lluch et al., 2001). Thus 
we used actin staining to examine the cell lines to see whether the cells 
expressing myc-δC2 show any differences in cytoskeletal structure. 
Our hypothesis is that the myc-δC2 domain will interfere with the endogenous 
action of PKC-δ. Using cell fractionation, we have examined PKC-δ localisation in 
order to see if by interfering with this action the localisation of PKC-δ is also 
interfered with. As the positioning of PKC-δ appears important in the actions it 
performs, it is likely that due to differing actions the localisation is also different.  
Following the examination of the cytoskeleton, and observing the differences 
correlating with the presence of the myc-δC2 domain, a short study of 
attachment was performed. 
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4.2  Results 
 
4.2.1 The myc-δC2  domain localises to the periphery of the cell in 
membrane protrusions 
In order to examine the localization of myc-δC2, cells were stained with DAPI 
(blue), which stains the nucleus, and an antibody to the myc-tag which was 
visualized using a fluorescently labelled secondary antibody (red). Several fields, 
taken from several slides, were selected in such a way that single cells could be 
observed. 
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Figure 4.1: Myc-tag staining (red) of four vector control and four myc-
δC2 cells (blue indicates DAPI staining of the nucleus). Little or no myc-
tag staining is seen in vector cells due to the lack of myc-δC2. Any 
staining present is due to non-specific binding to endogenous c-myc 
protein, as seen with the western blots. Myc-tag staining shows the 
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position of myc-δC2 at the cell periphery, primarily in protrusions from 
the bulk of the cell (see arrows).  
 
The myc-tag antibody bound the myc-δC2 where it was present in the cells. A low 
signal is seen in the vector control cells, possibly due to recognition of 
endogenous c-myc protein (Figure 4.1). The binding identified in the vector 
control cells was in the bulk of the cell surrounding the nucleus. In the myc-δC2-
expressing cells, more extensive staining was observed. There was a similar level 
of staining surrounding the nucleus in the bulk of the cell, but the majority of the 
staining appeared at the periphery of the cells. The cells expressing myc-δC2 
possessed protrusions from the bulk of the cell. Here the majority of the staining 
occurred. There is a degree of granularity in these images associated with 
problems with the myc-tag antibody binding. Low antibody binding required the 
microscope to be set up to allow detection of a larger degree of red fluorescence, 
subsequently some background fluorescence is also observed. 
The presence of protrusions may indicate an effect of myc-δC2 on the integrity of 
the normal cytoskeletal structure of the cell. Through staining of the cytoskeleton 
we examined firstly, if this is the case, and secondly, how the myc-δC2 staining 
relates to this. 
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4.2.2 The relationship of myc-δC2  localisation and actin 
localisation. 
Cells were stained, as before, with DAPI (blue) and an antibody to the myc-tag 
together with a fluorescently labeled  secondary antibody (red). In order to study 
the F-actin cytoskeleton in combination with myc-δC2 positioning, a FITC-
phalloidin stain, was used (green). This enables visualization of the actin 
structures present in the cell at time of treatment. Several fields, taken from 
several slides, were selected so that isolated cells could be studied. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
122 
 
 
  
 
 
Figure 4.2: Actin cytoskeletal staining (green) in combination with myc-
tag staining (red) of vector control and myc-δC2 cells (blue is nuclear 
DAPI staining). Little or no myc-tag staining is seen in vector cells due to 
the lack of myc-δC2. Any staining present is due to non-specific binding 
to endogenous c-myc protein, as seen with the western blots. In the myc-
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δC2 cells, myc-tag staining shows the position of myc-δC2 at the ends of 
the actin protrusions.  
 
The actin cytoskeleton appears to show extensions from the cell bulk in myc-δC2 
expressing cells. In Figure 4.1 we observed peripheral myc-δC2 staining, Figure 
4.2 shows that this is localised to the edges of the actin cytoskeleton. The actin 
cytoskeleton does not appear to show these extensions in the vector cells. 
In the myc-δC2 expressing cells, there does not appear to be any particular co-
localisation of the myc-δC2 and the f-actin. In fact the myc-δC2 appears primarily 
at the extremities of the actin cytoskeletal staining (Fig. 4.3). 
 
 
 
 
Figure 4.3: Graphic illustrating myc-δC2 positioning in relation to actin 
cytoskeletal protrusions in myc-δC2 cells. Red symbolizes myc-δC2 
positioning and green indicates actin. 
 
actin 
myc-δC2 
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In order to examine how frequently the myc-δC2 was found at the periphery of 
the actin cytoskeleton, a total of 54 myc-δC2 cells were examined by three 
people. They were asked to identify whether there was any indication of 9E10 
staining at the ends of any protrusions from the actin cytoskeleton. From Table 
4.1 it can be seen that the three people identified this staining pattern to occur in 
81.5 to 88.9% (mean 86%) of cases. 
 
Table 4.1: Number of myc-δC2 cells positive for 9E10 staining at the 
ends of protrusions from the actin cytoskeleton.  
 Person 1 Person 2 Person 3 
myc-δC2 cells 47/54 44/54 48/54 
Percentage positive 87.0% 81.5% 88.9% 
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4.2.3 Comparing the actin cytoskeleton structure between vector 
control and myc-δC2 expressing cells. 
Following the finding that myc-δC2 is found at the extremities of expressing cells 
at the end of actin protrusions, the actin cytoskeleton was examined in further 
detail using FITC-phalloidin staining. Differences were observed between the two 
cell types, where myc-δC2 containing cells demonstrated an increased level of 
cytoskeletal protrusions than the vector control cells. As with the cell stained for 
actin and myc-δC2, several fields were taken from several slides also selected 
where individual cells were present. From these fields, any cells which were in 
doublets or clumps were omitted from study.  
Examples of the images studied are shown in Figure 4.4, which compares the 
MDA-MB-468 vector control cells with the MDA-MB-468 myc-δC2 cells. Two 
images are shown for each cell type. The vector control cell green-stained actin 
cytoskeletons have a distinctly round profile and there are no protrusions from 
this circular state. The myc-δC2 cells however have a less rounded profile and 
several green-stained protrusions from the bulk of the cytoskeleton. 
 
 
 
 
126 
 
      MDA-MB-468 vector control cells            MDA-MB-468 myc-δC2 cells 
 
Figure 4.4: Actin cytoskeletal staining (green) of MDA-MB-468 myc-δC2 
and vector control cells (blue indicates nuclear DAPI staining).  
 
A total of 51 vector control cells and 50 myc-δC2 cells were examined by three 
people. They were asked to identify whether there was any indication of 
protrusions from the actin cytoskeleton in these cells. From Table 4.2 it can be 
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seen that they identified a higher degree of cells positive for protrusions in the 
cells over-expressing myc-δC2 (mean 80%) compared to vector only-transfected 
cells (mean 35.9%).  
 
Table 4.2: Number of cells showing protrusions from the actin 
cytoskeleton.  
 Person 1 Person 2 Person 3 
Vector control cells 22/51 13/51 20/51 
Percentage  43.1% 25.5% 39.2% 
myc-δC2 cells 41/50 39/50 40/50 
Percentage  82% 78% 80% 
 
The lack of actin protrusions in vector control cells and the presence in myc-δC2 
expressing cells may point to a role for PKC-δ in this phenomenon. The PKC-δC2 
domain may block an action of endogenous PKC-δ on the F-actin cytoskeleton. 
Since more protrusions are seen in the myc-δC2 over-expressing cells, this action 
would be to suppress the formation of protrusions. 
Actin can form several identifiable features, including: lamellopodia, filopodia, 
microvilli, ruffles and stress fibres (Allen et al., 1997). These protrusions may 
have a more fixed or a more transient nature. Lamellopodia, filopodia and 
membrane ruffles are more transient as they are associated with movement of 
cells (Nobes and Hall, 1995). Stress fibres are F-actin bundles, which can be 
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associated with connecting to a surface (Allen et al., 1997; Hall, 1994). 
Membrane ruffles and lamellopodia are broad structures seen across the leading 
edge of a cell. Lamellopodia extend from filopodia (Nobes and Hall, 1995). These 
formations are directional structures that would be associated with cell 
movement (Nobes and Hall, 1995); such directionality does not appear to be 
present in this study. In the data presented, extensions frequently project in 
numerous directions from the bulk of the cell. The extensions also vary in size. If 
the extensions do not show the directionality involved with cell movement, then 
attachment is a likely explanation, although the exact nature of the protrusions 
would require further investigation.  
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4.2.4  Studies of sub-cellular localisation of PKC-δ show similar 
profiles in vector and myc-δC2 cells 
As the cytoskeleton of myc-δC2 cells displayed differences from the myc-δC2 
cells, it was considered that there may be differences induced in the sub-cellular 
localisation of the endogenous PKC-δ. This was initially examined by immuno-
fluorescence, with confocal microscopy, but it was not possible to derive reliable 
detection of the endogenous PKC-δ. This may have been due to low levels of 
endogenous PKC-δ, weak antibody or a combination of the two. Thus the 
localisation was examined using sub-cellular fractionation. 
The sub-cellular fractionation protocol employed a kit system, which created five 
extracts. Figure 4.5 shows the manufacturer’s evidence for the protocol 
producing the correct fractions. The cytosolic fraction is obtained first. The buffer 
used induces selective membrane permeabilisation, releasing the soluble 
cytosolic components. Next the membrane fraction is collected using a buffer 
that solubilises all membranes except the nuclear membrane. This fraction 
contains all membrane constituents of the cell lysate: the plasma membrane, the 
Golgi, the endoplasmic reticulum and the mitochondria. The soluble nuclear 
fraction is the third fraction. A buffer that solubilises the nuclear membrane is 
used, releasing soluble components from the intact nuclei obtained previously. 
The chromatin-bound nuclear fraction is obtained utilising a micrococcal nuclease 
to release bound nuclear proteins. Finally the remaining pellet is extracted for 
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cytoskeletal proteins. This pellet can be quite crude and can contain a small 
amount of protein left over from the chromatin-bound nuclear fraction. 
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CE: cytoplasmic extract, ME: membrane extract, NE: nuclear extract, CB: chromatin-bound extract, 
PE: pellet extract. 
HeLa cells (2 x 106) were fractionated using the Sub-cellular Protein Fractionation Kit. 10 µg of 
each extract were analysed using Western blotting with antibodies against proteins from each 
fraction, including: cytoplasmic (HSP90), plasma membrane (EGFR), endoplasmic reticulum 
(calreticulin), nuclear soluble (SP1 and HDAC2), chromatin-bound (histone 3) and cytoskeleton 
(cytokeratin 18 and vimentin). The blots were probed with goat anti-rabbit HRP or goat anti-mouse 
HRP and detected with Thermo Scientific SuperSignal West Dura Chemiluminescent Substrate.  
Figure 4.5: Manufacturers evidence for the fractionation protocol 
providing the particular fractions as stated. (Image obtained from 
www.piercenet.com sub-cellular protein fractionation kit page) 
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Histone H3 is a chromatin associated protein, and a Histone 3 antibody (Fig. 4.6) 
was used to confirm the fractionation pattern as claimed by the manufacturer. 
Fig. 4.6 shows that after fractionation of MDA-MB-468 cells, Histone H3 is located 
to fraction 4, the chromatin bound nuclear fraction, and not to other fractions, 
providing evidence for the reliability of the fractionation protocol.  
 
                         
Figure 4.6: Check of the chromatin-bound nuclear fraction using histone 
3 antibody. Histone 3 is found in the fraction 4 (chromatin-bound 
nuclear) and a small amount in fraction 5 (cytoskeletal). This correlates 
with the manufacturers results. 
 
Fractionation of the vector control cells show the most PKC-δ is present in the 
membrane, the second largest fraction is the cytosolic fraction and the third the 
soluble nuclear fraction (Table 4.3). The myc-δC2 expressing cells show the 
largest amount of PKC-δ in the soluble nuclear and membrane fractions, followed 
by the cytosolic fraction. There are no significant differences between the cell 
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lines due to the wide variation of the extracts across the 5 occasions this was 
studied. However there are some commonalities in that the bound nuclear and 
cytoskeletal fractions are both low (Table 4.3 and Figure 4.7). 
 
Table 4.3: Distribution of PKC-δ amongst the five localisation extracts 
when cells are grown in normal growth conditions (10% serum). 
Percentage distribution shown ± standard deviation (n=3).  
 Cytosol Membrane Soluble 
nuclear 
Chromatin-
bound 
Nuclear 
Cytoskeletal 
Vector 32.78 ±18.1 41.68 ±14.0 22.70 ±13.4 2.00  ±2.1 3.90 ±6.2 
myc-δC2 27.46 ±9.7 37.62 ±9.3 35.12 ±9.4 1.18 ±0.8 1.58 ±1.3 
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Figure 4.7: Example of fractionation data showing distribution of PKC-δ. 
 
This indicates that the expression of myc-δC2 is not affecting gross PKC-δ 
localisation within the major cellular fractions, as hypothesized. It may be that 
further analysis would be required in order to identify any smaller differences, 
for example, a shift to or from the mitochondria or Golgi apparatus. 
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4.2.5  Degree of attachment differs between the vector and myc-
δC2  cell lines following a 15-minute incubation period.  
The data examining actin cytoskeletal structures in myc-δC2 and vector control 
cells showed actin extensions from myc-δC2 cells. This created a greater surface 
area. The literature indicates that PKC-δ plays a role in attachment of a cell (Kiley 
et al., 1999a).  Whilst it is difficult to predict the effect of the cellular actin 
protrusions for cell behaviour, one possible consequence could be a change in 
the way the cells attach/adhere to a surface (Hall, 1994). In order to briefly 
examine this concept, cells were introduced to a surface for 15 minutes and then 
removed. The cells remaining suspended, and thus unattached, were counted 
(Table 4.4). The myc-δC2 cells show a higher degree of attachment than vector 
control cells following incubation for 15 minutes. Perhaps the myc-δC2 is 
interfering with endogenous PKC-δ activity that would allow the cytoskeletal 
components to become disassociated, thus enabling detachment and motility.  
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Table 4.4: Percentage of cells unattached 15 minutes after introduction 
to a surface. The mean is shown ± the standard error of the mean. The 
differences between vector control and myc-δC2 are significant in a 
paired Student t-test (p≤0.05). 
 Expt 1 Expt 2 Expt 3 Mean 
Vector control 96.7% 83.3% 43.3% 74.4% (±10.7%) 
myc-δC2 66.7% 53.3% 30% 50% (±16.0%) 
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4.3 Discussion 
 
This chapter began by examining the localisation of myc-δC2 in the cell. This data 
was gathered using immuno-fluorescence where the nucleus was stained along 
with the myc-δC2 domain, through utilisation of the myc-tag. This showed that 
the myc-δC2 was present at the edges of the cells, extending from the bulk of the 
cytoplasm. Where actin staining was used, in addition to myc-δC2 staining, the 
myc-δC2 was found at the periphery of actin extensions. A more extensive 
cytoskeleton was also identified in the myc-δC2 cells over the vector cells. The 
protrusions were absent from the vector cells, indicating that they were induced 
due to the presence of the myc-δC2. Assuming myc-δC2 acts as a dominant 
negative against the function of endogenous PKC-δ, this suggests that the normal 
function of PKC-δ is to ‘round-up’ the cells and prevent the formation of these 
protrusions.  
Studies have examined the pathways associated with the development of 
particular actin formations. Activity of the proteins RhoA, Cdc42 and Rac have 
been shown to impact on the development of actin stress fibres, filopodia, and 
lamellopodia and membrane ruffling, respectively (Allen et al., 1997). Stress fibre 
formation is reliant on RhoA activity. Tyrosine phosphorylation of associated 
proteins pp125FAK and paxillin was detected upon RhoA activation (Barry and 
Critchley, 1994). PKC-δ was also found to localise to these stress fibres and focal 
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adhesions (Barry and Critchley, 1994). The importance of tyrosine 
phosphorylation in the configuration of these structures and the involvement of 
tyrosine phosphorylation in PKC-δ localisation, may suggest that tyrosine 
phosphorylation could also be involved in the targeting of PKC-δ to the area.   
However, the fractionation experiments showed that the localisation of PKC-δ 
did not alter; it remained in the membrane, cytosolic and soluble nuclear 
fractions. This could be due the level of myc-δC2 present in the cells not being 
sufficiently high to alter the localisation. The binding of myc-δC2 may induce 
observable differences as it may still have an effect on the binding partners. 
Perhaps this is by induced auto-effects, despite the fact that the kinase domain is 
missing and thus serine/threonine phosphorylation events cannot occur.  
The spreading effect of the myc-δC2 on the cytoskeleton increased the surface 
area that could bind to a surface. This was an indication that there may be an 
effect on cell surface attachment. This did appear to be the case, as shown by the 
experiment that showed increased level of attachment after incubation for 15 
minutes in myc-δC2 cells. This experiment is only a brief examination of this 
feature Further examination of this would be necessary to draw any definitive 
conclusions. Ability to attach to a surface is a consideration of invasive and 
metastatic properties of a cell. Cells which have increased attachment would be 
less likely to move and colonise a distant location. Cells which have this invasive 
ability are able to grow independent of anchorage. Further examination of these 
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characteristics is desirable to identify the extent to which differences exist. The 
literature has shown higher levels of PKC-δ are observed in more metastatic cells 
(Kiley et al., 1999a; Kiley et al., 1999b). In addition, the expression of PKC-δ in less 
metastatic cells can enhance this ability. Knockdown of PKC-δ inhibits E-cadherin 
internalisation, and thus cell scattering (Singh et al., 2009). This evidence 
illustrates PKC-δ has important roles in cell motility as increasing PKC-δ activity 
also increases movement, whilst reducing its activity prevents motility. 
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Figure 4.8: A suggested model for myc-δC2 domain action with respect 
to cytoskeletal differences. The myc-δC2 blocks the interaction of the 
endogenous PKC-δ to the cytoskeleton and focal adhesions, which would 
allow the cell to detach and become more motile. 
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A model can be established (Fig. 4.8) following the idea that the myc-δC2 
interferes with the PKC-δ interactions with the cytoskeleton. When these 
interactions are affected, the actin forms protrusions from the bulk of the 
cytoskeleton, thus allowing more extensive surface binding. However the 
localisation data shows that the positioning of PKC-δ is unaffected by myc-δC2; 
therefore it may be that a variation on this premise occurs. As suggested above, 
the amount of myc-δC2 in the cells may not be sufficient to interfere with the 
localisation of the PKC-δ. Instead, interactions could be made whereby binding of 
the C2 domain induces alterations in the binding partner.  
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 Chapter 5: Investigation of the apparent growth advantage associated with myc-δC2 expression 
 
In Chapter 3 it was noted that there appeared to be a proliferation difference 
between the cell lines developed from MDA-MB-468 and MDA-MB-231 cells. 
However this did not appear to be the case for the MCF-7 transfected cell lines. 
This chapter further examines the transfected cell lines for proliferation 
differences by studying changes in cell number over time. In MDA-MB-468 and 
MDA-MB-231 cell lines, the presence of myc-δC2 was associated with higher cell 
numbers. This was also true where myc-PKC-δ was expressed in MDA-MB-231 
cells. There was no difference in MCF-7 cell lines where myc-δC2 was expressed. 
However, myc-PKC-δ expression was associated with lower cell numbers. 
Apoptosis was examined in these cell lines to investigate whether this could 
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explain cell number differences. This was the case for the MDA-MB-468 cell lines, 
but not for the MDA-MB-231 or MCF-7 cell lines. 
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5.1  Introduction 
 
The un-transfected breast cancer cell lines exhibit several differences (see 
Chapter 1). For example, MCF-7 cells have higher endogenous levels of PKC-δ 
than MDA-MB-231 (Shanmugam et al., 2001). In Chapter 3, PKC-δ levels in MDA-
MB-468 were found to be greater than those in MCF-7 cells. The order of the 
development of transfectants appeared similar in all three cell lines. The cells 
where myc-δC2 was introduced appeared first, indicating there is a benefit to the 
cells when this domain is expressed. The transfectants of myc-PKC-δ appeared 
last, after the vector control cells, suggesting that PKC-δ over-expression may be 
detrimental. This response correlates with our hypothesis that the myc-δC2 
would competitively inhibit the endogenous PKC-δ, thus producing an effect in 
the cells which opposes the role of the endogenous PKC-δ.  
By examining the three groups of cell lines, we aim to further characterise the 
effects of over-expressing PKC-δ and expression of the C2 domain on cell 
proliferation. This will allow a better understanding of the role of PKC-δ in these 
cells.  
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5.1.1 Analysing proliferation of a population by cell number 
Proliferation of a cell population can be described as an increase in cell number. 
In order to study an increase in a cell population, cell numbers can be counted 
over a series of days, and the data charted in order to observe changes. By 
seeding the same amount of cells for each cell line considered, the proliferation 
rates can be compared. However, it is worth considering the balance of cell 
proliferation and apoptosis where a lesser increase in cell number does not 
necessarily identify lower proliferation, but may indicate a greater degree of 
apoptosis. 
 
5.1.2 Flow cytometry 
Flow cytometry can be used to examine phenotypic aspects of a cell population, 
including apoptosis. Flow cytometry is a process by which cells are passed 
through a 488nm laser beam in single file. Cell samples are mixed with sheath 
fluid which enables hydrodynamic focusing of the sample stream. This means the 
cells move through the laser beam one at a time along the same path and 
ensures sample analysis is undistorted. Cells can be studied based on the 
scattering of light to show their size and granularity. The forward scattering of 
light indicates a cell’s size; this is measured at the opposite side of the flow cell to 
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the laser beam. Side scattering of light indicates a cells granularity, which is 
detected by the reflection of the 488nm laser beam on a filter at 90° (Fig. 5.1).  
 
Figure 5.1: Configuration of the sensors and filters in the Coulter Epics 
XL Flow Cytometer. 
 
Fluorescence occurs when light of one wavelength excites electrons from their 
ground energy state to an excited state. The electrons quickly relax to the lowest 
vibrational state of the excited energy level. Light is emitted at a longer 
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wavelength when the electrons return to the ground energy state. The 488nm 
laser can be used to excite fluorescent probes, for example FITC or propidium 
iodide (PI). Probes can be attached to antibodies. These can then be used to 
study numerous cell characteristics, such as the presence of a molecule on the 
cell surface. When these probes are excited and light is emitted at a longer 
wavelength, this light travels through a series of optical filters and can be 
detected, depending on its wavelength, at several detectors (Fig. 5.1). Prior to 
the fluorescent detectors is a 488nm blocking filter which blocks any remaining 
laser light so that only fluorescent light enters the remaining parts of the flow 
cytometer. The first sensor, FL1, detects light separated by the 550 DL filter and 
the 525 BP (band-pass) filter, of 505nm to 545nm wavelength. An example of a 
fluorophore detected at FL1 is FITC. The light transmitted through the 550 DL 
filter is further separated at the 600 DL filter. Reflected light hits the 575 BP filter 
to be detected at FL2 between 560nm and 590nm. An example of a fluorophore 
detected at FL2 is R-Phycoerythrin. The light transmitted through the 600 DL 
filter is then further separated at the 645 DL filter, and reflected light enters the 
FL3 sensor though the 620 BP filter at a wavelength of 605nm to 635nm. An 
example of a fluorophore detected at FL3 is PI. Any light remaining that has been 
transmitted through the 645 DL filter is finally filtered by a 675 BP filter which 
allows light of 660nm to 700nm through to the FL4 detector. An example of a 
fluorophore detected at FL4 is Cy5. 
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5.1.3 Analysing apoptosis 
Apoptosis can be analysed using the AnnexinV – propidium iodide (AnnV - PI) 
flow cytometry assay (Vermes et al., 1995). The assay involves incubation with 
FITC tagged AnnexinV protein. AnnexinV is a Ca2+ dependent phospholipid-
binding protein. It has a high affinity for phosphatidylserine (PS), a component of 
phospholipid bi-layer membranes. During the apoptotic process, PS is flipped 
from the inner membrane leaflet to the outer membrane leaflet (Vermes et al., 
1995). Following this, FITC-AnnexinV can bind to the PS. Binding of FITC-AnnexinV 
to cells is thus a reflection of their apoptotic state (Schutte et al., 1998).  
Another component of the assay is propidium iodide (PI). This is a ‘vital dye’, 
named as such as it is excluded from viable cells which have intact membranes, 
but not from dead and damaged cells, such as those in later stages of apoptosis. 
In early apoptosis cell membranes exclude PI, whereas in later apoptosis they 
cannot; thus the PI enters and intercalates with the DNA. 
The flow cytometer detects the fluorescence of the FITC and PI and displays the 
cells according to their properties related to these two molecules. Quadrants are 
then drawn around the populations formed. If FITC-AnnexinV has not bound and 
PI has not intercalated, i.e. no fluorescent signal is detected, the cells are viable. 
If FITC-AnnexinV has not bound and PI has intercalated the cells are termed 
‘leaky’; they are damaged but aren’t undergoing apoptosis. It may be that the 
processing of the cells for the assay has damaged them; generally this quadrant 
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only contains a very low percentage of the cell population. If FITC-AnnexinV has 
bound and PI has not intercalated, the cells are early apoptotic. These cells have 
initiated apoptosis but have not gone that far through the process to the point 
where the membrane is permeable and they break up. If FITC-AnnexinV has 
bound and PI has intercalated, these cells are late apoptotic or necrotic. The 
assay cannot distinguish between late apoptosis and necrosis here as the 
membranes are distorted and permeable. However, a sizable population in the 
early apoptotic quadrant indicates that the cells in the late apoptotic and 
necrotic quadrant are likely to have gone through initiation and progression of 
apoptosis (Fig 5.2). 
 
 
Figure 5.2: An example of the AnnexinV - PI apoptosis data showing the 
four quadrants which enable determination of the apoptotic status of 
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the population. Data shows apoptotic profile of MDA-MB-468 vector 
control cells treated with 500nM camptothecin. FL1 LOG shows the 
degree of FITC fluorescence displayed on a logarithmic scale. FL3 LOG 
shows the degree of PI fluorescence displayed on a logarithmic scale. 
 
Apoptosis can be initiated through treatment with a trigger, for example, 
camptothecin. Camptothecin is an alkaloid which inhibits Topoisomerase I, thus 
blocking the elongation phase of DNA replication, thereby inducing apoptosis 
(Pommier, 2006). Analogues of camptothecin, irinotecan and topotecan, are used 
in the clinic (Pommier et al., 2010). Triggering apoptosis, in this case with 
camptothecin, may reveal differences in the apoptotic response of the cell lines. 
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5.2 Results 
 
5.2.1  MDA-MB-468 
5.2.1.1  Cell numbers are higher in myc-δC2  than vector cells 
During culturing of the MDA-MB-468 cells, the clones expressing myc-δC2 
appeared to be growing faster compared to the vector control clones. In order to 
quantify this effect a proliferation experiment was performed, whereby the cell 
numbers were tracked over several days.  
Two clones expressing myc-δC2 (A and B) and two vector control clones (A and B) 
were studied. Figure 5.3 shows that the myc-δC2-expressing cells grow at a 
higher rate.  
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Figure 5.3: The effect of myc-δC2 expression on proliferation rates of 
two clonal populations of MDA-MB-468 transfected cells when 
compared to two clonal populations of the vector control cells. A: shows 
the proliferation of two individual clones for each cell line type (n=2). B: 
shows the average growth of each clone type. myc-δC2 clone average 
shows an increased proliferation rate by Day 6 over the vector clone 
average. 
A 
B 
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It may be argued that the differences could be due to clonal variation, as the 
clones examined had developed early in the process, rather than being 
associated with the transfected agent. Thus in order to verify that the observed 
effect was not an artefact of the selection process, the pooled populations of 
myc-δC2 expressing cells and vector control cells were also studied (Fig. 5.4). 
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Figure 5.4:  The effect of myc-δC2 expression on proliferation rates of 
MDA-MB-468 transfected cells when compared to the vector control. 
Error bars are standard error of the mean (n=6). myc-δC2 cells grow at 
an increased rate to vector cells by Day 6, (p≤0.05) in a paired t-test. 
The data was analysed in Excel using a paired t-test, in which one data 
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point from one repeat of the experiment for one cell line was paired 
with the equivalent data point from the other cell line.  
 
By Day 6, increased cell numbers were associated with MDA-MB-468 pooled cells 
expressing myc-δC2 (Fig 5.4). The cells increased in number by 1.8 times over the 
vector control. Thus for MDA-MB-468 cells, either clone or pool, the presence of 
myc-δC2 is associated with higher proliferation rates. Perhaps the myc-δC2 is 
blocking an interaction of the endogenous PKC-δ C2 domain with a binding 
partner that would induce apoptosis of the cells; thus allowing the cells to survive 
and the proliferation to continue at a greater rate than the vector cells (see 
Chapter 1).  
 
5.2.1.2  Cells expressing myc-δC2  have higher viability than 
vector cells 
In order to examine the reasons for the proliferation differences identified above, 
the level of apoptosis within the pool populations were measured using the 
Annexin V-propidium iodide assay. 
The presence of myc-δC2 was associated with a greater percentage of 'alive' cells 
under normal cell culture conditions (Fig. 5.5). Also, there are significantly fewer 
cells in the early apoptotic fraction of myc-δC2 cells than the vector control. 
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There is no significant difference between the two cell lines in the late 
apoptotic/necrotic fraction. This data suggests that the expression of the myc-
δC2 protein has a protective effect upon the MDA-MB-468 cells. 
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Figure 5.5: Analysis of apoptosis in the MDA-MB-468-myc-δC2 and MDA-
MB-468 vector control cell lines using the AnnexinV - propidium iodide 
assay illustrated the decrease in levels of apoptosis in cells. The 
differences indicated by * are significant in a paired Student’s t-test 
(p≤0.05). Error bars are standard error of the mean (n=4). 
 
* 
* 
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The MDA-MB-468 cell lines were treated with 500nM camptothecin to induce 
apoptosis (Fig. 5.6). This concentration was chosen as it induced apoptosis, but 
did not kill all the cells within the 24 hours of treatment.  
Apoptosis increases in both cell lines, but more so in the presence of myc-δC2 
where the decrease in viable cells is from 77.4% to 31.3% (46.1 percentage 
points). Whereas in vector cells viability is reduced by 36.4 percentage points 
from 60.7% to 24.3% (compare Figures 5.5 and 5.6). The previously significant 
differences between the cell lines were lost. The protective effect of myc-δC2 
seen in untreated cells does not continue when cells are camptothecin treated in 
order to induce apoptosis.  
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Figure 5.6: Analysis of apoptosis in the MDA-MB-468-myc-δC2 and MDA-
MB-468 vector control cell lines when apoptosis is induced by 
camptothecin treatment using the AnnexinV - propidium iodide assay. 
Error bars are standard error of the mean (n=4). 
 
In summary, in the MDA-MB-468 cell lines a clear difference is seen where the 
presence of myc-δC2 is associated with higher levels of 'alive' cells. Differences 
are also clear where the presence of myc-δC2 is associated with lower levels of 
early apoptosis. This data correlates with the proliferation data shown in Figure 
5.3, where the myc-δC2 is associated with a greater number of cells following 6 
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days. This is due to a decreased level of apoptosis due to a protective effect of 
myc-δC2. The myc-δC2 may be interrupting the pro-apoptotic PKC-δ signal.  
The treatment of these cell lines with camptothecin prevents the protective 
effect of the myc-δC2. Camptothecin blocks Topoisomerase I. This means that 
DNA replication is halted. This DNA damage is an internal trigger to begin 
apoptosis. Under conditions where the drug is absent, and thus this does not 
occur, this DNA damage induced internal mechanism will not be activated. In 
untreated conditions, an alternate internal mechanism or an external trigger may 
be activated, where the C2 domain may play a role. It may be the case that the 
differing response of the cells, where myc-δC2 provides a protective effect in one 
case but not the other, could be due to the pathways involved in apoptosis 
induction. For example, FADD is involved in extrinsically-stimulated apoptosis, 
but not where intrinsic signals stimulate apoptosis. The myc-δC2 may only 
associate with a partner involved in a particular pathway. Alternatively, perhaps 
the concentration of camptothecin is too great and as such prevents observation 
of a protective effect. This could be tested by inducing apoptosis using lower 
concentrations of camptothecin. 
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5.2.2  MDA-MB-231 
 
5.2.2.1  Cell numbers of myc-δC2  expressing cells increase 
greater than vector cells. 
Considering the effects of myc-δC2 expression on the proliferation rates of the 
transfected MDA-MB-468 cell lines, the MDA-MB-231 transfected cell lines were 
also tested. Similar to the MDA-MB-468 cells, the pooled population of myc-δC2 
expressing cells also showed a significant increase in cell number over vector 
control cells (Fig. 5.7). 
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Figure 5.7: The effect of myc-δC2 expression on proliferation rates of 
pool populations of MDA-MB-231 transfected cells when compared to 
the vector control pool cells. Error bars show standard error of hte 
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mean (n=6). The myc-δC2 pool cells showed a significantly increased 
proliferation rate by Day 6, p≤0.002 in a paired t-test. 
 
The increase in proliferation in MDA-MB-231 cells is somewhat greater than that 
observed in the MDA-MB-468 cells. They have grown to 2.3 times the number of 
vector control cells by day 6 (1.8 times with MDA-MB-468).  
 
5.2.2.2 The myc-δC2  cells have lower viability than vector 
cells 
In order to examine whether the differences in cell number would correlate with 
apoptosis, as they did in the MDA-MB-468 cells, apoptosis was examined in the 
MDA-MB-231 cell lines (Fig. 5.8). In this case the viability levels were significantly 
lower in myc-δC2 cells. The late apoptosis/necrosis fraction of myc-δC2 cells 
showed a significant increase over vector control cell levels. 
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Figure 5.8: Analysis of apoptosis in the MDA-MB-231-myc-δC2 and MDA-
MB-231 vector control cell lines using the AnnexinV - propidium iodide 
assay. The differences indicated by * are significant according to 
unpaired Student’s t-test where p≤0.005 for ‘Alive’ and p≤0.02 for ‘Late 
apoptotic/necrotic’. Error bars are standard error of the mean (n=6).  
 
Next, camptothecin was used to induce apoptosis. It transpired that in contrast 
to MDA-MB-468 cells, which required 500nM to become apoptotic, 2 uM 
camptothecin was need to induce apoptosis in MDA-MB-231 cells. This illustrates 
a further difference between the two cell lines. The differences in apoptosis 
* 
* 
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between myc-δC2 cells and vector cells were lost when they were treated with 
camptothecin (Fig. 5.9).  
The camptothecin treatment induced significant changes in the ‘alive’ proportion 
of vector control cells, but not in the myc-δC2 cell line. Significant changes were 
also observed in the early apoptotic fraction of myc-δC2 cells following 
camptothecin treatment. However this was not seen in the vector cells.  
 
Al
ive
Ea
rly
 ap
op
tos
is
La
te 
ap
op
tos
is/
ne
cro
sis
0
20
40
60
80
100 Vector + CPT
myc-δC2 + CPT
%
 c
el
ls
 
Figure 5.9: Analysis of apoptosis in the MDA-MB-231-myc-δC2 and MDA-
MB-231 vector control cell lines when apoptosis is induced by 
camptothecin treatment using the AnnexinV - propidium iodide assay. 
Error bars are standard error of the mean (n=6). 
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The myc-δC2 expressing cells appear to be less affected by the camptothecin 
treatment (compare Fig. 5.8 and 5.9). In these cells the percentage of viable cells 
drops 4.93 percentage points, whereas the vector cells show a decrease of 12.5 
percentage points, a 2.5 times greater decrease. When induced to apoptose, the 
myc-δC2 appears to demonstrate a protective effect for the cells.  Perhaps there 
are differences between the cell types, which mean that in this cell line, the 
function of PKC-δ and its C2 domain is required. The myc-δC2 may block a 
required interaction of the endogenous PKC-δ C2 domain, thus limiting the levels 
of apoptosis. 
The MDA-MB-231 cell lines show a different pattern to that exhibited by MDA-
MB-468. Whereas in MDA-MB-468 cell lines the presence of myc-δC2 reduced 
apoptosis; in MDA-MB-231 cells the presence of myc-δC2 resulted in significantly 
less viable and more ‘late apoptotic/necrotic’ cells. This data does not 
complement the cell number data (Fig. 5.7) where myc-δC2 cells proliferated at 
an increased rate over the vector control. Considering that the apoptosis data 
does not explain the differences in proliferation rate, it is likely that a 
proliferative pathway may be affected by PKC-δ, and that the C2 domain is 
important in facilitating this. The dominant negative effect of the myc-δC2 on 
PKC-δ activity with respect to cell survival may suggest that the abundant myc-
δC2 protein is blocking an interaction of PKC-δ that is pro-survival. Indeed, the 
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literature supports the premise of PKC-δ demonstrating a pro-survival effect in 
this cell line (Lønne et al., 2009). Lønne et al illustrated the involvment of PKC-δ 
in suppressing the overactive ERK1/2 pathway in MDA-MB-231 cells. However, 
the literature did not examine the involvement of the C2 domain specifically. The 
lower viability of MDA-MB-231 myc-δC2 expressing cells demonstrates that it is 
crucial in facilitating the action of PKC-δ in this pathway. 
Upon camptothecin treatment of the MDA-MB-231 pool cell lines, the levels of 
viable cells decreased where myc-δC2 was present and also in the vector control. 
However the myc-δC2 cells show a lower decrease in viability than the vector 
control cells. This could suggest that the myc-δC2 is providing a protective effect 
under treatment with camptothecin. The role of PKC-δ in apoptosis is considered 
to be complicated and varied. Perhaps in the MDA-MB-231 cell line the role of 
PKC-δ depends on the origin of the apoptotic signal. In normal conditions, where 
campothecin does not induce DNA damage, PKC-δ is anti-apoptotic. However, 
where DNA damage is induced, e.g. by camptothecin, and detected through an 
internal mechanism to trigger apoptosis, the response and involvement of PKC-δ 
may differ and a pro-apoptotic role may transpire. 
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5.2.2.3  Expression of myc-PKC-δ is associated with 
increased cell numbers over vector control cells 
The MDA-MB-468 cell line was not successfully transfected with myc-PKC-δ, 
perhaps due to a pro-apoptotic role of PKC-δ. However in the case of MDA-MB-
231 cells, myc-PKC-δ expressing transfectants were successfully established.  
Over-expression of PKC-δ in the MDA-MB-231 increased cell numbers by 1.7 
times (at day 6 from the point of seeding) (Fig. 5.10). The increase is not as great 
as observed in cells expressing myc-δC2 (which was 2.25 times over the vector 
control).  
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Figure 5.10: The effect of over-expression of myc-PKC-δ in MDA-MB-231 
cells is to increase the rate of proliferation compared to the vector 
control cells. The increased proliferation rate is significant to p≤0.004 
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in a paired Student’s t-test. Error bars show standard error of the mean 
(n=6). 
 
The increase in proliferation caused by the presence of myc-δC2 may indicate 
that the endogenous PKC-δ would normally have an inhibitory effect on cell 
growth. Thus when the PKC-δ protein is over-expressed it could be perceived that 
a decrease in proliferation over the vector would be identified. However, this is 
not seen. In fact, an increase in proliferation is seen, albeit lower than that with 
C2 domain. The increase is somewhat supported by the literature showing PKC-δ 
to be pro-survival in MDA-MB-231 cells (Lønne et al., 2009).  
Perhaps when over-expressing the myc-δC2 domain the myc-δC2 prevents an 
endogenous PKC-δ activity to limit proliferation, thus allowing greater levels of 
proliferation. However endogenous PKC-δ may act in both an anti-proliferative 
activity and also a pro-proliferative activity, but perhaps the C2 domain is only 
involved in the former. Where PKC-δ is over-expressed it acts in both pathways, 
but perhaps more so in the latter, due to lower levels of a binding partner in the 
former pathway, thus overall increasing proliferation of the population.  
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5.2.2.4  Apoptosis does not differ between vector cells and 
PKC-δ over-expressing cells 
As with myc-δC2 expressing cells, apoptosis was examined in order to see if the 
effects of PKC-δ over-expression could explain the cell number differences (Fig. 
5.11). This was assessed with and without camptothecin treatment at 2μM (Fig. 
5.11 and 5.12). In neither case was a difference seen between the vector cells 
and myc-PKC-δ cells.  
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Figure 5.11: Analysis of apoptosis in the MDA-MB-231-myc-PKC-δ and 
MDA-MB-231 vector control cell lines using the AnnexinV - propidium 
iodide assay. Error bars are standard error of the mean (n=6). 
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Camptothecin treatment induced a difference (p≤0.005) in the percentage of 
alive vector cells. This was not seen with the myc-PKC-δ cells. MDA-MB-231 myc-
PKC-δ cells appear to show an acquired resistance to camptothecin at 2μM, 
through the over-expression of myc-PKC-δ. This could be an example of a 
protective effect of PKC-δ in these cells. It is surprising that the protective effect 
of PKC-δ is not more obvious considering the reported involvement of PKC-δ as a 
pro-survival factor (Lønne et al., 2009). However, as seen in the experiments with 
the myc-δC2 expressing cells, the pathway involved in camptothecin apoptotic 
induction may be complex. 
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Figure 5.12: Analysis of apoptosis in the MDA-MB-231-myc-PKC-δ and 
MDA-MB-231 vector control cell lines when apoptosis is induced by 
camptothecin treatment using the AnnexinV - propidium iodide assay. 
Error bars are standard error of the mean (n=6). 
 
Differences in apoptosis are not observed with PKC-δ over-expression in MDA-
MB-231 cells. This is somewhat surprising given the effect on cell numbers, 
where PKC-δ over-expression induced a 1.66 times increase over vector control 
cells, and the reported pro-survival activity of PKC-δ (Lønne et al., 2009). 
However as the cell number is a balance of apoptosis and cell proliferation, it is 
perhaps the latter that is the predominant reason for the increase in numbers. 
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5.2.3  MCF-7 
 
5.2.3.1  Cell numbers do not differ between vector and myc-
δC2  expressing cells 
Expression of myc-δC2 in MCF-7 cells did not significantly change the number of 
cells (Fig. 5.13) at any point along the time course.  
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Figure 5.13: The effect of myc-δC2 expression on proliferation rates of 
pool populations of MCF-7 transfected cells compared with the vector 
control pool cells. Error bars show standard error of the mean (n=6). 
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The MCF-7 cells may not respond to the presence of myc-δC2 in the same way 
due to a part of the pathway differing in these cells; perhaps a key protein in the 
pathway is not expressed. For example, MCF-7 cells do not express caspase-3 
(Janicke, 2009), which has been shown to participate in apoptosis involving PKC-δ 
(Reyland, 2007). 
 
5.2.3.2  Apoptotic profiles do not differ between myc-δC2 
and vector cells 
Analysis of the MCF-7 stable cell lines failed to show any differences between 
apoptotic profiles of the vector and myc-δC2 containing cell lines (Fig. 5.14). The 
lack of difference between the cell line apoptotic profiles correlates well with the 
cell number data. In both cell lines a large proportion of the population is in the 
‘alive’ category. The very low proportion of cells in the ‘early apoptotic’ division 
suggests they are not undergoing apoptosis.  
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Figure 5.14: Analysis of apoptosis in the MCF-7 myc-δC2 and MCF-7 
vector control cell lines using the AnnexinV - propidium iodide assay. 
Error bars are standard error of the mean (n=6). 
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Figure 5.15: Analysis of apoptosis in the MCF-7-myc-δC2 and MCF-7 
vector control cell lines when apoptosis is induced by camptothecin 
treatment using the AnnexinV - propidium iodide assay. Error bars are 
standard error of the mean (n=6). 
 
The treatment of camptothecin (Fig. 5.15) induces significant changes (p≤0.03) in 
the myc-δC2 cell line in the ‘Alive’ division and in both the myc-δC2 and vector 
cell lines in ‘Late apoptotic/necrotic’ division, but not in ‘early apoptotic’. 
Comparison of the myc-δC2 expressing and vector control cell lines, when 
treated with camptothecin, also fails to show any difference. As with the 
untreated samples (Fig. 5.14), the error bars reduce the ‘early apoptotic’ fraction 
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values down to approximately 0%. The increase in the ‘Late apoptotic/necrotic’ 
division suggests the camptothecin may induce necrosis of these cells. 
MCF-7 cell lines do not show any differences in apoptotic profile. Although 
viability decreases with camptothecin treatment, the cell lines respond in the 
same manner and no differences are seen. This data correlates with the cell 
number data presented in Figure 5.13, where no differences can be observed 
between the myc-δC2 containing and vector control cell lines. 
 
5.2.3.3  PKC-δ over-expressing cells show decreased cell 
numbers from the vector control at day 5.  
The MCF-7 cell line was successfully transfected with myc-PKC-δ and the 
proliferation was examined. 
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Figure 5.16: There is no effect on the proliferation rate where there is 
over-expression of PKC-δ in MCF-7 cells compared to the vector control 
cells. Day 5 decrease in growth in myc-PKC-δ cells is significant to 
p≤0.05 (in a paired Student’s t-test). Error bars show standard error of 
the mean (n=6). 
 
Over-expression of PKC-δ in the MCF-7 cells has a limited effect on the 
proliferation rate of cells, compared to the vector control transfected cells (Fig. 
5.16). On day 6 there is no significant difference in cell number. However there is 
a significant difference in cell number on day 5, showing that the over-expression 
of PKC-δ is detrimental to the MCF-7 cells. In cell proliferation profiles, cells will 
normally expand exponentially and then reach a plateau where space and 
nutrients becoming limiting factors to cell proliferation. It appears that the vector 
control cells may reach this plateau at an earlier point than the myc-PKC-δ cells. 
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There was a decrease in proliferation rate of PKC-δ from the vector cells at day 5. 
Here the PKC-δ is producing an inhibitory effect on cell numbers. The inhibitory 
effect of PKC-δ over-expression is somewhat surprising given the absence of any 
effect of myc-δC2 expression, and the clear involvement in the apoptotic 
programs of MDA-MB-468 and MDA-MB-231 cell lines. This would suggest that 
any effect of PKC-δ is not mediated by interactions of the C2 domain. 
 
5.2.3.4  There are no differences in apoptosis between PKC-δ 
over-expressing and vector cells 
The MCF-7 PKC-δ over-expressing cell were assessed for apoptosis and compared 
with vector cells (Fig. 5.17). In untreated cells there is no significant difference 
between the vector cells and the myc-PKC-δ cells. When the apoptosis profile 
was also assessed following camptothecin treatment at 2μM, there was no 
significant difference between the cell lines in any division (Fig. 5.18). The error 
bars suggest that there is no real proportion of ‘Early apoptotic’ cells, as the error 
reduces to 0%. 
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Figure 5.17: Analysis of apoptosis in the MCF-7-myc-PKC-δ and MCF-7 
vector control cell lines using the AnnexinV - propidium iodide assay. 
Error bars are standard error of the mean (n=6). 
 
It is worth noting that significant increases are induced by camptothecin 
treatment in the ‘Late apoptotic/necrotic’ division of the vector control cell line. 
This increase in the ‘Late apoptotic/necrotic’ quadrant following camptothecin 
treatment is not seen in the PKC-δ over-expressing cell line, suggesting a 
protective effect of the over-expression. As the differences are minimal between 
the ‘Late apoptotic/necrotic’ fractions of untreated and treated PKC-δ cells, the 
effect does not appear to carry pronounced influence on cell-survival.  
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Figure 5.18: Analysis of apoptosis in the MCF-7-myc-PKC-δ and MCF-7 
vector control cell lines when apoptosis is induced by camptothecin 
treatment using the AnnexinV - propidium iodide assay. Error bars are 
standard error of the mean (n=6). 
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5.3 Discussion 
 
The 3 cell lines have been found to differ from each other, despite their similar 
origin (see Chapter 1). This is mirrored in their response to manipulation of PKC-
δ. The MDA-MB-468 cell lines have demonstrated that endogenous PKC-δ holds a 
pro-apoptotic role. This is indicated by the anti-apoptotic effect of myc-δC2 
expression and also the inability to develop a PKC-δ over-expressing cell line. The 
literature describes a pro-apoptotic role for PKC-δ involving nuclear translocation 
and cleavage of the regulatory portion (Humphries et al., 2008). Tyrosine 
phosphorylation (of Y64 and Y155) has been shown to be vital for this effect. One 
of these residues is in the C2 domain of PKC-δ, thus indicating a role for the C2 
domain in this apoptotic process. The data described in this chapter further 
supports the premise that the C2 domain is important in this process. Further 
research would be required to identify whether this role is more extensive than 
the previously identified phosphorylation aspect (perhaps demonstrating the 
effect illustrated in Fig. 5.19). As the C2 domain is a known protein binding 
domain (Dekker and Parker, 1997; Lopez-Lluch et al., 2001), it is possible that this 
role could be interlinked with the tyrosine phosphorylation, whereby it facilitates 
a key interaction in PKC-δ apoptotic activity. 
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Figure 5.19: A suggested model for the response to myc-δC2 expression 
in MDA-MB-468 cells. The myc-δC2 interrupts the endogenous PKC-δ 
binding with the ‘apoptotic protein’ thus preventing apoptosis induction 
and allowing cell numbers to increase. 
 
 The MDA-MB-231 cell lines indicated an anti-apoptotic role for PKC-δ through 
the myc-δC2 studies. The PKC-δ over-expressing cell data did not correlate with 
this. A straight-forward deduction would expect the over-expressing cells to have 
higher viability than the vector cells; however the PKC-δ over-expressing cells did 
not show a difference from the vector control. It may be that the myc-δC2 is 
inhibiting an interaction of the PKC-δ in an anti-apoptotic role, but that the over-
expression of PKC-δ cannot further stimulate this to induce greater survival. If the 
binding partner involved in transmitting this effect is not widely available in the 
cell, and there are already greater levels of endogenous PKC-δ relative to this 
binding partner, it is possible that the involved binding protein cannot ‘work 
 
180 
harder’. The endogenous PKC-δ levels are lower in these cells than the other two 
cell lines examined in this study (Chapter 3). Perhaps the MDA-MB-231 cells are 
particularly sensitive to PKC-δ activity. It appears that the levels seen in the other 
cell lines are not required here in order to function normally. 
The PKC-δ over-expressing MDA-MB-231 cells appear to illustrate a pro-
proliferative role for PKC-δ. Cell numbers are higher in over-expressing cells, but 
apoptosis is unaffected. It may be that the C2 domain of PKC-δ is not involved in 
this pro-proliferative role; thus the role is only apparent under these PKC-δ over-
expressing conditions. 
In MDA-MB-231 cells, the differences observed under camptothecin treated 
conditions were suspected to be due to the involvement of PKC-δ and the C2 
domain within different apoptotic induction mechanisms. Apoptosis can be 
induced through extrinsic or intrinsic pathways, where either cell-surface 
signalling or a DNA damage induced response initiates the pathway (Rossi and 
Gaidano, 2003). The two pathways are linked in certain areas (e.g. caspase-3) but 
are the result of separate initiation events. It could be that the presence of myc-
δC2 in the cells undergoing apoptosis induced from an extrinsic pathway led to 
greater levels of apoptosis due to prevention of the pro-survival PKC-δ role. 
However, where cells were camptothecin treated, and thus the intrinsic pathway 
was initiated, the PKC-δ may play an alternative role. Thus interference of myc-
δC2 with endogenous PKC-δ has alternative effects.  
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The literature describes cleavage of PKC-δ in the nucleus during apoptosis, 
between the regulatory and catalytic fragments by caspase-3 (DeVries-Seimon et 
al., 2007). The free catalytic domain further stimulates apoptosis. Caspases can 
have overlapping roles in cell signalling. In some cases other caspase family 
members can take over a role of a missing caspase. However, analysis of similar 
caspases 7 and 6, as well as caspases 1, 2 and 4 found they were incapable of 
performing the cleavage of PKC-δ (Ghayur et al., 1996). Thus without the 
caspase-3 this pro-apoptotic process cannot occur. MCF-7 cells do not express 
caspase-3 (Janicke, 2009); thus where absent, PKC-δ would not be cleaved and 
apoptosis may be averted. This may explain the lack of myc-δC2 effect on the 
MCF-7 cells, as it cannot interfere with a process which is not occurring.  
In the MCF-7 cells, the PKC-δ over-expressing cells show lower cell numbers. This 
is not related to higher apoptosis levels. Perhaps the cells cycle at a lower rate. 
This would allow lower numbers of cells, without affecting apoptotic 
mechanisms. This would indicate an anti-proliferative effect of PKC-δ, and that 
the C2 domain is not important in this action. However further investigation 
would be required to confirm this.  
 
The MDA-MB-468 cell line data shown in this chapter indicates a pro-apoptotic 
role for PKC-δ, which is prevented through the action of the myc-δC2. In Chapter 
4 we observed that the myc-δC2 had an effect on the cytoskeletal structure of 
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the cells (compared the vector control). If the more extensive structure is indeed 
aiding attachment of the cells to the surface, the levels of apoptosis in the 
population would be likely to decrease. This would be due to cells entering 
apoptosis when unattached, through the process of anoikis (Chiarugi and 
Giannoni, 2008). If this is the case the data from Chapter 4 and 5 indicate the C2 
domain has an important role in preventing apoptosis of MDA-MB-468 cells by 
aiding attachment. 
 
The effects in the three cell types are different. There does not appear to be a 
general PKC-δ role across all breast cancers. This mirrors the heterogeneity of 
tumours in the clinic and differential responses to treatments amongst patients. 
It seems clear that tumour profiling would be important in identifying treatment 
options with respect to any drugs developed as a result of this research. 
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 Chapter 6: Investigations of the apoptotic pathway in MDA-MB-468 under starvation conditions 
 
In Chapter 5 it was shown that in 10% serum, the expression of the myc-δC2 
domain provided a pro-survival signal to MDA-MB-468 cells. PKC-δ activity has 
been shown to be affected by tyrosine phosphorylation of specific residues (Blass 
et al., 2002; Humphries et al., 2008). Tyrosine phosphorylation has also 
demonstrated a role within regulation of apoptosis. The signal for tyrosine 
phosphorylation can be received from numerous stimuli (Brodie and Blumberg, 
2003). By using serum starvation we aimed to prevent this process and study 
how the cells responded to the absence of this stimulation. Using this method, 
the apoptotic response of the transfected MDA-MB-468 cell lines was studied. 
When MDA-MB-468 cells were starved, expression of myc-δC2 had a pro-
apoptotic effect, which is opposite to the observation in 10% serum. This action 
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suggests an anti-apoptotic role for PKC-δ under starvation conditions. In parallel, 
the presence of the myc-δC2 domain was associated with increased ERK1/2 
phosphorylation, without affecting ERK1/2 levels. Furthermore, proteasome 
blockers prevented the pro-apoptotic effects associated with myc-δC2 
expression, demonstrating the importance of proteasome activity in facilitating 
the role of PKC-δ. 
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6.1 Introduction 
 
The MDA-MB-468 cells transfected with myc-δC2 showed an altered apoptotic 
response (See Chapter 5). In order to further examine the involvement of PKC-δ 
and its C2 domain within apoptosis in the MDA-MB-468 cell lines, the cells were 
scrutinized using several assays. Cells were serum-starved to examine whether 
the survival advantage provided by myc-δC2 would be continued, and even 
enhanced, under stress conditions. 
Tyrosine phosphorylation is involved in the regulation of PKC-δ activity in 
apoptosis (Brodie and Blumberg, 2003). Tyrosine residues are phosphorylated 
following stimulation of particular signalling pathways. Kajimoto et al revealed 
that the Src family of kinases were important in tyrosine phosphorylation related 
to nuclear activation and apoptosis (Kajimoto et al., 2010). The Src family can 
become activated following extracellular signalling events (Parsons and Parsons, 
1997). Where serum is absent such signalling events would not be triggered. 
Serum starvation could thus be expected to silence tyrosine phosphorylation, 
altering the apoptotic response. By silencing the effect of tyrosine 
phosphorylation, it may be that the effects of the C2 domain on apoptosis would 
also be neutralised.  
Further examination of pathways can be achieved through treatment with 
inhibitors. Commercially available PKC-δ inhibitors are not sufficiently specific. 
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However investigations can be performed on associated proteins in order to 
illustrate the role of PKC-δ. The role of tyrosine kinases in targeting and 
controlling PKC-δ activity appears to be extensive (Brodie and Blumberg, 2003). 
The Src family of kinases have demonstrated involvement in PKC-δ activity. 
Inhibition of Src may reveal further information about PKC-δ in apoptosis.  
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6.2 Results 
 
6.2.1 When cells are serum-starved the apoptotic profile alters 
so that cells containing myc-δC2  show more apoptosis 
MDA-MB-468 transfected cells were starved for 72 hours and the apoptotic 
profile analysed in order to examine whether any differences between the 
response of myc-δC2 and vector cells would be seen.  
The profile illustrated a large difference between the myc-δC2 and vector cells in 
‘alive’, ‘early apoptotic’ and ‘late apoptotic/necrotic’ groups. This difference was 
such that the myc-δC2 cells showed lower viability than the vector cells and 
higher levels of apoptosis in both early and late apoptotic/necrotic groups. 
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Figure 6.1: Apoptosis measured following 72 hours starvation showed 
myc-δC2 cells have lower viability and more apoptosis than vector cells. 
Error bars are standard error of the mean (n=4). Differences (*) are 
significant in an unpaired t-test (p≤0.03). 
 
The lower viability in the myc-δC2 cells suggests the protein fragment is pro-
apoptotic. As an inhibitor of the normal PKC-δ function, it can thus be deduced 
that the PKC-δ would exert an anti-apoptotic effect. This is in contrast with the 
role identified in Chapter 5 under 10% serum conditions. 
* 
* 
* 
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6.2.2 Src does not appear to be involved in PKC-δ tyrosine 
phosphorylation. Overall tyrosine phosphorylation levels do not 
differ between the vector and myc-δC2  cells. 
 
6.2.2.1 Src inhibition using SU 6656. 
Src has been implicated in tyrosine phosphorylation of PKC-δ (Kajimoto et al., 
2010). Src activity would be stimulated by the effects of serum. Thus if Src 
tyrosine phosphorylation is involved in the targeting of PKC-δ to demonstrate the 
anti-apoptotic activity exemplified in Figure 6.1, then the inhibition of Src in the 
presence of serum should produce the equivalent result as when serum is 
omitted. Src inhibition would encourage PKC-δ to act in the anti-apoptotic role 
identified in serum-starved conditions. The myc-δC2 would be expected to block 
the endogenous PKC-δ activity, as observed in starvation. Thus cells would show 
greater levels of apoptosis than the vector control cells.  
The cells were grown in serum and treated with 100nM inhibitor for 24 hours 
prior to examination of apoptotic status. The concentration used was selected 
following testing to investigate a suitable concentration. Tests revealed that the 
inhibitor is toxic to the cells, but at this concentration the cells were able to 
survive for the required period. We used a treatment time of 24 hours, despite a 
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30 minute treatment window being utilised in the literature, to be sure that the 
signalling pathway would be appropriately affected by the treatment. Too short a 
period may not allow enough time for the serum stimulated effects to dissipate 
and the effect of the inhibitor to be seen.  
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Figure 6.2: The effects of Src inhibitor SU6656 on MDA-MB-468 myc-δC2 
and vector cells following 24 hour treatment. Error bars are standard 
error of the mean (n=6). Differences (*) are significant in an unpaired t-
test (p≤0.04). 
 
Where the Src inhibitor is present there is greater apoptosis in both vector 
control and myc-δC2 expressing cells (Fig. 6.2). However, the differences 
* 
* 
* 
* 
* 
* 
 
191 
observed under starvation between the vector control cells and the myc-δC2 
expressing cells did not persist under Src inhibition. Differences were identified in 
the ‘Late apoptotic/necrotic’ fraction between vector control cells and myc-δC2 
containing cells with and without treatment, where vector control cells show 
higher proportions of cells in this fraction. However the numbers within these 
portions are not high in either case; thus the differences, although significant, are 
minimal. The treatment induced changes in both the vector control cells and the 
myc-δC2 cells, where the number of cells in the ‘Alive’ portion is decreased by 
treatment and the number in the ‘Early apoptotic’ section is increased. 
It is worth noting that the data obtained in this experiment is not comparable to 
the data in Figure 5.5 due to differences in the methods used. These differing 
methods are possibly the reason for the variation observed between Figures 5.5 
and 6.2 with respect to the proportion of viable vector control and myc-δC2 
expressing cells. 
The lack of effect by the SU6656 inhibitor, to induce the differences seen 
between vector control cells and myc-δC2 cells under starvation conditions, 
suggests that Src is not a key part of the process in this case.  
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6.2.2.2 Tyrosine phosphorylation 
PKC-δ is subject to tyrosine phosphorylation by other kinases (Steinberg, 2008). 
This phosphorylation is involved in PKC-δ activation and targeting (Reyland, 
2007). The tyrosine phosphorylation of particular residues, one in the C1 domain 
and one in the C2 domain, are key to the targeting of PKC-δ to the nucleus where 
it can be cleaved and becomes involved in apoptosis (Humphries et al., 2008; 
Kajimoto et al., 2010; Steinberg, 2008). Thus as tyrosine phosphorylation is of 
such importance to PKC-δ activity, we examined the tyrosine phosphorylation of 
both the PKC-δ, and in the myc-δC2 cells, the myc-δC2 domain.  
As PKC-δ activation regularly involves tyrosine phosphorylation, cells were 
treated with a known activator of PKC-δ in order to test if tyrosine-
phosphorylation status was altered. Phorbol 12-myristate 13-acetate (PMA), a 
phorbol ester compound, was thus used to treat a flask of each cell type prior to 
lysis.  
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Figure 6.3: Two IP results where PKC-δ was used to immuno-precipitate 
and anti-p-tyrosine used to probe. Both experiments show a similar 
pattern, whereby no difference is seen between vector control and myc-
δC2 cells with or without PMA stimulatory treatment. 
 
The band intensity did not vary between the vector control cells or myc-δC2 cells, 
whether PMA treated or not (Fig. 6.3). Although a difference in activity was 
expected, as exemplified by tyrosine phosphorylation, the experiment indicates 
that the activity levels are comparable across all conditions. The PKC-δ in the cells 
may be equally tyrosine phosphorylated; however the tyrosine residues that are 
phosphorylated may differ. This is not taken into consideration when probing 
with phospho-tyrosine antibody. In order to do this, antibodies against 
phosphorylation of particular tyrosine residues would have to be used.  
The PMA binds the C1 domain of the PKC-δ to activate the protein (Cho, 2001). 
However, PMA does not necessarily induce tyrosine phosphorylation. The 
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absence of a difference between the cell lines, whether PMA treated or not, does 
not indicate that the PMA treatment has not activated the protein, just that the 
overall tyrosine phosphorylation levels are unaffected in this case.  
The presence of the myc-δC2 domain alters the cell profile (as seen in Chapters 4 
and 5). As tyrosine phosphorylation is used to control PKC-δ function, and the 
endogenous PKC-δ function appeared to be altered by the presence of myc-δC2, 
it was possible that the tyrosine phosphorylation process may be interfered with. 
However, as the PKC-δ demonstrated similar levels of tyrosine phosphorylation 
under all the conditions examined, it does not seem to be the case that the myc-
δC2 interferes with the tyrosine phosphorylation status. This was somewhat 
confirmed by the examination of the myc-δC2 IP with phospho-tyrosine probe 
(Fig. 6.4), where there was no identifiable signal for tyrosine phosphorylation of 
the C2 domain. It could be that the kinases responsible for the tyrosine 
phosphorylation identified in the literature can only interact with the whole 
protein, and not solely the C2 domain. 
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Figure 6.4: IP results of myc-δC2 tyrosine phosphorylation study. Panel 
A shows tyrosine phosphorylation probe, panel B shows 9E10 myc-tag 
probe. No tyrosine phosphorylation of the myc-δC2 domain is seen, the 
IP of the myc-δC2 domain was confirmed by probing with 9E10 
antibody. 
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6.2.3 Proteasome activity is vital for anti-apoptotic activity 
under starvation conditions. 
The literature has previously described an anti-apoptotic role for PKC-δ in MDA-
MB-231 cells (see Chapter 1). This pathway was active due to a ras mutation, and 
was found to be dependent on proteasome activity. Although a ras mutation in 
MDA-MB-468 cells has not been described in the literature, the effects of 
starvation on the cells advocated further examination of the pathway. This may 
provide evidence that the pathway is somehow implicated in the effects 
identified under starvation.  
The cells were starved for 72 hours, and selected samples treated with MG132 
for the final 5 hour period of this interval. The cells showed the same pattern 
with starvation as seen in Figure 6.1, where myc-δC2 containing cells showed 
lower viability than the vector control cells. However with MG132 treatment the 
levels of viability in myc-δC2 cells increased to a similar level as the vector control 
cells (Fig. 6.5). The increase in viability was significant, and when MG132 treated 
there was no longer a significant difference between the myc-δC2 cells and 
vector control cells. 
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Figure 6.5: The effects of proteasome inhibitor MG132 and starvation on 
cells following 72 hours of starvation including the final 5 hours MG132 
treatment. Error bars are standard error of the mean (n=6). Differences 
(*) are significant in an unpaired t-test (p≤0.04). 
 
The cells were also tested for effects following 24 hours of starvation and MG132 
treatment (Fig. 6.6). The results demonstrated that the cells did not appear to be 
fully starved, as the myc-δC2 had yet to produce the detrimental effects on the 
cell survival. However the treatment with MG132 did produce significant 
differences in viability of the myc-δC2 containing cells which was absent in the 
vector control cells. The myc-δC2 cells showed lower viability and higher 
proportions in both ‘Early apoptotic’ and ‘Late apoptotic/necrotic’ fractions. The 
* 
* 
* 
* 
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increase in ‘Late apoptotic/necrotic’ cells was minimal, with an increase from 1.1 
to 2.8%. There is also a significant difference between vector control cells and the 
myc-δC2 cells in the ‘Late apoptotic/necrotic’ fraction. However, once again the 
difference is minimal with vector control averaging 1.9 and myc-δC2 1.1%. 
Examination of this data is complicated due to the mixed status of these cells 
between 10% serum and 72 hour starvation conditions. The presence of a 
difference between the effects of the MG132 on the myc-δC2 cells and the 
vector control cells suggests a possible further role for the C2 domain of PKC-δ. 
Further investigation would be required to elucidate this role. 
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Figure 6.6: The effects of proteasome inhibitor MG132 and starvation on 
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the mean (n=5). Differences (*) are significant in an unpaired t-test 
(p≤0.01). 
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6.2.4 ERK phosphorylation status 
The differences identified in apoptosis levels in the cells when starved (and 
where treated with proteasome inhibitor MG132), is possibly due to the action of 
a pathway involving ERK1/2 phosphorylation, since the level of ERK1/2 
phosphorylation has been associated with apoptosis (Lønne et al., 2009; Lu and 
Xu, 2006; Subramaniam and Unsicker, 2010). PKC-δ is also known to be an 
upstream activator of ERK (Schonwasser et al., 1998). 
Blots of MDA-MB-468 vector control and myc-δC2 containing cell lines were 
examined to identify the levels of phosphorylated ERK1/2, but also the levels of 
total ERK1/2. This check ensured that the differences seen in the phosphorylation 
status were not due to increases and decreases in the levels of the ERK1/2 
proteins themselves.  
 
6.2.4.1 ERK1/2 phosphorylation in not-starved and starved 
conditions  
The phosphorylation status of the ERK1/2 protein is an indication of the activity 
status of the protein. Western blots of MDA-MB-468 vector control and myc-δC2 
containing cell lines were probed with phosphorylated ERK1/2 antibody and 
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quantified, in order to examine the degree of ERK1/2 phosphorylation in the 
cells. 
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Figure 6.7: Phosphorylated and Total ERK1/2 levels in vector control 
and myc-δC2 cells under 10% serum conditions. 
 
Under not-starved conditions the levels of phosphorylated ERK1/2 do not vary 
greatly between the vector control and myc-δC2 expressing cells (Figure 6.7). In 
two out of three cases the degree of phosphorylation increases slightly, as shown 
in Figure 6.8. The levels of total ERK1/2 do not vary between the vector control 
and myc-δC2 cells, as also confirmed in Figure 6.8.  
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Phosphorylated and total ERK1/2 levels in vector control cells and myc-δC2 cells 
under not-starved conditions were quantified (Fig 6.8). 
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Figure 6.8: Comparison of phosphorylated (a) and total (b) ERK1/2 
levels in not-starved myc-δC2 cells where the not-starved vector is set at 
100%. Error bars are standard error of the mean (n=3). 
 
Little difference was seen between the levels of phosphorylated ERK1/2 under 
non-starved conditions (Fig. 6.8 (a)). The data was inconsistent.  One data set 
showed a sharp decrease in phosphorylation, whilst the other two data sets 
showed an increase in phosphorylation in the myc-δC2 cells. Whether the 
conflicting data set is included in the mean, or not, there is only a modest 
increase in phosphorylation. 
(a) (b) 
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Figure 6.8 (b) shows that total ERK1/2 levels are unmoved, thus the differences in 
phosphorylation of ERK1/2 are not due to variation in the general ERK1/2 level. 
 
Starvation induced a difference in apoptotic response between the vector and 
myc-δC2 expressing cells. As ERK1/2 phosphorylation can be associated with 
apoptosis, the differences were also examined between the vector control cells 
and the cells expressing myc-δC2 under and starvation conditions (Fig. 6.9). 
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Figure 6.9: Phosphorylated and Total ERK1/2 levels in vector control 
and myc-δC2 cells under starvation conditions (72 hours). 
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In starved conditions the phosphorylation status of ERK1/2 displays greater 
variation (Figure 6.9). In two out of three occasions, there is a clear increase in 
phosphorylated ERK1/2 levels from vector control to myc-δC2 expressing cells, 
which is also indicated in Figure 6.10 (a). On the third occasion there was also an 
increase, but to a lesser degree. The levels of total ERK1/2 remain broadly 
unaffected (Figures 6.9 and 6.10). 
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Figure 6.10: Comparison of phosphorylated (n=2*) and total (n=3) 
ERK1/2 levels in myc-δC2 starved cells where starved vector cells are 
set at 100%. In (b) error bars are standard error of the mean. * The 
phosphorylation levels relative to vector control in starved cells could 
not be calculated for the third set of data as there was no 
phosphorylation of ERK in the vector cells under these conditions. 
 
(a) (b) 
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The phosphorylation levels relative to vector control in starved cells could not be 
calculated for the third set of data. However phosphorylation was seen in the 
myc-δC2 cells, indicating an increase in ERK1/2 phosphorylation in corroboration 
with the data that could be analysed. 
Figure 6.10 (b) shows that Total ERK1/2 levels remain unchanged, thus the 
differences in phosphorylation of ERK1/2 are not due to alterations in the overall 
level of ERK1/2. 
 
6.2.4.2 ERK1/2 phosphorylation following MG132 treatment 
Proteasome activity was shown to be important in the anti-apoptotic activity of 
PKC-δ in starved conditions. Thus ERK1/2 phosphorylation levels were examined 
following MG132 treatment (Figs. 6.11 and 6.12). Figure 6.11 is an example of a 
gel showing phosphorylated ERK1/2 amounts (and total ERK1/2 amounts) in 
starvation conditions, with and without MG132 treatment.  The phosphorylated 
ERK1/2 levels are considerably lower in the vector control cells over the myc-δC2 
cells, whether MG132 is present or not. The levels of phosphorylated ERK1/2 in 
the myc-δC2 cells is also seen to decrease, although not the vector control cell 
levels, with MG132 treatment. The total levels of ERK1/2 are quite similar (as 
seen when analysed in Figure 6.13) across the conditions. 
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Figure 6.11: Phosphorylated ERK1/2 and total ERK1/2 showing 
differences with vector control and myc-δC2 in starved conditions, with 
and without MG132 proteasome inhibitor present.  
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Figure 6.12: Comparison of phosphorylated ERK1/2 levels in starved 
myc-δC2 cells with MG132 treatment where starved and MG132-treated 
vector cell are set at 100% (n=1). 
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The phosphorylation is greater in the myc-δC2 cells than the vector control cells. 
However, overall the difference is lower in this case than in the untreated starved 
cells (see Fig. 6.10). This indicates a lower level of phosphorylation of ERK1/2 in 
myc-δC2 cells where MG132 treatment was given. This decrease indicates that 
prevention of proteasome activity is correlated with ERK1/2 de-phosphorylation. 
The phosphorylation levels relative to vector control in starved cells treated with 
MG132 could not be calculated for the second set of data, as there was no 
phosphorylation of ERK in the vector cells under these conditions. However there 
was phosphorylation in the myc-δC2 cells. Thus the data supports the data set 
shown in Figure 6.12. The levels of ERK1/2 phosphorylation are very low, or non-
existent in the vector cells. This limits the ability to analyse the data.  
Figure 6.13 shows that total ERK1/2 levels vary little; thus the differences in 
phosphorylation of ERK1/2 are not due to differences in the total level of ERK1/2. 
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Figure 6.13: Total ERK1/2 levels in (a) starved and MG132 treated cells 
where vector is set at 100%; (b) shows starved untreated and treated 
cells where the untreated vector cells are set at 100% (n=2). 
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6.2.5 Sub-cellular fractionation demonstrates that although the 
cell lines do not demonstrate any significant differences between 
each other, starvation does induce differences in the profile of 
PKC-δ localisation  
In starved cells (Table 6.1) the bound nuclear and cytoskeletal fractions are low. 
In the vector control cells the membrane fraction contains the highest level of 
PKC-δ, with the soluble nuclear and then cytosolic fractions containing 
progressively less. From the non-starved cells, the decrease in the amount in the 
cytosolic fraction is significant (paired Student’s t-test, p≤0.02). This could be due 
to the PKC-δ becoming activated under cellular stress and localising to alternate 
cellular compartments. In myc-δC2 expressing cells the highest amount of PKC-δ 
is seen in the membrane fraction, followed by the soluble nuclear and the 
cytosolic fractions. This is a similar pattern as seen with the vector control cells. 
Significant differences were also induced in the PKC-δ profile in the myc-δC2 cells 
through starvation. A significant increase was seen in the membrane fraction 
(p≤0.04) and a significant decrease in the cytosolic fraction (p≤0.01). This 
suggests a shift of the PKC-δ from the cytosol to the membrane, presumably in 
response to activation through starvation allowing targeting to the 
compartments where it is required for action. 
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Table 6.1: Distribution of PKC-δ amongst the five sub-cellular extracts 
comparing not-starved cells and starved cells. Percentage distribution 
shown ± standard deviation. 
 Cytosol Membrane 
Soluble 
nuclear 
Chromatin-
bound 
nuclear 
Cytoskeletal 
Vector – 
10% serum 
32.78 ±18.1 41.68 ±14.0 22.70 ±13.4 2.00 ±2.1 3.90 ±6.2 
Vector – 
starved 
4.58 ±4.3 63.96 ±19.7 31.44 ±21.7 0.04 ±0.1 0.00 ±0.0 
myc-δC2 – 
10% serum 
27.46 ±9.7 37.62 ±9.3 35.12 ±9.4 1.18 ±0.8 1.58 ±1.3 
myc-δC2 - 
starved 
9.50 ±7.9 53.38 ±11.2 37.12 ±12.6 0.00 ±0.0 0.00 ±0.0 
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6.3 Discussion 
 
The response of MDA-MB-468 cell lines to starvation was surprising due to the 
opposite effect being identified in 10% serum conditions. However, the literature 
has previously described an anti-apoptotic role for PKC-δ, in MDA-MB-231 cells. 
The pathway described in MDA-MB-231 cells is reliant on the presence of a ras 
mutation which activates the ERK1/2 proteins to such a level that, without a 
suppressive action of PKC-δ, it would be lethal (Lønne et al., 2009). This pathway 
is described in Figure 6.14. This raises the question of what is happening in the 
MDA-MB-468 cells, where a ras mutation has not been identified. The ERK1/2 
phosphorylation status of MDA-MB-468 cells was shown to be lower than in 
MDA-MB-231 cells, but still higher than another breast cancer cell line MCF-7 
(Lønne et al., 2009). Thus perhaps these cells have an alternative mutation that is 
affecting and activating the pathway in some manner.  
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Figure 6.14: The anti-apoptotic pathway in which PKC-δ is involved 
(Lønne et al., 2009) 
 
Studies have identified PKC-δ activity to be affected by phosphorylation. Src 
activity is a possible method of achieving this phosphorylation. A Src inhibitor 
was used to examine whether the cellular apoptotic profile would respond to 
show a similar effect to starvation conditions. This was not the case, and thus 
suggests that Src is not the key factor in facilitating the phosphorylation of PKC-δ 
in this situation. There are other tyrosine kinases that would need to be 
examined in order to identify the participating component. Alternatively, perhaps 
PKC-δ activation is achieved through action of DAG binding.  
Tyrosine phosphorylation status of the protein in general was also examined to 
see whether this was altered by the presence of the myc-δC2 in the system. This 
did not appear to differ between the two situations. However this is not a 
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conclusive examination of the tyrosine phosphorylation status of PKC-δ as this 
only examined overall tyrosine phosphorylation. Numerous papers have 
identified that the particular tyrosine residues phosphorylated in PKC-δ differs 
according to the stimulus (Blass et al., 2002; Hall et al., 2007; Konishi et al., 2001; 
Li et al., 1996). Thus examination of the particular residues would be required to 
create a more substantial profile of any tyrosine phosphorylation differences. 
However it may be that tyrosine phosphorylation is not involved in PKC-δ 
targeting and it is another factor. Perhaps DAG and PS binding is involved, or PKC-
δ activation and targeting is more complex than initially thought. 
We investigated further whether the cells responded in a similar manner to other 
aspects of the MDA-MB-231 study. The study identified proteasome activity as 
vital to the action of PKC-δ. As shown in Figure 6.14, MKP3 activity is important 
for cell survival as it de-phosphorylates the ERK1/2 to a level at which the cells 
are able to remain viable. MKP3 levels are regulated through ubiquitinylation and 
proteasome degradation. Thus the activity of the proteasome is key for 
breakdown of ubiquitinylated MKP3 and reduction of the protein levels. Without 
this breakdown the MKP3 may still instigate de-phosphorylation of ERK1/2, thus 
returning ERK1/2 phosphorylation to a level at which cells can survive. The 
literature has shown that where PKC-δ is active in this pathway, in this case 
under starvation conditions for 72 hours, the cells are able to survive. The 
literature also demonstrates that PKC-δ depletion leads to increased ERK1/2 
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phosphorylation and cell death. Where myc-δC2 is present, and thus PKC-δ is 
unable to act, the cells would be expected to die, as seen in Figure 6.1.  
The literature illustrates the combined effect of PKC-δ depletion and proteasome 
inhibition to be increased MKP3 levels, resulting in de-phosphorylation of ERK1/2 
and thus cell survival. As the myc-δC2 appears to act in a similar way to depletion 
of PKC-δ, the effects combined with the MG132 treatment would be expected to 
be the same, where the cell viability returns to the level seen with the vector 
control cells. Vector control cells treated with MG132 would be expected to show 
little difference to untreated cells, as the NEDD4 remains inhibited and the MKP3 
remains free to de-phosphorylate ERK1/2. This shows that the part of the 
pathway requiring the proteasome identified in MDA-MB-231 cells is also vital in 
the MDA-MB-468 cells when starved, and suggests a similar pathway is in effect.  
ERK1/2 phosphorylation has been demonstrated to be involved with cell survival 
and death (Lu and Xu, 2006; Subramaniam and Unsicker, 2010). The Lønne study 
(2009) showed that phosphorylation levels of ERK1/2 were important in whether 
the cells were viable or not, where extremely high levels induced apoptosis. The 
higher levels of apoptosis in starved MDA-MB-468 myc-δC2 cells correlated with 
higher ERK1/2 phosphorylation than that seen in vector cells. This effect was not 
due to differing levels of the proteins themselves, but solely to phosphorylation 
levels.  
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Figure 6.15: The C2 appears to be involved in ‘sensing’ the serum status 
and appropriately directing PKC-δ activity. 
 
Altogether this evidence illustrates that it is likely that the pathway identified in 
the MDA-MB-231 cells is also active in the MDA-MB-468 cells when they are 
serum-starved. The difference in the cells where serum is present and where it is 
absent is an indication that the C2 domain may be involved in ‘sensing’ the serum 
status of the cells and appropriately directing the activity of the PKC-δ (Fig. 6.15). 
Thus far there has been no identification of a ras mutation in MDA-MB-468 cells. 
This is a hindrance to understanding the pathway involved. However the ras 
pathway is highly complex, involving numerous other proteins. It seems possible 
that mutations may be present, but have not yet been identified. The pathway 
only appears to be active under serum-starved conditions, where other pathways 
are not stimulated. This suggests a reason for why this effect has not been 
previously noted and examined. Further investigation into the pathway would be 
necessary to identify relevant mutations. 
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 Chapter 7: Conclusions 
 
The premise of the study was to examine more closely the role of the PKC-δ C2 domain 
within a breast cancer system, in order to further understand its roles in effecting the 
function of PKC-δ itself. 
This study utilised three breast cancer cell lines; the MDA-MB-468, which the study 
focused on, as well as the MDA-MB-231 and MCF-7 cell lines. The MDA-MB-468 and 
MDA-MB-231 cell lines are triple negative cell lines. The triple negative status is relevant 
to tumours of a basal type and refers to the absence of oestrogen, HER2 and 
progesterone receptors. Identification of PKC-δ C2 domain as a drug target in these cells 
would be particularly advantageous as they are notoriously difficult to treat. The MCF-7 
cell line is positive for the oestrogen receptor and was selected due to this difference. All 
three cell lines have been well studied in the literature; this will hopefully allow a more 
thorough interpretation of any results. 
In order to examine the role of the PKC-δ C2 domain, a construct was created containing 
PKC-δ C2 sequence and transfected into cells. Expression of the myc-δC2 domain protein 
in the cells was anticipated to act as a dominant negative for the endogenous PKC-δ. The 
C2 domain is a regulatory region of the PKC-δ protein, and has been shown to have 
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protein binding effects; thus expression was projected to interfere with protein binding 
functions of endogenous PKC-δ C2 domain through competitive inhibition. This would 
have a negative effect on the endogenous PKC-δ function. A further construct was also 
developed which contained the whole PKC-δ sequence with a myc-tag. Expression of this 
would enable visualisation of the effects of over-expression of PKC-δ on the cells.  
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7.1 Preparing the cell lines 
The constructs were transfected into the three cell lines and stably transfected cells 
selected. Chapter 3 described the development of only vector control and myc-δC2 
transfectants in MDA-MB-468 cells. In addition to developing the vector control and 
myc-δC2 stable transfectants, the MDA-MB-231 and MCF-7 cell lines also developed 
myc-PKC-δ transfectants. The fact that the MDA-MB-468 cells could not be transfected 
with myc-PKC-δ implies that the over-expression of PKC-δ in this cell line is highly 
detrimental to these cells. This could be the case if it had a pro-apoptotic role within 
these cells. The literature describes a pro-apoptotic role for PKC-δ where it translocates 
to the nucleus and is cleaved by caspase-3 into an active catalytic fragment (Reyland, 
2007). With transfectants arising in the MDA-MB-231 and MCF-7 cells, the role of the 
PKC-δ does not appear to be comparative. There is evidence in the literature for PKC-δ 
employing an anti-apoptotic role in MDA-MB-231 cells (Lønne et al., 2009). Thus the 
beneficial effect of PKC-δ could explain the development of myc-PKC-δ expressing cells 
in relation to this cell line. The MCF-7 cells were also successfully transfected with myc-
PKC-δ. There is no evidence in the literature for a similar effect of PKC-δ to that in MDA-
MB-231 cells which have a ras mutation (Lønne et al., 2009). However, a mutation in the 
caspase-3 gene  that renders this protein inexpressible can explain the development of 
these cells (Janicke, 2009). The pro-apoptotic role of PKC-δ relies on the activity of 
caspase-3. Therefore if this protein is not present this could not occur, and the 
detrimental effects seen in MDA-MB-468 cells, where the myc-PKC-δ cell line did not 
develop, would not occur. The development of stable cell lines containing myc-δC2 
indicates that the presence of this is not particularly detrimental to the cells. If the roles 
insinuated by the discussion above are true with respect to the pro-apoptotic role in 
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MDA-MB-468 cells, it may be that there is in fact an advantageous outcome to myc-δC2 
expression. 
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7.2 The cytoskeleton 
The MDA-MB-468 cell lines were examined using immuno-fluorescence to identify the 
positioning of the myc-δC2 domain within the cells. This showed the localisation of myc-
δC2 to the ends of actin protrusions from the bulk of the cytoskeleton, which did not 
appear to be a direct co-localisation event. Following the data obtained for the myc-δC2 
positioning study, the differences in the actin cytoskeleton were examined 
independently. The cells expressing the myc-δC2 showed a more spread-out actin 
cytoskeleton with protrusions extending from the main bulk of the structure. This was 
absent in the vector cells where the cytoskeleton was more rounded and displayed 
fewer protrusions, which were generally less extensive. PKC-δ C2 domain has been 
identified as a binding partner of actin (Lopez-Lluch et al., 2001).Thus it could be 
hypothesized that the expression of myc-δC2 may have an effect on the cytoskeletal 
structures.  
The literature has identified numerous structures that actin may form under particular 
conditions. The ‘spread-out’ nature of the protrusions seen in Chapter 4 did not suggest 
directionality that would be identified if a cell was moving in a particular direction. Thus 
it seemed more probable that the protrusions were in fact associated with attachment 
of the cell to a surface. 
The cytoskeleton is a complex of numerous proteins, some of which have a role in 
stabilisation of the structure, such as adducin. Protrusions from the main cell mass are 
likely to have a different complement of proteins, partially due to their positioning at the 
extremities, where there are fewer core cellular processes, i.e. key organelles such as the 
mitochondria and nucleus are in the core of the cell. Thus, overall these protrusions are 
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likely to have a certain complement of active proteins, which raises the question: which 
other proteins are localised to these protrusions that the C2 domain could be binding? 
 PKC-δ has activity at cell membranes throughout the cell, and in the nucleus for 
apoptosis, for example, but can also be associated with the cytoskeleton. However as 
the myc-δC2 is not positioned throughout the cytoskeleton it may suggest that any 
interactions are related to the activity restricted to these protrusions. As the C2 should 
be inhibiting the action of the endogenous PKC-δ, it is interesting to consider the 
endogenous role. It could be considered that PKC-δ would normally prevent the 
attachment of protrusions to a surface, perhaps through inhibiting a link of the 
cytoskeleton to the focal adhesions. Where C2 is present it is inhibiting this inhibition, 
thus the cytoskeleton is firmly linked to the focal adhesions and the cell remains firmly 
attached to a surface.  
The differences between the myc-δC2 and vector control cell lines indicated PKC-δ may 
play a role in cell motility that over-expression of myc-δC2 is preventing. There is 
evidence that PKC-δ has some involvement with the invasive and metastatic properties 
of cells. Kiley et al showed higher levels of PKC-δ were present in more invasive cell lines 
(Kiley et al., 1999). Where they increased the levels of the protein, the cells increasing 
grew independent of attachment, indicating a more invasive and metastatic profile. In 
addition to this they found regulatory domain expression prevented this effect, which 
could have been due to the action of the C2 domain, as a comparative effect can be 
identified in these studies. 
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7.3 Cell numbers 
A difference was noted between the MDA-MB-468 myc-δC2 and vector control cell lines 
in terms of how fast they appeared to be growing. Counts of the cells showed a 
consistently larger number of cells were found in the myc-δC2 expressing cells over the 
vector control cells. This was also the case for the MDA-MB-231 cell lines, but not the 
MCF-7 cell lines. In the MDA-MB-231 cells there was also an increase in the myc-PKC-δ 
expressing cell lines, although to a lesser degree. The MCF-7 cell line expressing myc-
PKC-δ appeared to show a decrease in cell number over the vector control.  
Cell number can be considered as a balance between the cells proliferating and the cells 
apoptosing. Where proliferation is greater than apoptosis cell number increases, and 
where apoptosis is greater than proliferation cell number decreases.  If, between two 
cell lines  the proliferation is greater in one, and the degree of apoptosis similar, then cell 
number increases greater in that one more than the other. Equally, the effect on cell 
number will be the same if the level of proliferation is similar between the cell lines, but 
in one cell line apoptosis occurs to a greater degree, this one would display a lower cell 
number.  
The effects on cell number of the MDA-MB-468 and MDA-MB-231 cells expressing myc-
δC2 could be due to the C2 inhibiting a pro-apoptotic action of PKC-δ, thus allowing the 
cells to survive, and the cell numbers to increase. However for the MDA-MB-231 cells 
this would not fit with the literature, or the ability to develop a myc-PKC-δ cell line. 
Alternatively it could be due to the C2 inhibiting an anti-proliferative action of PKC-δ, 
thus allowing proliferation to continue and cell numbers to increase. The absence of an 
effect in the MCF-7 cells could link the effect to apoptosis through the caspase-3 
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dependant pathway described previously. Where the caspase-3 is absent the pro-
apoptotic pathway does not occur, thus the inhibition of this is extraneous. Therefore 
there would not be an effect to expressing myc-δC2. 
However, the expression of myc-PKC-δ in MDA-MB-231 cells had the effect of increasing 
cell numbers, although not to the same degree as with myc-δC2 expression. At first 
glance this does not appear to fit with the idea that the myc-δC2 is inhibiting the PKC-δ 
action. However, it could be that this is still happening, but that the over-expression of 
PKC-δ is to such a degree that it is ‘flooding’ the pathways, and a clear role for PKC-δ 
cannot be defined in this situation. The literature describes many roles for PKC-δ, some 
of which may have opposing effect. By allowing so many protein molecules to be 
expressed, without the control normally associated with cell metabolism, several of the 
pathways have become active and the result of multiple effects is being seen, illustrated 
by an increase in cell number. However if an anti-apoptotic effect is present in these 
cells, this could explain the benefit of PKC-δ over-expression, but it does not aid 
understanding of myc-δC2 effects. 
In the MCF-7 cells, the effects of expression of myc-PKC-δ did not have comparative 
effects to any of the other cell lines. In fact, the expression had the opposite effect and 
the cells had lower cell numbers than the vector control cells. The hypothesis for there 
being no effect of myc-δC2 expression is that there is no pro-apoptotic effect to inhibit 
as the pathway cannot occur due to the lack of caspase-3. Thus if this pathway is not 
occurring, then over-expression of PKC-δ would not have an effect either. If the effects 
are not associated with apoptosis it would be likely that the effects could be in 
proliferation. If PKC-δ has an anti-proliferative action, the over-expression may 
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exacerbate this effect leading to lower cell numbers. It could be that no effect is seen 
with the myc-δC2 cells as the C2 domain is not involved with this role. Perhaps the C1 
domain is involved in regulation of this action. 
Little could be clearly defined at this point of the study; however one thing that stood 
out was that the roles of PKC-δ are highly cell line dependent. 
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7.4 Apoptosis  
The MDA-MB-468 cells have been the focus of this study, and the effects noted with the 
addition of the myc-δC2 on cell number may be explained by differences in apoptosis; 
thus the apoptotic profiles of these cell lines were examined. The myc-δC2 expressing 
cells demonstrated a higher level of viability than the vector control cells, in conjunction 
with a lower level of early apoptosis. This data indicates that through blocking the 
endogenous PKC-δ action, the myc-δC2 is having a protective effect on the cells, thus 
reducing apoptosis, and resulting in the population showing an increased cell number. 
This is indicative of a pro-apoptotic effect of PKC-δ, as demonstrated in the literature. 
However, the involvement of the C2 domain in facilitating this process has not been 
previously noted.  The pro-apoptotic pathway describes the tyrosine phosphorylation of 
a tyrosine residue in the C2 domain, as well as one in the C1 domain. This allows 
targeting of the PKC-δ to the nucleus through revealing a nuclear localisation sequence. 
It maybe that the PKC-δ C2 domain is vital for facilitating the interaction with the 
tyrosine kinase that is involved in this phosphorylation, and subsequent redirection of 
PKC-δ. Thus the fact that the C2 is widely present in the expressing cells would 
competitively inhibit the interaction of the tyrosine kinase with the C2 domain, thus 
preventing the pro-apoptotic role. 
Bearing in mind the discoveries of an altered cytoskeleton in chapter 4, it is worth 
considering that the effects on apoptosis identified here could be attributed to the state 
of anoikis (Frisch and Screaton, 2001). Anoikis is a form of apoptosis related to a lack of 
anchorage to a surface. Where there is no anchorage a cell can be forced into an 
apoptotic program. This can be considered as a protective mechanism for preventing 
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invasive and metastatic phenotypes. Where the cells expressing myc-δC2 have a more 
extensive actin cytoskeleton, they could be better attached and thus anoikis is 
prevented; this would allow for a higher level of viability within the population. PKC-δ 
endogenous activity has been shown to encourage anchorage-independent growth. This 
may induce a program of anoikis-related apoptosis. If this were the case, the C2 domain 
is of obvious importance in this activity. It could be blocking an interaction of the C2 
domain on endogenous PKC-δ to allow cytoskeletal flexibility. 
The effect was not seen in the MDA-MB-231 cells however. In fact the opposite effect 
was seen. The vector control cells demonstrated an increased level of viability over the 
myc-δC2 cells; and although no difference was identified in the early apoptotic fraction 
(both populations were positive for early apoptotic cells), there was a lower level of late 
apoptotic/necrotic cells. This would suggest the myc-δC2 domain is interfering with an 
anti-apoptotic effect of PKC-δ in this cell line. This anti-apoptotic effect of PKC-δ is 
supported in the literature, which also stated they did not see this effect in the MDA-
MB-468 cell line. In Lønne et al (2009) they described a ras mutation that caused high 
phosphorylation levels of ERK1/2. The cells did not appear to be able to cope with this 
and would apoptose if it were not for the action of PKC-δ on NEDD4, and subsequently 
MKP3, to de-phosphorylate the ERK1/2 to a level at which apoptosis was not induced. 
Thus as a ras mutation is not present in the MDA-MB-468 cells, they would not 
demonstrate this apoptotic profile. However, this does not explain the beneficial effects 
of expressing myc-δC2 on the cell numbers. Due to cell numbers being considered as a 
balance of apoptotic and proliferative abilities, it seems sensible to deduce that the 
effects seen in cell number are associated with a proliferative effect, whereby myc-δC2 
interferes with an anti-proliferative action. 
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In the PKC-δ over-expressing cell line, no differences could be identified in the apoptotic 
profile of the vector control cells and the over-expressing cells. From the myc-δC2 cell 
data it may be expected that the identified anti-apoptotic effect of PKC-δ within this cell 
line would lead to an increased viability in the PKC-δ over-expressing cells; however this 
increase does not occur. Perhaps the absence of this viability increase is due to the fact 
that a binding partner of the PKC-δ is a limiting factor, i.e. there are only so many 
molecules of this binding partner, and the endogenous PKC-δ is already meeting the 
level which is necessary for the binding partner and the PKC-δ to bind and generate an 
effect. 
The lack of an explanation for the increase in cell number of the myc-PKC-δ cells with the 
apoptosis data suggests that the answer may, as with the myc-δC2 cells, lie with effects 
of PKC-δ in cell proliferation. Perhaps there may be several pathways involved here for 
both the PKC-δ over-expressing and myc-δC2 expressing cell lines to demonstrate an 
increase in cell number, although to a differing degree, over the vector control cell line. 
This area would need further investigation within this cell line to identify any pathways 
and clarify the role of PKC-δ and the C2 domain within them. However, whatever 
network of interactions is involved, it is clear that the C2 domain can be considered vital 
to at least some of these, in order to allow the effects on cell numbers in myc-δC2 
expressing cells. 
Despite the MCF-7 cells showing no difference in cell number with myc-δC2 present, 
these cells were also examined for apoptosis. No differences were identified between 
the vector control and myc-δC2 cells, supporting the cell number data described above. 
PKC-δ has been demonstrated to act through a pro-apoptotic mechanism involving 
 
228 
activation of the caspase cascade, a key component of which is caspase-3. However the 
MCF-7 cells do not express caspase-3. Thus this agrees with the data and the literature 
that, with the absence of caspase-3, the pro-apoptotic pathway cannot occur, and thus 
cell numbers are unaffected. 
The PKC-δ over-expressing cell line was also studied and apoptosis data showed no 
differences between the vector control and over-expressing cell lines. The difference in 
cell number at day 5, where the PKC-δ over-expressing cell line was lower, does not 
appear to be due to the effects of apoptosis. It could be due to an anti-proliferative 
effect of PKC-δ activated through its over-expression; however further investigation 
would be required in order to clarify any mechanism by which this would take place. The 
lack of effect with the C2 domain on cell numbers is indicative of the C2 domain not 
being key in the interactions facilitating this role. The MDA-MB-231 data indicates that a 
proliferative effect could involve a network of pathways, and that the C2 is important for 
some, and not for others. Thus, perhaps the pathway where C2 is not important would 
be the active one in MCF-7 cells. 
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7.5 The effects of no serum 
In order to further examine the apoptotic pathways involved in the MDA-MB-468 cells, 
the cells were serum-starved in order to induce stress, and cause apoptosis. The 
starvation of these cells produced an unexpected result, whereby the myc-δC2 
expressing cells displayed a significantly lower viability than the vector control cells. This 
was mirrored by an increase in the level of early apoptosis and late apoptosis/necrosis. 
Under starvation conditions, the cells expressing myc-δC2 responded in an opposing 
manner to 10% serum. This blocked the endogenous PKC-δ role and induced apoptosis; 
thus illustrating an anti-apoptotic role for PKC-δ where serum is absent.  
In MDA-MB-231 cells the PKC-δ also demonstrated an anti-apoptotic role in our 
apoptosis study, and also in the literature, but under full serum conditions. The pathway 
was active due to the effects of a ras mutation (Figure 6.2). There has, thus far, been no 
identification of a ras mutation in the MDA-MB-468 cell line. However the anti-apoptotic 
effects of PKC-δ in starved conditions, led us to examine aspects of the pathway, in order 
to study whether a similar situation was transpiring. Lønne et al (2009) used the 
proteasome inhibitor MG132 to identify whether preventing proteasomal degradation 
whilst using PKC-δ siRNA allowed MKP3 to continue its de-phosphorylating activity with 
regards to ERK1/2, which it did. We have used myc-δC2 as an inhibitor of PKC-δ 
endogenous action, instead of siRNA. Thus by treating with MG132 as well, we could 
identify if a comparable effect occurred. The effect of myc-δC2 in starved cells was 
reversed with the MG132 treatment, so that the viability was no longer significantly 
different from the vector control cells. This indicated that the pathway active in the 
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starved MDA-MB-468 cells also required the action of the proteasome, as in the MDA-
MB-231 cells grown under normal conditions. The effect of myc-δC2 expression indicates 
that the C2 domain of PKC-δ is important in the interactions essential for this pathway. 
The pathway described by Lønne et al (2009) described PKC-δ inhibiting NEDD4 action. It 
could be that the C2 domain is the region that binds this protein, perhaps near, or in, the 
active site, thus blocking its activity, or perhaps at an alternative location and inducing a 
conformational change preventing activity. 
This pathway is important in the MDA-MB-231 cells as there is a ras mutation driving 
ERK1/2 phosphorylation excessively high. Therefore an important factor of this pathway 
is the phosphorylation status of ERK1/2. In MDA-MB-231 cells the ERK phosphorylation 
was lowered by PKC-δ activity; prevention of this activity increased phosphorylation and 
thus cell death. In the MDA-MB-468 cells we saw higher cell death in the starved cells, 
and thus examined whether an appropriate increase occurred in phosphorylation status, 
as this would indicate to what extent the pathway mirrored the situation in MDA-MB-
231 cells. The ERK phosphorylation data identified a considerably higher level of ERK1/2 
phosphorylation in the serum-starved myc-δC2 cells, i.e. where endogenous PKC-δ 
activity is prevented. 
The data obtained under serum starved conditions highlights a key role for the C2 
domain in this pathway. It would be interesting to investigate whether this role is also 
present in the MDA-MB-231 cells, although the investigation into the similarities of the 
pathway between the two cell lines has shown strong correlation, thus it seems likely 
that the role of the C2 would remain conserved.  
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The differences identified in the myc-δC2 expressing cell lines where serum is either 
present or absent is indicative of a ‘sensing’ role for the C2 domain. The variations of the 
method by which this could occur are extensive. However it could be that, due to the 
known action of tyrosine phosphorylation on PKC-δ targeting, tyrosine residues may 
become differentially phosphorylated. Perhaps binding of serum factors to receptors at 
the cell surface could lead to a cascade of reactions, some of which being to de-
phosphorylate certain residues, and phosphorylate others. The experiments performed 
in Chapter 6 began to examine this idea. They showed that there was no overall 
difference in the level of tyrosine phosphorylation of PKC-δ between the myc-δC2 and 
vector control cell line. However more in-depth examination of specific residues may 
reveal differences. In addition, the experiments showed that the myc-δC2 was not 
tyrosine phosphorylated. This may be due the kinase in question requiring the whole 
protein in order to act, or maybe that the phosphorylation would not involve the C2 
domain directly. Perhaps the C2 domain would bind the kinase, but the phosphorylation 
would occur elsewhere in PKC-δ. 
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7.6 Key discoveries 
• The C2 domain of PKC-δ is very important in mediating the roles of PKC-δ 
examined in this study. 
• In MDA-MB-468 cells myc-δC2 localises to the extremities of actin protrusions. 
• In MDA-MB-468 cells inhibition of PKC-δ by myc-δC2 allows cells to develop a 
more extensive cytoskeleton. 
• In MDA-MB-468 cells myc-δC2 prevents a pro-apoptotic role for PKC-δ. 
• In MDA-MB-231 cells myc-δC2 prevents an anti-apoptotic role for PKC-δ. 
• In serum-starved MDA-MB-468 cells PKC-δ fulfils an anti-apoptotic role; the myc-
δC2 prevents this. 
• Proteasome activity is vital to the PKC-δ anti-apoptotic role in starved MDA-MB-
468 cells. 
• ERK1/2 phosphorylation appears to be higher in starved MDA-MB-468 myc-δC2 
cells than vector control cells, correlating with an increase in apoptosis of myc-
δC2 cells. 
The C2 was examined with the aim of investigating its role and discovering if it could be a 
suitable drug target. This research has indicated that it has an important role in directing 
PKC-δ activity. Depending on the conditions relevant to a tumour situation, it shows 
promise as a suitable drug target. However, there is a large amount of further work that 
remains to be undertaken to clarify roles in certain areas before a drug discovery 
program could be of value. 
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7.7 Further work 
There are several aspects of this project that require further investigation as this project 
seems to have only scratched the surface of the complexity of the roles of PKC-δ within 
breast cancer. Expression of myc-δC2 produced changes with respect to the cytoskeletal 
structure. Further investigation would be required to clarify the function of these 
changes. Although PKC-δ is already known to interact with the cytoskeleton, less is 
known regarding its effects. The C2 domain is obviously important in this interaction, but 
further research would be necessary to elucidate the role of this interaction. The data in 
this study have indicated that PKC-δ may have a destabilising action with respect to the 
cytoskeleton and the focal adhesions; further investigation would be required.  
The apoptosis studies indicated differences where myc-δC2 was interfering with the PKC-
δ activity. It could be that this is linked to the cytoskeletal effects with reference to the 
phenomenon of anoikis; this should be investigated. However, the responses elicited 
through myc-δC2 expression may be attributed to better understood apoptotic PKC-δ 
mechanisms; thus the binding partners involved in transmitting the effects of PKC-δ 
should be investigated.  
The MDA-MB-231 apoptotic pathway, with relation to PKC-δ, has been examined in the 
literature. The anti-apoptotic effect of PKC-δ in these cells correlates with the effects of 
myc-δC2 expression. However the lack of effect with PKC-δ over-expression should be 
further investigated. It seems likely that a binding partner could be a limiting factor in 
this pathway, but this should be confirmed.  
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The apoptotic pathway effects shown with myc-δC2 expression can be explained by the 
literature. However, the differences in cell number with the MDA-MB-231 cell lines 
remains to be explained. There were also differences seen with MCF-7 cell line cell 
numbers. This did not relate to apoptotic differences. Thus this data suggests a key area 
of investigation should be PKC-δ effects in cell proliferation. It would appear, from the 
data obtained during this project, that the role of PKC-δ in proliferation may well be a 
cell dependant phenomenon, as MCF-7 and MDA-MB-231 cells appear to show PKC-δ 
having anti-proliferative and pro-proliferative effects, respectively. 
Serum-starvation produced an interesting effect in MDA-MB-468 cells, whereby the 
apoptotic role of PKC-δ appeared reversed from 10% serum conditions. Investigation of 
this effect showed correlation with the study of an anti-apoptotic effect in MDA-MB-231 
cells. However in MDA-MB-231 cells there is a ras mutation facilitating this process. The 
status of the RAS-RAF-MAPK-ERK pathway requires further investigation in the MDA-MB-
468 cells. The entire pathway needs to be mapped out and examined in order to reveal a 
mutation which would allow the observed response to transpire. It could be that any 
stage of the pathway has been altered; it may be from the receptor level onwards 
through the pathway.  
The differences between serum status responses would require investigation to examine 
a more relevant state of serum levels for a tumour situation. This would allow further 
study into the pathways that are active in this case. This would further allow 
consideration of whether the C2 would be a suitable drug target. The C2 does appear to 
be important in somehow ‘sensing’ the serum status; thus the methods by which this 
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occur should also be scrutinised in order to allow deliberation of the C2 domain 
suitability as a target for drugs. 
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